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Abstract 
 
Huntington’s disease is a progressive neurodegenerative disease caused by a mutation in the 
huntingtin protein. Although the mutation has been identified, the molecular mechanisms 
underlying Huntington’s disease pathology are not fully understood. Dysfunction of cholesterol 
homeostasis has been previously associated with Huntington’s disease, however detailed 
examination of potential changes has not been undertaken. The aim of this project was to 
identify cholesterol homeostatic alterations in HD that may be relevant to mechanisms that 
underlie neurodegeneration, or potentially identify associated molecules to be used as 
biomarkers of Huntington’s disease. Using a novel triple quadrupole gas chromatography-mass 
spectrometry method, we have conducted 3 separate studies in R6/1 mice. Firstly, 
comprehensively characterising the physical phenotype and cholesterol homeostatic alterations 
during disease progression. These were then used for reference when R6/1 mice were subject 
to environmental enrichment, and anthocyanin dietary supplementation. Human HD post 
mortem tissue was also analysed for cholesterol synthetic precursors, metabolites and oxidation 
products. A progressive dysfunction of cholesterol synthesis was detected in both striatum and 
cortex of the R6/1 mouse. At later stages in the disease model, the major brain cholesterol 
metabolite, 24(S)-hydroxycholesterol, was also significantly reduced. Novel age-related changes 
pertaining to brain cholesterol homeostasis were also detected in these mice. Environmental 
enrichment of R6/1 mice attenuated the progression of motor dysfunction in male mice. 
Cholesterol oxidation products, markers of oxidative stress, were also reduced in the cortex of 
both wild type and R6/1 mice receiving enrichment. Dietary supplementation with anthocyanins 
also delayed the onset of motor dysfunction in female R6/1 mice. These studies have highlighted 
a potential sex differences in HD. Human HD post mortem tissue revealed a specific disturbance 
to cholesterol synthesis in the putamen, as well as elevated cholesterol oxidation products. 
Consistent with the R6/1 mouse model, 24(S)-hydroxycholesterol levels were significantly 
xv 
 
reduced in the striatum (caudate and putamen). Enzymes involved in brain cholesterol 
metabolism (cholesterol 24-hydroxylase) and synthesis (delta(24)-sterol reductase) were also 
significantly depleted in the putamen. In conclusion we have identified disturbances in 
cholesterol metabolic and synthetic pathways in both human and R6/1 mouse brain tissue. In 
addition to being potentially useful biomarkers of disease severity and progression, these 
alterations may provide further insight into the effects of lipid alterations in HD pathophysiology, 
and potentially other neurodegenerative disorders.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1                                          
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 Cholesterol 
 
Cholesterol represents an important component of eukaryotic cell membranes; structurally, 
cholesterol modulates membrane fluidity and organisation (Yeagle, 1985) where it can alter 
signalling functions, membrane protein organisation and lipid raft structure (Moran & Miceli, 
1998; Sheets et al., 1999; Zajchowski & Robbins, 2002; Kannan et al., 2007).  Cholesterol is also 
involved in vitamin D production and synthesis of steroid hormones. Cholesterol has the 
common structure of a sterol, containing a carbon 3 hydroxyl group and a tetracyclic steroid 
ring. Specifically, cholesterol contains a 3β hydroxyl group and an isooctyl hydrocarbon tail 
(Figure 1.1). The opposing polarity of the hydroxyl group and hydrocarbon structure of the 
remaining molecule gives cholesterol its amphipathic nature. 
 
 
 
 
 
 
 
 
 
Figure 1.1 Chemical structure of cholesterol. The C3 hydroxyl group and tetracyclic steroid ring is shared 
by all sterols.  The 8 carbon branched alkyl chain adds to the nonpolar steroid ring; the resultant molecule 
is amphipathic. 
 
1.1.1 Cholesterol in cell membranes 
 
The opposing polarity of the cholesterol molecule facilitates its incorporation into the lipid 
bilayer of the eukaryotic cell membrane, where the hydroxyl group is exposed. The distribution 
of cholesterol in membranes is not random, rather it is found in discrete domains. The rigid, 
3 
 
polycyclic structure of cholesterol in the membrane can have the effect of restricting the 
movement of neighbouring hydrocarbon chains, introducing order. This can also disrupt tightly 
packed alkyl chains that make up the hydrophobic interior of the cell membrane. These chemical 
features of cholesterol are important when considering the dynamics of cholesterol in the cell 
membrane, and the potential disturbances caused by altered levels of cholesterol. 
1.1.2 Cholesterol in lipid rafts 
 
Lipid rafts are highly dynamic, heterogeneous, cholesterol and sphingolipid rich microdomains 
found in the lipid bilayer of membranes;  functioning to segregate and concentrate proteins that 
carry out cellular processes (Simons & Ikonen, 1997; Pike, 2006). Lipid rafts are associated with 
essential cellular functions, including signal transduction (Janes et al., 2000), membrane 
trafficking (Brown & London, 1998) and membrane associated proteolysis (Vetrivel et al., 2005). 
Lipid rafts are essential for normal brain function and have been identified in glia and neurons 
(Tsui-Pierchala et al., 2002; Gielen et al., 2006). The dysfunction of lipid rafts may have serious 
consequences in the brain, and this has been associated with several neurodegenerative 
diseases (Urano et al., 2005; del Toro et al., 2010; Fabelo et al., 2011). Since lipid rafts are 
enriched with cholesterol,  it has been proposed that altered cholesterol homeostasis in the 
brain may lead to a disturbance of lipid raft structure and their associated functions (Rojo et al., 
2006). 
 
1.2 Cholesterol in the brain 
 
The brain contains the highest concentration of cholesterol of any tissue in the body; accounting 
for approximately 25% of the total cholesterol, in an organ that only makes up 2% of the total 
body mass. The distribution of cholesterol is not homogenous in the brain, 70% is found in the 
myelinated axons of white matter, and the remaining 30% in the membranes of neurons and 
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glia (Norton & Autilio, 1965; Snipes & Suter, 1997). Although cholesterol is highly concentrated 
in the brain, it is not able to move across the blood brain barrier (BBB) (Jurevics & Morell, 1995). 
The isolation of the brain from peripheral sources of cholesterol suggests that strict cholesterol 
homeostasis is required within the brain to maintain function. A clear example of this is genetic 
mutations in cholesterol synthetic enzymes leading to severe neurological dysfunction 
(desmosterolosis and Smith-Lemli-Opitz syndrome) (Wassif et al., 1998; Waterham et al., 2001). 
Altered cholesterol metabolism has also been associated with several neurodegenerative 
diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease 
(HD) (Wahrle et al., 2002; Cordy et al., 2003; Gibson Wood et al., 2003; Lim et al., 2011). Whether 
this is a cause or effect has not been established. 
1.2.1 Synthesis of cholesterol in the brain 
 
Cholesterol cannot cross the BBB, therefore de novo synthesis is required to supply the brain 
with cholesterol (Jurevics & Morell, 1995). Brain cholesterol synthesis follows the same pathway 
as in peripheral tissues, a process where acetate is converted to cholesterol in over 20 steps. 
The major enzymes and intermediates of the lower ('post-squalene') cholesterol synthetic 
pathway are represented in Figure 1.2. The cholesterol synthetic pathway is split, with the last 
common precursor lanosterol. The Bloch pathway has a major intermediate of desmosterol, 
while the Kandutsch-Russell pathway utilises lathosterol (Bloch, 1965). Squalene occurs earlier 
in the pathway before cyclisation of the steroid ring. The rate limiting enzyme in the cholesterol 
biosynthetic  pathway has been previously identified as 3-hydroxy-3-methylglutaryl-coenzyme-
A reducatase (HMG-CoAred) (Snipes & Suter, 1997), which appears early in the pathway. 
Negative feedback regulates HMG-CoAred through degradation (Gardner & Hampton, 1999) 
and transcriptional control (Reynolds et al., 1984). As the cholesterol synthetic pathway is 
involved in producing multiple products along the pathway, more complex regulation is likely to 
occur. Recent studies specifically investigating the regulation of the "post-squalene" cholesterol 
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synthetic pathway, have suggested the synthetic enzyme delta(24)-sterol reducatse (DHCR24) 
to have regulatory roles beyond catalysing the final step in the Bloch pathway (Luu et al., 2015). 
As these findings are quite recent, the importance of DHCR24 levels in brain cholesterol 
homeostatic regulation is unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Simplified pathway showing cholesterol synthesis, metabolism and free radical oxidation 
relevant to this thesis. Major “post-squalene” cholesterol synthetic precursors shown follow a branched 
pathway, the Kandutsch-Russell pathway or Bloch pathway. Cholesterol can be oxidised enzymatically to 
form 24(S)-hydroxycholesterol (24-OHC) or 27-hydroxycholesterol (27-OHC) by cholesterol 24-
hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1) respectively. Reactive oxygen species 
(ROS) can oxidise cholesterol to form 7-ketocholesterol and 7β-hydroxycholesterol. The position of 
delta(24)-sterol reductase (DHCR24), a cholesterol synthetic enzyme is also shown. Broken lines indicate 
intermediates that have not been shown in this simplified scheme. 
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Although cholesterol synthesis and metabolism in peripheral tissues is relatively well 
understood, the difficulty of performing in vivo studies in brain tissue has left many cellular 
processes involving cholesterol synthesis and metabolism undefined. However, in vitro studies 
examining isolated neurons and glial cells have identified some brain specific processes involved 
in cholesterol regulation and trafficking. Embryonic neurons have been identified to synthesise 
cholesterol (Saito et al., 1987), however cholesterol synthesis in adult neurons is unsustainably 
low (Nieweg et al., 2009). These findings support the hypothesis that cholesterol synthesis is 
mostly abandoned in neurons shortly after foetal development during which the majority of 
cholesterol is synthesised in the brain (Pfrieger, 2002). As neurons have a high demand for 
cholesterol, specifically for axon growth (Hayashi et al., 2004), maintenance of dendrites (Fan et 
al., 2002), and synaptogenesis (Mauch et al., 2001); the source of neuronal cholesterol in the 
mature brain has been investigated. In vitro studies suggest neurons source cholesterol from 
astrocytes, and this has been demonstrated to be essential for neuron growth in vitro (Mauch 
et al., 2001; Nagler et al., 2001). Further support for the 'outsourcing' hypothesis has been 
demonstrated through the in vivo disruption of squalene synthase (an essential enzyme for 
cholesterol synthesis) in adult neurons, resulting in normal brain morphology in mice 
(Funfschilling et al., 2007). This indicates adult neurons are able to survive independent of their 
own cholesterol synthesis. Pfrieger et al. (2002) proposed that an apolipoprotein shuttle from 
astrocytes to neurons is the mechanism by which neurons obtain cholesterol, and there is 
evidence that neurons have the capability to process cholesterol in lipoprotein particles through 
the endosome-lysosome pathway (Parton et al., 1992; Brown et al., 1997). There may be several 
reasons that neurons outsource cholesterol synthesis to astrocytes. The high energy cost, and 
the need for a large number of enzymes in different cellular compartments, may explain why 
neurons, whose primary function is electrical synaptic transmission, abandoned cholesterol 
synthesis after foetal development. The elongated shape of the neuron may also hinder 
transport of cholesterol, from where it is produced in the cell body, to where it is needed 
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(synapses). Oligodendrocytes maintain cholesterol synthesis in adulthood and synthesise 
cholesterol at a rate that exceeds the level in astrocytes (Saito et al., 1987; Nieweg et al., 2009).  
It is unclear if neurodegeneration alters cholesterol synthesis in the brain and if intermediates 
accumulate or diverge into different metabolic pathways. There is evidence for decreased levels 
of cholesterol synthetic precursors in aging (Thelen et al., 2006) and AD (Kolsch et al., 2010), 
however, since many analytical techniques are unable to detect these low level compounds, 
much of the current literature does not contain enough information to interpret the extent of 
changes occurring.  
1.2.2 Cholesterol metabolism in the brain 
 
Cholesterol synthesis in the adult brain is slow, in the order of µg/h (Spady & Dietschy, 1983), 
which is surprising, as the brain is one of the most metabolically active tissues in the body. 
Although the rate of synthesis is low, excess cholesterol must still be removed from the brain. 
The BBB is impermeable to cholesterol, therefore simple diffusion of cholesterol into the plasma 
does not occur. It has been suggested that cholesterol can move into the cerebrospinal fluid 
(CSF) in apolipoprotein E (ApoE) particles and then into the plasma (Pitas et al., 1987a). However, 
this accounts only for a small amount of cholesterol removed to the periphery, indicating other 
mechanisms must be at play. 
1.2.2.1 Formation of 24(S)-hydroxycholesterol 
 
 A key finding in brain cholesterol homeostasis was the identification of a brain specific 
elimination mechanism involving the enzymatic hydroxylation of the cholesterol molecule 
(Lutjohann et al., 1996; Bjorkhem et al., 1997). The addition of a hydroxyl group to the alkyl 
chain of the cholesterol molecule significantly increases cell membrane permeability; side chain 
oxidised sterols move across membranes approximately 1500 times faster than cholesterol 
(Meany et al., 2002). 24(S)-hydroxycholesterol (24-OHC) is formed by the addition of a hydroxyl 
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group in the 24S position of cholesterol (Figure. 1.3). A cytochrome P-450, cholesterol 24-
hydroxylase (CYP46A1), expressed primarily in neurons, catalyses this reaction (Lund et al., 
1999). Although the liver is the site of most cholesterol metabolism in the body, CYP46A1 
expression is almost exclusive to neurons (Lund et al., 1999), suggesting a brain specific role in 
cholesterol metabolism.  Studies involving CYP46A1 knockout mice (Lund et al., 2003) and 18O2 
incorporation into 24-OHC  in rats (Bjorkhem et al., 1997), have estimated that 24-OHC is 
responsible for 40-60% of the cholesterol eliminated from the brain. A rise in 24-OHC levels 
between the brachial artery and jugular vein in human subjects is consistent with these findings 
that demonstrate there is a net flux from the brain into circulation (Bjorkhem et al., 1998). 
Taking into account mechanisms of cholesterol elimination from the brain, the complete 
turnover of cholesterol in the human brain is estimated to be in the order of 5 years (Bjorkhem 
et al., 1998).  
 
 
 
 
 
Figure 1.3 Chemical structure of 24(S)-hydroxycholesterol. 24(S)-Hydroxycholesterol (24-OHC) is the 
major elimination product of cholesterol from the brain, formed by the enzymatic hydroxylation of 
cholesterol by cholesterol 24-hydroxylase (CYP46A1).  
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1.2.2.2 Possible regulation of brain cholesterol homeostasis by 24(S)-hydroxycholesterol 
 
The current understanding of cholesterol synthetic regulation is that a complex interplay exists 
between sterol sensing elements [sterol regulatory element-binding proteins (SREBPs)] and 
transcription factors responsible for producing cholesterol synthetic enzymes (Brown & 
Goldstein, 1999). Whether these mechanisms are active in neurons and astrocytes has not been 
established. Ong et al. (2000) found that SREBPs are present in the neurons of the neocortex 
and hippocampus, however their function in terms of sterol regulation in these regions is 
unknown. The hypothesis that neurons import the majority of cholesterol from astrocytes is 
supported by several studies (Mauch et al., 2001; Funfschilling et al., 2007), and thus it is 
believed that a mechanism is in place to regulate this exchange (Vance & Hayashi, 2010). 24-
OHC is an activator of the nuclear receptor liver X receptor-β, that has the downstream effect of 
activating ATP binding cassette transporter A1 (Repa et al., 2000), a cholesterol transport 
mediator that resides in astrocytes. A convenient hypothesis suggests that metabolised 
cholesterol in the form of 24-OHC promotes the delivery of cholesterol from astrocytes to 
neurons (Figure 1.4) (Pfrieger, 2003), however there is evidence that synthesis and delivery of 
cholesterol are regulated by separate mechanisms (Abildayeva et al., 2006). Further research is 
necessary to elucidate the physiological importance of this mechanism, and potential impacts 
of altered cholesterol metabolism in the brain.  
1.2.2.3 27-Hydroxycholesterol 
 
27-Hydroxycholesterol (27-OHC) is a major metabolic product of cholesterol in peripheral tissue, 
entering the bloodstream to be further metabolised in the liver (Martin et al., 1993; Lund et al., 
1996). 27-OHC is formed by the enzymatic hydroxylation of cholesterol at the 27 carbon position 
(Figure 1.5) by the cytochrome P450, cholesterol 27-hydroxylase (CYP27A1). This reaction takes 
place in all cells; however the expression of CYP27A1 in the brain is significantly less than in 
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other tissues (Lein et al., 2007). A concentration gradient results in a net movement of 27-OHC 
from circulation into the brain (Heverin et al., 2005), where it is quickly metabolised into more 
polar products (including dihydroxysterols and cholestenoic acids), catalysed by the enzymes 
CYP27A1 and 5-hydroxycholesterol 7-α-hydroxylase (CYP7B1) (Meaney et al., 2007). These 
products then move back into circulation where they are efficiently absorbed by the liver (Lund 
et al., 1996; Meaney et al., 2007). It has been previously demonstrated that circulating levels of 
27-OHC are positively correlated to cholesterol levels in the blood (Babiker et al., 2005). It is 
unknown if increased levels of 27-OHC entering the brain from circulation are detrimental, and 
this is potentially relevant to neurodegenerative diseases as hypercholesterolemia has been 
associated with AD and PD (Kivipelto et al., 2001; Hu et al., 2008).  
 
 
 
Figure 1.4 A hypothesised mechanism of cholesterol regulation between neurons and astrocytes 
(Pfrieger, 2002). 24(S)-Hydroxycholesterol (24-OHC) binds the nuclear receptor LXR which activates the 
cholesterol transport mediator ABCA1. It is unknown what promotes cholesterol synthesis in this 
mechanism. Adapted from Bjorkhem (2006). 
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Figure 1.5 Chemical structure of 27-hydroxycholesterol. 27-Hydroxycholesterol (27-OHC) is a cholesterol 
metabolite primarily produced in peripheral tissue where it enters the bloodstream to be further 
metabolised in the liver. 27-OHC is formed by the enzymatic hydroxylation of cholesterol by cholesterol 
27-hydroxylase (CYP27A1). 
 
 
1.2.3 Toxicity of cholesterol metabolites 
 
Several in vitro experiments have shown that cholesterol metabolites also have cytotoxic 
activity. It is unknown what causes specific changes in brain cholesterol metabolism resulting in 
the production, or excess production of potentially toxic oxysterol species. 27-
hydroxycholesterol is toxic to human monocyte-macrophages in vitro (Clare et al., 1995); 
similarly 24-OHC  has toxic effects towards differentiated neuroblastoma cells (Kolsch et al., 
2001). 24-OHC is a major endogenous cholesterol metabolite in the brain, however, as the 
majority of studies rely on in vitro models, the importance of this potential toxicity is yet to be 
established in vivo. 
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Figure 1.6 The major movements of 24(S)-hydroxycholesterol and 27-hydroxycholesterol across the 
blood-brain barrier. The blood brain barrier is impermeable to cholesterol and requires side chain 
oxidation to move across this membrane. Cholesterol is metabolised to 24-hydroxycholesterol (24-OHC) 
by cholesterol 24-hydroxylase (CYP46A1). This pathway represents the major route of cholesterol 
elimination from the brain. The formation of 27-hydroxycholesterol (27-OHC) is catalysed by cholesterol 
27-hydroxylase (CYP27A1) and occurs primarily in peripheral tissues. A concentration gradient causes a 
net flux of 27-OHC into the brain where it is further metabolised to cholestenoic acids. Cholesterol 
metabolites are removed from circulation in the liver where they are converted to bile acids. Enzymes are 
shown in italics.  
 
1.3 Cholesterol oxidation products 
 
'Cholesterol oxidation products' (COPs) is an arbitrary classification within this thesis, classifying 
cholesterol oxides that are formed by reactive oxygen species (ROS) and not endogenous 
enzyme activity. The most susceptible location on the cholesterol molecule is the area 
surrounding the 5,6 double bond (Smith, 1991), where the addition of an epoxide, ketone and 
hydroxyl functional group can occur. 7β-Hydroxycholesterol (7β-OHC) and 7-ketocholesterol (7-
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KC) are formed by ROS attack at the 5,6 double bond (Fig. 1.7). These are elevated in diseases 
and pathological models that involve oxidative stress including atherosclerosis (Iuliano et al., 
2003; Jenner et al., 2007), cystic fibrosis (Iuliano et al., 2009) and retinal photodamage 
(Rodriguez & Fliesler, 2009). In vitro studies describe toxicity of 7-KC and 7β-OHC towards 
neuroretinal and cerebellar granule cells (Chang & Liu, 1998b; Chang & Liu, 1998a), however the 
concentrations at which these compounds were toxic was 1000 times greater than 
concentrations found in plasma (Zieden et al., 1999) and 100 times greater than in brain tissue 
(Tint et al., 1998). Due to the high concentration of cholesterol in the brain, COPs represent 
potentially important biomarkers for neurodegenerative diseases. 
Figure 1.7 Chemical structure of 7β-hydroxycholesterol and 7-ketocholesterol. These compounds are 
formed by oxygen free radical attack at the 5,6 double bond of cholesterol. 7β-hydroxycholesterol and 7-
ketocholesterol have been previous used as lipid peroxidation biomarkers in plasma and represent 
potentially powerful oxidative stress biomarkers in the brain due to the large concentration of cholesterol 
in this tissue.  
 
1.4 Phytosterols 
 
Phytosterols are plant derived sterols exhibiting a similar structure to cholesterol. Common 
phytosterols found in food are campesterol, β-sitosterol and stigmasterol (Phillips et al., 2005; 
Dreher & Davenport, 2013). Although structurally similar to cholesterol, phytosterols have a 
greater degree of branching on the alkyl chain, and in the case of stigmasterol and brassicasterol 
the presence of a double bond (Figure 1.8). High levels of phytosterols in the diet have been 
14 
 
found to compete with intestinal cholesterol absorption, reducing plasma levels of cholesterol 
(Ikeda et al., 1988; Katan et al., 2003). The reduction of cholesterol solubility in phospholipid bile 
salt micelles in the presence of β-sitosterol demonstrated by Ikeda et al. (1988) is also explained 
by the thermodynamically favourable interaction of phytosterols with micelles (Armstrong & 
Carey, 1987). Dietary phytosterols present a viable option in lowering cholesterol absorption 
from diet, which is also accompanied by increased phytosterol absorption and incorporation 
into various tissues in the body (Plat et al., 2008). Phytosterols are able to cross the BBB and 
have been measured in animal brain tissue (Plat et al., 2008). The long-term cellular effects of 
phytosterols incorporated into the brain have not been established and further studies are 
necessary to examine their impact on human health. 
Figure 1.8 The chemical structure of common phytosterols; campesterol, β-sitosterol, stigmasterol and 
brassicasterol. Phytosterols are produced in plants and share a similar structure to cholesterol, differing 
in the degree of branching and presence of double bonds on the alkyl chain (highlighted). Phytosterols 
are absorbed from food and accumulate in tissues including the brain.    
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1.5 Cholesterol and neurodegenerative disease 
 
Cholesterol is an essential molecule for cellular function; however, excess cholesterol circulating 
in the body can be harmful. It has been established that high levels of cholesterol in the blood 
contributes to a number of diseases, in particular atherosclerosis and cardiovascular disease. 
The influence of altered cholesterol homeostasis in neurodegenerative diseases is however, not 
as well understood. Cholesterol levels have been reported to alter in vitro protein aggregation 
relevant to PD (Bar-On et al., 2008). Several studies have also highlighted altered brain 
cholesterol levels in AD (Mason et al., 1992; Wahrle et al., 2002; Cordy et al., 2003), and may  
influence amyloid beta formation by altering the physical properties of cell membranes (Rojo et 
al., 2006). It is also hypothesised that cellular redistribution of cholesterol without changes in 
total cholesterol levels may play a role in AD (Gibson Wood et al., 2003). Due to conflicting 
reports of cholesterol levels in neurodegenerative brain tissue, the exact influence of altered 
cholesterol homeostasis in neurodegenerative diseases is currently unknown.   
1.5.1 Huntington's disease 
 
HD is an autosomal dominant, progressive, neurodegenerative disease characterised by the 
expansion of a trinucleotide repeat on the N-terminus of the huntingtin protein (HTT). The 
cytosine-adenine-guanine (CAG) repeat, coding for glutamine, is located on exon 1 of the HTT 
gene (MacDonald et al., 1993). Full penetrance of the disease is observed when an individual 
has 42 or more repeats (Brinkman et al., 1997), with 36-41 repeats resulting in incomplete 
penetrance (Kremer et al., 1994; Rubinsztein et al., 1996; Brinkman et al., 1997). Although 
disease symptoms are not associated with a repeat number of 29-35, CAG repeat expansion in 
successive generations is possible (Trottier et al., 1994; Ranen et al., 1995). Expansion of CAG 
repeats occurs almost exclusively during spermatogenesis, causing the appearance of HD in 
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individuals without a family history of the disease. Juvenile onset HD, characterised by a long 
CAG expansion (~100), is also much more likely from paternal inheritance (Kremer et al., 1995).  
1.5.2 Symptoms 
 
HD was previously known as Huntington's chorea due to the involuntary movements exhibited 
by patients (Huntingon, 1872).  Mutant gene carriers show subtle symptoms before clinical 
diagnosis in a period referred to as pre-manifest, pre-symptomatic or pre-diagnostic. Pre-
manifest HD patients have been shown to have dysfunction in tongue force, grip strength and 
finger tapping tasks (Bechtel et al., 2010; Reilmann et al., 2010a; Reilmann et al., 2010b). The 
first overt symptoms of HD  are typically involuntary movements, usually accompanied with 
depression (Kirkwood et al., 2001). Other symptoms include abnormal eye movement (Penney 
et al., 1990) and clumsiness (Kirkwood et al., 2001). During progression there is weight loss 
(Sanberg et al., 1981; Morales et al., 1989; Djousse et al., 2002), cognitive decline, speech 
difficulties and memory loss (Kirkwood et al., 2001). In late stages of the disease, HD patients 
have difficulty swallowing; the aspiration of food into the lungs is a major cause of death in these 
cases (Sorensen & Fenger, 1992). The progression and severity of disease after onset does not 
correlate strongly with CAG repeat length in the range of 40-60 (Squitieri et al., 2002). However, 
the correlation between the age of onset and CAG repeat length is well established (Ranen et 
al., 1995). Rare juvenile cases of HD with 100+ CAG repeats do, however, have accelerated 
progression of the disease (Squitieri et al., 2002).  
1.5.3 Neuropathology 
 
The neuropathological progression of HD was classified in detail by Vonsattel et al. (1985), and 
was adopted to grade HD brain tissue. This revealed the disease progressed from the caudate 
nucleus and putamen (striatum) with degeneration moving in a lateral basal direction. Early 
changes include moderate astrocytosis of the caudate nucleus and putamen in grade I, followed 
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by macroscopic atrophy and neuronal loss in grade II. Neuron loss continues in grade III with 
overt shrinkage of the striatum. Grade IV was classified by extreme shrinkage of the striatum, 
including the globus pallidus. Astrocyte numbers were also increased compared to control at 
this stage in the disease. Brain mass was also found to be negatively correlated to the disease 
grade, with an average 20% reduction in brain mass by grade IV. More sensitive magnetic 
resonance imaging (MRI) techniques have also identified volume reduction in the hippocampus, 
cerebral cortex and amygdala of HD patients, with the cerebellum relatively spared (Rosas et al., 
2003). Along with neuron loss, astrocytosis and increased oligodendrocyte densities are also 
observed in severely affected regions of the HD brain (Myers et al., 1991). 
1.5.4 Huntingtin protein 
 
HTT is made up of >3100 amino acid residues and has a molecular mass of approximately 349 
kDa depending on the length of the CAG repeat (Gil & Rego, 2008). HTT is expressed throughout 
the body, with the highest expression in the brain and testes (Strong et al., 1993; 
Landwehrmeyer et al., 1995). It is localised to a number of subcellular compartments and has 
functions in intracellular trafficking, clathrin mediated endocytosis, transcriptional regulation 
and cell signalling (Harjes & Wanker, 2003; Li & Li, 2004). The protein is believed to be essential 
for early development in mice, as knockout of the HTT mouse homologue (Hdh) is embryonically 
lethal (Leavitt et al., 2001).  
1.5.5 Toxicity of mutant huntingtin 
 
The exact role of the CAG mutation on the HTT protein in HD pathogenesis is still debated. It is 
not completely clear if mutant huntingtin (mHTT) has a toxic gain of function or if a loss of 
function is responsible for disease, or possibly a combination of both factors. The heterozygous 
disruption of the HTT gene does not cause a HD phenotype in human cases, suggesting the loss 
of function in one allele is not entirely responsible for disease pathology (Ambrose et al., 1994). 
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Expression of normal length HTT can reduce the toxicity of mHTT in mice (Leavitt et al., 2001), 
also suggesting compensation for loss of function. Another confounding finding is that human 
mHTT can rescue the embryonic lethality of the Hdh knockout mouse (Leavitt et al., 2001). 
However, this may simply be a reflection of the role of HTT in developmental processes, similar 
to the human disease where patients develop normally, only manifesting symptoms later in life.  
Another debated hypothesis of mHTT toxicity involves protein aggregation. Aggregation of 
mHTT is a hallmark of HD, however, this may not be an accurate predictor of cell death. 
Aggregate formation is higher in cortical neurons, which are relatively spared compared to the 
selectively vulnerable striatal neurons that contain fewer aggregates (Kuemmerle et al., 1999). 
In vitro studies investigating mHTT aggregation have also reported neuronal death without the 
formation of inclusions, and that cells forming inclusions had reduced risk of death (Arrasate et 
al., 2004). In this study, cells forming inclusions had reduced levels of mHTT in the rest of the 
cell, suggesting that inclusion formation may be protective. Although inclusions may not be 
directly linked to cell death, other lines of evidence suggest that proteasomal disruption in cells 
caused by mHTT aggregates may be neurotoxic (Jana et al., 2001; Waelter et al., 2001). It is also 
possible that undiscovered neurotoxic aggregates are too small for detection by light microscopy 
as suggested by Bates (2003).  
1.5.6 Mouse models of Huntington’s disease 
 
Prior to the HTT gene identification in 1993 (MacDonald et al.), the primary rodent models of 
HD were based on the production of brain lesions by neurotoxin injections into the striatum. 
Injection of glutamic acid, kainic acid (McGeer & McGeer, 1976; Schwarcz & Coyle, 1977)  and 
quinolinic acid (Beal et al., 1986) replicated some of the biochemical changes observed in the 
human HD brain, and highlighted a potential involvement of NMDA mediated excitotoxicity in 
HD pathogenesis. Since the identification of the HTT gene and the expanded CAG repeat that 
causes HD, genetic models were generated for more accurate replication of the human 
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condition. Common mouse models have used multiple approaches to model HD, including 
knock-in models and transgenic models expressing full length and truncated forms of human 
HTT. 
The R6 mouse models are widely used to study HD pathology and therapeutic interventions. 
These mice were generated by the insertion of a truncated form of human HTT that codes for a 
CAG expansion and 67 amino acids of exon 1 human HTT under the human promoter (Mangiarini 
et al., 1996). The R6/1 mouse expressing truncated HTT with approximately 115-120 CAG 
repeats, and the R6/2 with 140-150 repeats, are the best characterised variants of this model. 
R6 mice mimic several pathological hallmarks including early striatal degeneration, and physical 
phenotypes of HD such as motor dysfunction and uncontrolled movements (Mangiarini et al., 
1996). These features and the relatively short disease onset are reasons why this model has 
been widely used in the study of HD. Instability of the CAG repeat between generations can 
result in CAG expansion. This can cause variation in the specific CAG repeat length between 
colonies (Mangiarini et al., 1997). Selectively breeding mice without expanded repeats is able to 
control CAG expansion in subsequent generations.  
A model expressing full length expanded human HTT was also generated using a yeast artificial 
chromosome (YAC). These mice expressing HTT with a normal number of repeats (18), and 
expanded CAG repeats (46, 72, and 128), have also been characterised to have striatal 
degeneration, motor deficits, exhibit motor abnormalities and mHTT aggregation (Hodgson et 
al., 1999; Slow et al., 2003). 
Knock-in of a CAG repeat expansion into the Hdh gene has also been used to generate HD models 
that express an expanded form of mouse HTT under endogenous transcriptional control 
(Wheeler et al., 1999; Wheeler et al., 2000). Heterozygous and homozygous knock-in mice 
expressing 92 (HdhQ92) and 111 (HdhQ111) CAG repeats have been commonly examined in 
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previous literature; knock-in models also exhibit degenerative pathologies (Wheeler et al., 
2002). 
There are benefits and drawbacks in each model; this includes the severity of the disease in mice 
where R6 models are most representative due to the long CAG repeat that causes a relatively 
rapid onset of symptoms. HTT sequences found in transgenic models (R6 and YAC) however, 
become randomly inserted into the genome and therefore do not have the endogenous mouse 
promoter as well as the endogenous protein still being expressed. Therefore models that knock 
in expanded CAG repeats into the mouse HTT sequence (e.g. HdhQ111) more accurately 
represent the disease from a genetic perspective. 
1.5.7 Cellular and fly models of Huntington’s disease 
 
Several models of HD have been generated in Drosophila where an expanded fragment of exon 
1 human HTT is expressed (Httex1pQ93 and Htt128Q). These models have been used in several 
studies as they provide a number of phenotypes including photoreceptor degeneration, motor 
abnormalities as well as reduced lifespan (Steffan et al., 2001; Lee et al., 2004). A number of cell 
models expressing forms of expanded HTT have been developed since the identification of the 
affected gene. A model developed in yeast that expresses exon 1 HTT with 75 CAG repeats has 
been used to assess HTT aggregation (Ehrnhoefer et al., 2006). A model in a neuronal cell line 
(PC12) developed to express exon 1 HTT has also been used to examine the effects of mutant 
huntingtin on extracellular signalling (Aiken et al., 2004; Maher et al., 2011). 
1.5.8 Alteration of cholesterol homeostasis in Huntington's disease 
 
While it is not fully understood how the polyglutamine expansion causes cellular dysfunction in 
HD, mHTT has been identified to alter membrane order (del Toro et al., 2010) and HTT-
phospholipid interactions (Kegel et al., 2009).  Despite the genotypic identification of mHTT 
carriers, there is a lack of reliable biomarkers to predict HD progression or effectiveness of 
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therapies. Several studies have identified that cholesterol synthesis and metabolism in HD cell 
lines and animal models is significantly disturbed and suggest these to be potential biomarkers 
of HD (Valenza et al., 2005; Valenza et al., 2007b; Valenza et al., 2010), but the mechanisms and 
metabolic pathways affected have not been fully examined in human or mouse models of HD. 
1.5.9 Alterations of cholesterol biosynthesis in Huntington's disease 
 
Gene transcription profiles of HTT-inducible cells identified a possible dysregulation of lipid 
homeostasis in HD (Sipione et al., 2002). This study reported the reduction of several mRNAs 
coding for cholesterol biosynthetic enzymes, including that of 7-dehydrocholesterol reductase 
(DHCR7), the final enzyme of the Kandutsch-Russell pathway (Sipione et al., 2002). Further 
investigation into HD fibroblasts, R6/2 mice and HD post mortem brain tissue, identified a 
consistent reduction of several other mRNAs coding for enzymes in the cholesterol synthetic 
pathway (Valenza et al., 2005). The active nuclear form of SREBP was also found to have a 50% 
reduction in human HD fibroblasts and in brain tissue of mice (Valenza et al., 2005). Brain lipid 
analysis of R6/2 and YAC 128 mice has also revealed a consistent reduction in the cholesterol 
synthetic precursors lathosterol and lanosterol (Valenza et al., 2007a; Valenza et al., 2007b). 
Further association of brain cholesterol synthesis and mHTT was demonstrated by a CAG repeat 
dependant reduction of lathosterol in YAC mice, and reduced levels of lathosterol in the 
homozygous knock-in mouse (HdhQ111/111) compared to the heterozygous knock-in (Valenza et 
al., 2010). The current understanding of cholesterol biosynthesis in HD has been previously 
limited by the analysis of a small number of synthetic precursors in a pathway with over 20 steps. 
Analysis of a wider range of synthetic precursors is likely to provide a more complete story of 
the potential changes occurring in HD. In addition to this, a detailed analysis of cholesterol 
synthetic precursors in human post mortem tissue is yet to be reported in the literature.  
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1.5.10 Cholesterol levels in Huntington's disease 
 
Although a significant reduction of cholesterol biosynthetic precursors were observed 
previously in these mouse models, the total level of brain cholesterol remains relatively stable. 
Unchanged levels of cholesterol were observed in the striatum or whole brain of R6/1 and R6/2 
models (Valenza et al., 2007b; del Toro et al., 2010), while only a small reduction in brain 
cholesterol levels were observed in the HdhQ111, YAC72 and YAC128 mice (del Toro et al., 2010; 
Valenza et al., 2010). A previous study examining cholesterol levels in human HD post mortem 
tissue identified an increase in cholesterol, however the sample size (n = 3) was too small to 
draw a firm conclusion regarding cholesterol levels in human HD brain (del Toro et al., 2010). 
Mechanisms to eliminate cholesterol may also be downregulated to maintain constant 
cholesterol levels in the brain, highlighting the potential involvement of altered cholesterol 
metabolism in HD. 
1.5.11 Cholesterol metabolic alterations in Huntington's disease 
 
The major elimination product of cholesterol in the brain, 24-OHC, is also believed to have an 
important role in cholesterol homeostatic regulation in the brain. Reduced brain levels of 24-
OHC have been consistently demonstrated in multiple rodent models of HD, including knock-in 
models and transgenic models expressing truncated and full length HTT (Valenza et al., 2007a; 
Valenza et al., 2010). Plasma measurements of 24-OHC in the YAC 128 model reflect the reduced 
level in brain (Valenza et al., 2007a); plasma studies in HD patients have also identified reduced 
24-OHC levels in symptomatic individuals (Leoni et al., 2008; Leoni et al., 2013). Since CYP46A1 
expression is primarily localised to neurons (Lund et al., 1999), it has been suggested that 
generation of 24-OHC (as measured in plasma) is a marker of metabolically active neurons in the 
brain (Bjorkhem, 2006). Recent evidence suggests that changes in CYP46A1 and 24-OHC brain 
levels may play a role in neurodegeneration (Kolsch et al., 2002; Papassotiropoulos et al., 2003; 
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Brown et al., 2004; Tian et al., 2010), however, the exact role this might play in HD pathogenesis 
has not been established. Comprehensive examination of cholesterol synthesis and metabolism 
in human HD, beyond plasma biomarkers is currently lacking in the literature.  This represents a 
significant gap in the current knowledge that would help confirm the validity of rodent HD 
models examining this particular metabolic pathway in relation to HD pathology.  
1.5.12 Proposed mechanisms altering cholesterol homeostasis in Huntington's disease 
 
Consistent demonstration of cholesterol homeostatic perturbation in HD models has led to the 
identification of several associations of HTT and mHTT with cholesterol synthetic regulation. A 
hypothesised mechanism of reduced cholesterol biosynthesis in HD involves an interaction of 
mHTT with SREBPs (Kaltenbach et al., 2007). It has been suggested that the CAG expansion 
causes a diminished capacity of mHTT to translocate SREBP to the nucleus where it has functions 
to activate cholesterol synthetic genes (Guan et al., 1995; Lloyd & Thompson, 1995). HTT is 
known to have cellular trafficking properties, and this hypothesis is consistent  with the finding 
that transgenic HD cells contain less active nuclear SREBPs than controls (Valenza et al., 2005).  
Another factor causing reduced cholesterol synthesis is related to decreased levels of brain-
derived neurotrophic factor (BDNF) that have been observed in human HD and HD mouse 
models (Zuccato et al., 2001; Spires et al., 2004; Zuccato et al., 2005). BDNF is known to increase 
cholesterol content of lipid rafts in vitro and increase neurotransmitter release dependant on 
BDNF-elicited cholesterol (Suzuki et al., 2007). In vivo, abnormal synaptic plasticity in R6/2 mice 
(Murphy et al., 2000; Picconi et al., 2006) may also be related to dysfunction of BDNF-mediated 
cholesterol levels in the cell. 
With the complex control of cholesterol homeostasis in the brain, it is likely that other 
undiscovered factors, potentially involved with cholesterol metabolism, may be involved in 
altering cholesterol synthesis in the presence of mHTT. Further investigation into cell-type 
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specific cholesterol homeostatic alterations will also contribute to understanding how these 
altered pathways affect whole tissue.   
1.6 Therapeutics in Huntington's disease mouse models 
 
There is currently no cure or effective therapies for the treatment of HD. Due to the late onset 
and possibility of early identification of mHTT carries, there is a relatively long timeframe 
(decades) to implement potential therapies for HD suffers. It also allows for close study of the 
manifestation of neurodegenerative pathologies that may be relevant to understanding 
'sporadic' neurodegenerative diseases such as AD. Mouse models of HD, particularly the R6 
models, have been used to examine several therapeutic strategies including dietary 
supplementation (Ehrnhoefer et al., 2006; Maher et al., 2011), tissue transplantation (van Dellen 
et al., 2001), drug treatments (Ferrante et al., 2002; Schiefer et al., 2002) and gene therapies 
(Popovic et al., 2005). This thesis will focus on the use of environmental enrichment (EE) and 
dietary supplementation in HD.  
1.6.1 Environmental enrichment and Huntington's disease  
 
Increased cognitive activity is believed to be a factor in reducing the risk of developing dementia 
and neurodegenerative diseases later in life (Karlsson et al., 1988; Stern et al., 1994; Evans et 
al., 1997). Substantial evidence also suggests that increased physical, sensory-motor and 
cognitive activity associated with EE has positive effects in the brain to improve memory, 
cognition and reduce the severity of neurodegenerative phenotypes in animal models 
(Wainwright et al., 1993; Kempermann et al., 2002; Jankowsky et al., 2005; Lazarov et al., 2005). 
Recently it has been discovered that EE may also be beneficial in HD.  Studies in mouse models 
of HD illustrate that EE delays onset of physical phenotypes (van Dellen et al., 2000), improves 
motor co-ordination (Hockly et al., 2002; Spires et al., 2004) and improves survival (Carter et al., 
2000), compared to mice with standard housing. Rodent studies utilising EE usually involves a 
25 
 
larger cage with a greater number of animals, the addition of novel objects (toys), tunnels, 
additional nesting materials and in some cases running wheels (van Praag et al., 1999; van Dellen 
et al., 2000; Hockly et al., 2002; Hockly et al., 2003; Spires et al., 2004). A study in human 
populations has also identified that environmental factors also influence the age of onset of HD 
(Wexler & Res, 2004). Increased neurogenesis in the hippocampus has been identified to explain 
some of the positive effects on memory seen in EE animal studies (van Praag et al., 1999; Lazic 
et al., 2006), however specific mechanisms improving the disease severity in HD, which involves 
striatal atrophy, requires further investigation. Whether cholesterol homeostatic perturbations 
observed in mouse models are altered by EE is currently unknown. 
1.6.2 Flavonoid supplementation 
 
Flavonoids are phenolic micronutrients in foods derived from plants. A large area of study has 
identified multiple health benefits of dietary flavonoids with potential beneficial effects in 
cardiovascular diseases (Nakagawa et al., 1999; Ruel et al., 2005) and cancer (Murphy et al., 
2003; Ferguson et al., 2006). Recently dietary supplementation of flavonoids and other plant 
derived phytochemicals have revealed an influence on the brain, including positive effects on 
cognitive function in human studies (File et al., 2001; Duffy et al., 2003; Casini et al., 2006) and 
improvement of neurodegenerative phenotypes in animal models of AD (Li et al., 2015; 
Nakajima et al., 2015; Sabogal-Guaqueta et al., 2015). 
1.6.2.1 Anthocyanins and Huntington's disease 
 
Anthocyanins are a class of flavonoid that have the backbone structure of an anthocyanidin 
(Figure 1.9), with the addition of a glycoside (O-linked sugar). Anthocyanins found in plants are 
primarily 3-glycosides of anthocyanidins. In addition to the location and species of sugar, 
different structures of anthocyanins are derived from the position of hydroxy and methoxy 
functional groups on the anthocyanindin backbone. Berries, including blueberries, blackberries, 
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and blackcurrants, are rich in a variety of different anthocyanins; several predominant species 
in these berries are cyanidin 3-glucoside, cyanidin 3-rutinoside, dephinidin 3-glucoside and 
delphinidin 3-rutinoside (Figure 1.10) (Wu & Prior, 2005; Scalzo et al., 2008). Dietary 
supplementation with berry extracts (BE) has been previously shown to improve motor and 
cognitive function in rodents during ageing (Joseph et al., 1998; Casadesus et al., 2004; Galli et 
al., 2006; Duffy et al., 2008). Fruit extracts that are rich in phenolic phytochemicals have also 
been demonstrated to ameliorate the disease pathology of a cell, fly and mouse model of HD 
(Ehrnhoefer et al., 2006; Maher et al., 2011). However, the specific benefits of BE 
supplementation, rich in anthocyanins, has not been previously investigated in HD models. 
While the benefits of flavonoids and BE supplementation are measureable from the physical 
phenotype and biological markers, the exact mechanisms through which these phytochemicals 
confer benefit is not well established, particularly in the context of HD neurodegeneration.  
 
 
 
 
 
 
 
Figure 1.9 The basic chemical structure of an anthocyanidin. Anthocyanins share the same backbone 
structure with the addition of a glycoside, commonly at the R3 position. Hydroxy and methoxy functional 
groups are also typically present on the aromatic rings.  
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Figure 1.10 The chemical structure of anthocyanins predominantly found in berries (blueberry, 
blackberry, blackcurrant). Different structures of anthocyanins arise from the arrangement of hydroxy 
and methoxy functional groups on the anthocyanidin backbone, and the location and species of sugar that 
is attached to the molecule. In the pictured molecules the glycosides are glucose and rutinose.  
 
1.7 Biological markers of neurodegeneration 
 
Diagnosis is an essential process in order to apply the correct treatment to combat disease. 
Currently there is a need for diagnostic tests for neurodegenerative diseases, not only due to 
their inevitably fatal nature, but also due to the increasing prevalence of these diseases. Ideally 
biomarkers can be obtained from saliva, urine or blood as these require little or no invasive 
procedures to obtain. Although more invasive procedures such as CSF samples or a brain biopsy 
may result in a faster, more sensitive diagnosis, the stress on the body is usually unjustifiable. In 
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the case of HD where mutant carriers can be easily identified, biomarkers are of most benefit to 
therapeutic trials in assessing the efficacy of treatment. In human patients a plasma biomarker 
is ideal; however, examining post-mortem brain tissue from human and animal models may give 
insight into changes that can be measured in the circulation. Post mortem brain biomarkers are 
also useful in assessing treatments in animal trials where brain tissue is available from test 
subjects. Since HD, as well as other neurodegenerative diseases have a significant association 
with altered cholesterol metabolism in the brain, cholesterol metabolites and synthetic 
precursors are potentially useful to track the progression of disease. 24-OHC levels in brain 
tissue and plasma reflect turnover of cholesterol in the brain, however further investigation into 
this metabolite is required before its clinical usefulness can be established. This is due to 24-
OHC plasma levels being variable in humans, dependant on hepatic metabolism and brain:liver 
mass ratio (Bretillon et al., 2000a). It is known that 24-OHC is reduced in plasma of HD patients 
and correlates to volume loss in the striatum (Leoni et al., 2008); however longitudinal studies, 
that would be most effective in tracking brain metabolic dysfunction over time, currently do not 
exist. Little is known about the concentration and location of other cholesterol synthetic 
precursors and metabolic products in the HD brain, these being potentially powerful indicators 
of disease severity and progression. Further investigation into biomarkers that correlate well 
with HD severity will clearly increase the current understanding of fundamental mechanisms of 
HD pathology and invariably accelerate the search for effective therapies. 
 
1.8 Aims 
 
The aim of this thesis was to investigate the involvement of brain cholesterol homeostasis in HD, 
and identify sterol-related biomarkers associated with the disease using a novel and highly 
sensitive analytical technique. We aimed to comprehensively quantify changes in brain 
cholesterol metabolites and synthetic precursors during the progression of HD, by investigating 
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the R6/1 mouse model over 5 stages of the disease. We also aimed to investigate the 
effectiveness of EE and BE supplementation to attenuate the physical phenotype and 
cholesterol homeostatic perturbation in the R6/1 model. Finally we aimed to identify changes 
to brain cholesterol homeostasis in human HD by conducting a comprehensive analysis of 5 
regions of HD post mortem brain tissue. 
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Chapter 2                                               
General materials and methods 
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2.1 Methods of sterol analysis  
 
The specific method of sterol analysis used in this thesis is a novel and important aspect that 
requires further explanation. Qualitative and quantitative analysis of chemical compounds is key 
to identifying and understanding reactions in biological systems. Different analytical methods 
have various strengths and weaknesses depending on compounds analysed, concentration of 
the analytes and the speed and expense of analysis. Only a small number of the established, and 
well characterised cholesterol metabolic products and synthetic precursors have been analysed 
in vivo and in vitro, therefore data pertaining to a limited number of sterols has been discovered. 
A number of techniques have been previously employed, however, sensitivity is crucial for the 
analysis of cholesterol metabolites and synthetic precursors that are usually found at 
concentrations 103-106 times less than cholesterol (Micheletta & Iuliano, 2006). 
Proton nuclear magnetic resonance has been used to quantify cholesterol in bile acids 
(Srivastava et al., 2005). Although successful, this method is limited to highly abundant sterols 
(µ-mg.mL-1), and may not be sensitive enough for low level intermediates and metabolic 
products that typically require measurement of ng.mL-1 concentrations (Dzeletovic et al., 1995).  
Gas chromatography coupled with mass spectrometry (GC-MS) has been demonstrated as a 
sensitive analytical tool in a study identifying 9 cholesterol oxides in plasma (Dzeletovic et al., 
1995). By using deuterated internal standards corresponding to each analyte, the study was able 
to achieve a high level of precision, with the ability to measure concentrations of 0.5-6 ng.mL-1. 
This method has been employed in a number of studies that examine the concentration of 24-
OHC and 27-OHC in plasma (Lutjohann et al., 1996; Bjorkhem et al., 1998). These metabolites 
are found in higher abundance relative to other known cholesterol metabolites (Dzeletovic et 
al., 1995), and thus sensitivity is not a limiting factor. In order to measure the low level 
intermediates involved in synthesis, metabolic pathways and mechanisms of oxidative damage, 
a higher degree of sensitivity is required.  
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2.1.1 Triple Quadrupole GC-MS 
 
Previously, gas chromatography and mass spectrometry has been used separately for qualitative 
and quantitative analysis. However, when coupled, GC-MS presents a powerful analytical tool. 
Triple quadrupole GC-MS (GC-MS/MS) operates on the same fundamental principles of a single 
quadrupole GC-MS, however, structurally it has two quadrupoles aligned in series, separated by 
a collision cell. Specific ions (formed by analyte ionisation) can be filtered by the first quadrupole, 
fragmented in the collision cell, and then filtered again in the third quadrupole. The ability to 
filter specific ions after two fragmentations gives high specificity towards the analyte of interest 
and often increases sensitivity due to an improved signal to noise ratio. GC-MS/MS has not been 
widely used as an analytical method for the detection of cholesterol synthetic precursors, 
metabolites and oxidation products, therefore the ion transitions required for analysis has not 
been previously established. The process of developing a multiple reaction monitoring (MRM) 
method for GC-MS/MS is purely experimental, as ion formation and fragmentation is dependent 
on chemical structure and difficult to be calculated theoretically. MRM transitions involve the 
formation of a precursor ion during ionisation, followed by fragmentation in the collision cell to 
form a second fragment known as the product ion. Precursor ions are fragmented by the 
collision with inert gas, typically N2 or Ar, at a specified collision energy (CE) (Hopfgartner et al., 
2004). High CEs commonly form small mass fragments; these fragments can have a higher signal 
than larger mass fragments, however they are less specific to the compound being measured 
(Hopfgartner et al., 2004). One ion transition is used for quantitation, however to increase 
confidence in identification, one or more 'qualifier' ion transitions can also be monitored. The 
presence and ratio of specific qualifier ion transitions is used to identify and measure 
compounds with a high degree of specificity.  With this high sensitivity, GC-MS/MS has  the 
potential to measure in the femtogram range (Agilent, 2008). 
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It is clear that new methods need to be established that have the ability to reliably measure low 
concentrations of sterols before any certainty can be reached regarding cholesterol metabolic 
and synthetic pathways and how they are disturbed in HD. This is especially crucial for the 
measurement of biomarkers which may only show small changes in concentration. 
 
2.2 Materials  
Materials  
Desmosterol-d6, zymosterol-d5, zymosterol and lanosterol-d6 were obtained from Avanti lipids 
(Alabaster, AL, USA). Tert- butylhydroxytoluene (BHT), cholesterol, -cholestane, 7–
hydroxycholesterol, 7-dehydrocholesterol and 7-ketocholesterol and squalene were from Sigma 
(St. Louis, MO, USA). Lathosterol, lanosterol, desmosterol, 27-hydroxycholesterol, campesterol, 
brassicasterol, -sitosterol and stigmasterol were obtained from Steraloids (Newport, RI, USA). 
Campesterol-d3, 7–hydroxycholesterol-d7, lathosterol-d4, -sitosterol-d7 and 7-
ketocholesterol-d7 were purchased from CDN Isotopes (Quebec, Canada). 27-
hydroxycholesterol-d5, 24-hydroxycholesterol and 24-hydroxycholestero-d7 were from Medical 
Isotopes, Inc. (Pelham, AL, USA). Squalene-d6 and 24,25-dihydro lanosterol-d6 were obtained 
from Toronto research chemicals (TRC, Ontario, Canada). All standards obtained were of the 
highest purity (>95%). Methanol, hexane, methyl tert-butyl ether (MTBE), acetonitrile, toluene, 
formic acid and NaOH were purchased from Ajax Finechem (Thermo Fisher Scientific, AU). 
CUQAX223 UCT Clean-Up QAX2 solid phase extraction columns and N,O-bis(trimethylsilyl) 
trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMCS) was purchased from PM 
Separations (Qld, Australia). 
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2.3 Methods 
 
2.3.1 Mice  
 
Transgenic R6/1 male mice were provided by Professor Anthony Hannan (The Florey Institute, 
Melbourne) and bred with CBB6 (CBA x C57/B6) F1 female mice at Australian Bio-Resources 
(Mossvale, Australia). Mice were genotyped at 4 weeks from ear clippings. Equal numbers of 
male and female R6/1 and wild type (WT) littermates were transported to the University of 
Wollongong animal housing facility at the age of 5 weeks. Unless otherwise stated, mice were 
housed in standard small rodent cages with a wire lid (30 cm x 12 cm x 13 cm), containing 
sawdust, pine shavings and a PVC tube. Mice were provided with standard rodent diet ("rat & 
mouse nut", Vella Stock Feeds, NSW, Australia) and water available ad libitum. All procedures 
that were undertaken conformed to the standards of the University of Wollongong ethics 
committee (ethics approval number: AE 13/20). 
2.3.2 RotaRod 
 
A RotaRod apparatus (TSE systems, Bad Homberg, Germany) was used to measure motor 
performance of mice. The RotaRod used consisted of a single rod (30 mm diameter, hard plastic 
with longitudinal grooves) divided into 5 lanes, allowing the simultaneous testing of multiple 
animals. Mice were acclimatised to the RotaRod over two days before initial testing. During the 
acclimatisation, mice were allowed to balance on the RotaRod without any rotation for 5 
minutes. The RotaRod was then operated at a slow speed of 4 RPM for 1 minute. Following this, 
the accelerating testing program was run (4 RPM for 5 sec followed by a linear acceleration from 
4 to 40 RPM over 200 sec). During the testing period mice from the same cage were placed on 
the rod before the accelerating testing program was initiated. The latency to fall was measured 
automatically by the RotaRod using light beam sensors. Once all mice had fallen from the rod 
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the procedure was repeated (5 times in total) and the average of the two longest run times was 
recorded for analysis. The RotaRod apparatus was cleaned with 70% ethanol and dried between 
test subjects. Testing was performed between 9 am to 11 am over the testing period.  
2.3.3 Hind paw clasping 
 
The hind paw clasping phenotype was tested by suspending the mouse by the tail and applying 
a light tap to the animals back with a finger (also known as tail test or tail suspension test). Mice 
that clasped both hind paws tightly to their body were considered to have a complete clasp 
phenotype. Mice that clasped one paw or both paws in an interrupted manner were considered 
to have a "half clasp" phenotype. 
2.3.4 Tissue collection 
 
At specific experimental time points mice were euthanised using slow flow CO2 asphyxiation. 
Perfusion of the mouse was performed by perforating the right atrium and injecting ice cold 1 x 
PBS into the left ventricle until the perfusate was clear (approximately 20-30 mL). The head was 
then excised and the whole brain removed and weighted. Cerebral cortex and striatum was 
dissected and snap frozen in liquid N2 and stored at -80oC prior to analysis. Brain dissection was 
performed on an aluminium block on ice.  
2.3.5 Lipid extraction 
 
Frozen brain tissue (~5-10 mg) was weighed directly into a 0.5 mL polypropylene tube containing 
5 Zircosil® ceramic beads (1.3 mm) (Klausen Pty Ltd, NSW, Australia), 150 µL methanol (0.01% 
BHT) and internal standards (4oC). Tissue was homogenised at 4°C using a Precellys 24 
homogeniser (Bertin Technologies) (2 x 20 s at 5,000 rpm) and the homogenate was transferred 
to a clean glass vial. The tube and ceramic beads were washed with 100 µL methanol (4°C) and 
was added to the homogenate with 250 µL of NaOH (1 M). The sample was hydrolysed at room 
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temperature for 16 h in the absence of light and then acidified with 330 µL of 1 M formic acid. 
The sample was made up to a final volume of 3 mL by the addition of 2.2 mL milliQ water. The 
final solution had a methanol concentration of 8% (v:v) and pH 4.5. Solid-phase extraction (SPE) 
was carried out on a 200 mg mixed C8/anion exchange quaternary amine column (CUQAX223, 
UCT Inc.) that had been preconditioned with 2 mL methanol and then 2 mL 40 mM formic acid 
buffer (pH 4.5). The lipid extract was loaded and the column washed with 2 mL methanol in 40 
mM formic acid (40:60). The SPE column was dried with N2 gas flow for 5 min. Sterols and 
oxysterols were eluted with 2 mL hexane followed by 2 mL hexane/MTBE (50:50).  
 
2.3.6 Triple quadrupole GC-MS sterol analysis 
 
The sterol/oxysterol fraction was dried under N2 gas flow at 37°C and derivatised by the 
addition of 20 µL acetonitrile and 20 µL BSTFA + 1% TMCS  for one hour at 37oC. Samples were 
dried under N2 and immediately reconstituted in 40 µL toluene for GC-MS/MS analysis. 
Selective reaction monitoring (SRM) analysis of sterols/oxysterols was carried out on an 
Agilent 7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC 
system gas chromatograph. A 20 m long Rxi-5sil MS column (Restek corp., Bellefonte, PA, USA) 
was used for chromatography. Analysis of all compounds except cholesterol was performed in 
a single chromatographic run using a splitless injection. The GC parameters used were as 
follows: Initial temperature of 200oC to 273oC at a rate of 50oC/min. This was followed by an 
increase to 300oC at a rate of 2.25oC/min. The flow rate was 0.8 mL/min. The mass 
spectrometer source temperature was 280oC with an electron energy of -60 eV. Cholesterol 
was quantified using the internal standard α-cholestane in a separate injection and 
chromatographic run using a 1:30 split ratio. The GC parameters used were as follows: Initial 
temperature of 240oC to 305oC at 50oC/min. This was held for 6 min. The flow rate was 1 
mL/min. The mass spectrometer source temperature was 280oC with an electron energy of -70 
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eV. Quantification was performed by Agilent Masshunter Quantitative software (V B.05.00) by 
comparison of specific SRM transitions of each compound with their corresponding heavy 
isotopes and using relative response factor calibration. A typical chromatogram of each analyte 
measured in mouse brain tissue is presented in Figures 1-2. Relative molar response factors of 
all analytes were calculated from calibration curves constructed from 5 different 
concentrations of authentic oxysterol mixed with deuterated standards in triplicate. The 
assayed concentrations - sterols/oxysterols (0.1-300 ng) and cholesterol (25 to 150 ug) covered 
the range expected from brain tissue. The linearality of standard curves was excellent as 
determined by simple linear regression (r2 > 0.985). Peak area of a single target transition was 
used for quantification, with at least one other transitions used for qualification. The 
calibration curve for each compound was constructed with the lowest calibration being at least 
5-10 fold lower than the analyte measured in the sample. No significant matrix effects that 
impacted on analysis were detected. This method has been fully validated for reproducibility, 
accuracy and sensitivity according to International Committee for harmony guidelines 
(International Council for Harmonisation, 2005). Method validation was performed on 6 mg 
tissue aliquots of a single pool of mouse cortex homogenate (60mg/ml), that was spiked with 
different concentrations of sterol. Percent recovery ranged between 89-104 %. Intra and inter 
day assay CV % was 0.1 - 7.9 and 1.5 – 8.1 respectively (Jenner, A.M. 2015, unpublished data). 
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Figure 2.1 Typical chromatograms of sterol compounds analysed by triple quadrupole GC-MS. These 
chromatograms are representative of lipid extracted from mouse striatum. 
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Figure 2.2 Typical chromatograms of sterol compounds analysed by triple quadrupole GC-MS. These 
chromatograms are representative of lipid extracted from mouse striatum. 
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Chapter 3                                              
Association of cholesterol metabolism 
with Huntington's disease progression in 
R6/1 transgenic mice 
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3.1 Introduction 
Significant research has been invested into determining HD pathology that involves a number of 
neurophysiological changes that manifest as behavioural, motor and cognitive impairments. 
These changes have been classified over the progression of the disease in humans and in a 
limited number of mouse models. Distinct biochemical alterations are also present in the HD 
brain. Among these changes is a defect in cholesterol biosynthesis and metabolism that has been 
consistently demonstrated in several mouse models. These models include mice expressing an 
expanded fragment of human HTT (R6/2), full length human HTT (YAC) and expanded mouse 
hungtingtin (hdhQ111). Due to the complexity of the cholesterol synthetic pathway (Bloch, 1965), 
previous studies have only measured a small number of synthetic intermediates and are unable 
to describe the full extent of the alterations that occur. 
In this chapter the R6/1 mouse model expressing a CAG expanded exon 1 of human HTT (~115-
120 repeats) was characterised in terms of cholesterol synthetic and metabolic changes. Physical 
phenotypic changes were also examined including, impaired motor performance, weight loss, 
reduced brain mass and involuntary clasping. Analysis of multiple time points and brain regions 
aimed to establish when specific alterations to the cholesterol synthetic and metabolic pathways 
occur, and the potential influence these have in the disease. A comprehensive analysis of sterol 
compounds was also undertaken to identify any potential biomarkers associated with HD in R6/1 
mice, to be used for future studies.  
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3.2 Materials and Methods 
 
Materials: Materials used in this study are listed in 2.2.  
Mice: R6/1 mice were generated as outlined in 2.3.1. Male and female mice (5-6 per group) were 
housed in cages of 4-5 mice, with at least 2 mice of each genotype per cage. Standard laboratory 
housing was provided (sawdust, pine shavings and a single PVC tube) with standard rodent diet 
(see 2.3.1) and water available ad libitum. Mice were acclimatised over 1 week and this included 
brief handling and weighing. All animal experiments were conducted with approval from the 
University of Wollongong ethics committee (ethics number AE 13/20). 
Body weight: Mouse weight was recorded every 4-5 days from 7 weeks of age until sacrifice. 
Hind paw clasping: Hind paw clasping was tested every 5-10 days following the procedure 
outlined in 2.3.3.   
RotaRod: Motor performance was measured using the RotaRod protocol outlined in 2.3.2. The 
RotaRod performance of mice was tested at 6, 11, 15, 19 and 23 weeks of age.  
Tissue collection: Mice were sacrificed at 5 time points (6, 12, 20, 24 and 28 weeks) using slow 
flow CO2 asphyxiation. Brain tissue was dissected and collected as described in 2.3.4. 
Lipid extraction and GC-MS/MS analysis of sterols: Quantification of cholesterol synthetic 
precursors, metabolites, oxidation products and phytosterols was performed as outlined in 2.3.5 
and 2.3.6. 
Statistical Analysis: Linear regression analysis was used to identify the rate of weight gain 
between genotypes and identify the relationship between age and sterol changes in mice. A 2-
way ANOVA was used to analyse RotaRod performance, body weight, brain lipid and brain mass 
data. Bonferroni post-tests were used to compare means at individual time points.  A student’s 
t test was also used to compare means at individual time points in the sterol data. P < 0.05 was 
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considered significant. All analyses were performed in Graphpad PRISM v5.0 (Graphpad 
Software Inc., USA). 
 
3.3 Results 
 
3.3.1 Physical phenotype 
 
The cohort of R6/1 and WT littermates housed until 28 weeks of age (n = 5 per genotype and 
sex) were tested periodically for physical changes that characterise the progression of the HD 
phenotype. These results are represented in Figures 3.1, 3.2 and 3.3.   
3.3.1.1 Weight loss in R6/1 mouse 
 
Mouse body weight was recorded every 4-5 days (Figure 3.1); male and female R6/1 body weight 
was significantly reduced compared to WT mice over the course of the study (p < 0.0001). The 
mean body weight of R6/1 mice did not increase after 16 weeks of age in males, and 19 weeks 
in females. Prior to weight loss (7-19 weeks) the rate of weight gain was significantly less in 
female R6/1 mice compared to WT (p = 0.00012). No significant difference in the rate of weight 
gain was detected between male R6/1 and WT mice in the 6-16 week period (p = 0.073). By the 
28 week time point the average weight increase in R6/1 mice from the earliest measurement (7 
weeks) was 8% in males and 19% in females.  
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Figure 3.1 Weight loss in R6/1 mice during HD progression. R6/1 mice had significantly reduced body 
weight compared to WT over the course of the study (p < 0.0001) (2-way ANOVA). The R6/1 weight loss 
phenotype is more severe in male mice compared to females. Male R6/1 mice began to lose weight after 
16 weeks compared to 19 weeks in females.  The average weight gain over 28 weeks was less in male R6/1 
mice (8%) compared to female R6/1 mice (19%). The rate of weight gain prior to weight loss was 
significantly slower in R6/1 females compared to WT (p = 0.00012) (linear regression analysis) while no 
difference was observed in male mice. n = 5 per group. Error bars represent + SEM. 
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3.3.1.2 Hind paw clasping phenotype  
 
The hind paw clasping phenotype previously observed in R6/1 and R6/2 mice (Mangiarini et al., 
1996) was also tested over the course of the study (Figure 3.2). The clasping phenotype was first 
observed at 12 weeks in males, with the percentage of mice showing positive for the phenotype 
increasing to 60% at the end of the study. Female R6/1 mice first exhibited the clasping 
phenotype at the age of 17 weeks. The percentage of female R6/1 mice showing the phenotype 
increased to 60% by the end of the study. A small proportion of WT mice showed positive to a 
"half clasp" phenotype at varying times throughout the study. 
3.3.1.3 Motor performance 
 
 A RotaRod apparatus was used to test motor performance in R6/1 mice (Figure 3.3). The 
average latency to fall from the RotaRod was significantly less in R6/1 mice compared to WT in 
both males (p = 0.0016) and females (p = 0.0004) over the course of the study. A significant 
difference at the 23 week time point was detected between male R6/1 mice and WT (p < 0.01). 
No difference in the RotaRod performance was detected between sexes of the same genotype 
(p = 0.81). 
3.3.1.4 Brain mass 
 
 Mouse brain (extracted for sterol analysis at each time point) was weighed prior to dissection. 
The brain mass of both male and female R6/1 mice was significantly less than WT littermates at 
later time points (Figure 3.4). The difference between WT and R6/1 male mice was highly 
significant at 20, 24 and 28 weeks (p < 0.0001). In female mice a significant difference was 
detected at 12 and 20 weeks (p < 0.05), becoming highly significant at 24 and 28 weeks (p < 
0.0001).  
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Figure 3.2 Hind paw clasping phenotype in R6/1 mice. R6/1 mice develop a phenotype where the hind 
paws are clasped to the body when suspended by the tail. Male R6/1 mice exhibited the phenotype prior 
to females; the occurrence of the phenotype increased in the population during disease progression with 
60% of the R6/1 mice showing a positive clasping phenotype by 28 weeks. A small proportion of WT mice 
appeared to exhibit a half clasp phenotype during the course of the study. n = 5 per group. 
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Figure 3.3 RotaRod motor performance of R6/1 mice. A progressive decline in motor performance was 
observed in both male and female R6/1 mice compared to WT littermates (p = 0.0016 and 0.0004 
respectively). No difference between male and female mice with the same genotype was detected. n = 5 
per group. Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test ** p < 0.01.  
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Figure 3.4 Brain mass of R6/1 mice during disease progression. Whole brain mass was significantly 
reduced in both R6/1 male and female mice compared to WT. The difference between WT and R6/1 in 
male mice was highly significant at 20, 24 and 28 weeks. In female mice a significant difference was 
detected at 12 and 20 weeks, becoming highly significant at 24 and 28 weeks. The brain mass was 
measured from mice sacrificed at each time point of lipid analysis. Each point represents 5-7 mice. Error 
bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p < 0.05 ***p < 0.0001 
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3.3.2 Sterol analysis of R6/1 brain tissue 
 
No major differences in sterols (cholesterol synthetic precursors, metabolites, oxidation 
products and phytosterols) were found between sexes in R6/1 or WT mice. To increase statistical 
power both sexes were combined and reanalysed. The level of all sterols measured for the 
individual sexes can be found in Appendix 1-3. The following results summarise the data for 
combined sexes. The sterol related compounds were detected in the brain tissue at 
concentrations ranging from 0.1 – 80 ng.mg-1 tissue. This consistent with the several compounds 
that have been previously investigated in mouse brain (Valenza et al., 2007b; Valenza et al., 
2010). 
3.3.2.1 Cholesterol synthetic precursors 
 
Several cholesterol synthetic precursors were significantly decreased in R6/1 striatum and 
cortex compared to WT (Figures 3.5A-D, 3.6A-D). Lathosterol levels were significantly reduced 
from the pre-symptomatic age of 6 weeks in R6/1 striatum (p < 0.001) and cortex (p < 0.05) 
when compared to WT mice. Lathosterol was consistently reduced in both cortex and striatum 
of R6/1 mice compared to WT in all later time points (12, 20, 24 and 28 weeks; p < 0.001). 
Lanosterol and zymosterol followed a similar consistent reduction; a significant difference in 
lanosterol levels was first detected at 12 weeks in striatum and cortex of R6/1 (cortex p < 0.05, 
striatum p < 0.01). R6/1 striatum exhibited an early reduction in zymosterol at 6 weeks (p < 
0.01), and at all later time points. The level of zymosterol in cortex tissue was only significantly 
reduced compared to WT at 28 weeks of age (p < 0.05). The cholesterol synthetic precursor 
24,25 dihydro lanosterol was not significantly altered in the R6/1 striatum or cortex although it 
was detected at lower mean levels than WT at all time points examined.  
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3.3.2.2 Cholesterol synthetic precursors during ageing 
 
Lanosterol, lathosterol, zymosterol and 24,25 dihydro lanosterol levels decreased at a similar 
rate over time in the striatum of WT and R6/1 mice (p < 0.01), however no significant difference 
in the slope was detected between R6/1 and WT (Figure 3.5A-D).  
Cortex tissue showed a different profile compared to striatum in terms of changes in cholesterol 
synthetic precursor levels over time. Both zymosterol and lanosterol decreased over time in 
R6/1 mice (p = 0.0184 and p < 0.0001 respectively) while WT levels did not significantly change 
(Figure 3.6B, C.).  Analysis of the linear regression confirmed the slopes of R6/1 were significantly 
different to WT (zymosterol p = 0.005 and lanosterol p = 0.0078). The level of 24,25 dihydro 
lanosterol did decrease significantly over time in R6/1 mice (p = 0.0018), however no difference 
in the rate of change was detected between WT and R6/1 (Figure 3.6D). Lathosterol decreased 
both in R6/1 and WT mice at a similar rate (Figure 3.6A). The correlation of cholesterol synthetic 
precursor change over time in WT and R6/1 mice is summarised in Table 3.1.  
Unlike upstream sterols in the cholesterol synthetic pathway, desmosterol levels did not 
significantly decrease over time in the striatum of R6/1 mice, being either elevated or unchanged 
at specific time points. Linear regression analysis identified that the rate of change in WT and 
R6/1 desmosterol levels was significantly different (p = 0.005); with R6/1 desmosterol levels not 
decreasing significantly over time (Figure 3.5E).  Comparing the means at individual time points 
identified desmosterol was significantly elevated in R6/1 striatum at 20 and 28 weeks compared 
to WT (t-test, p = 0.046 and p = 0.0138). Desmosterol levels in cortex were not altered over time 
in both WT and R6/1 mice, however there was a small but significant elevation of desmosterol 
in R6/1 mice at 28 weeks (t-test, p = 0.0431) (Figure 3.6E).  7-dehydrocholesterol levels did not 
decrease over time in cortex or striatum of R6/1 mice, and no difference between R6/1 and WT 
mice was detected at any time point (Figures 3.5F, 3.6F). 
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Figure 3.5: Cholesterol synthetic precursor levels in striatum tissue of R6/1 and WT littermates. 
Extracted sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A) Lathosterol, (B) 
lanosterol and (C) zymosterol  levels were significantly reduced early in the R6/1 mice compared to WT. 
(D) 24,25 dihydro lanosterol showed a trend to be decreased in R6/1 mice however there was no 
significant difference between WT and R6/1 at any time point. Lanosterol, lathosterol, zymosterol and 
24,25 dihydro lanosterol decreased over time in both R6/1 and WT mice (p < 0.01). Genotype had no 
effect on the rate of change over time.  The rate of change over time in (E) desmosterol levels in WT and 
R6/1 was significantly different (p = 0.005). Desmosterol did not significantly decline in R6/1 mice, and 
was significantly elevated at 20 and 28 weeks compared to control. (F) 7-Dehydrocholesterol did not 
significantly decline in R6/1 mice and no significant differences were detected between R6/1 and WT at 
any time point examined. Each data point represents combined results from male and female mice, n = 
10-13 per group.  Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p < 0.05 **p < 0.01 
***p < 0.0001. t-test Ψp < 0.05 
A B 
C 
E F 
D 
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Figure 3.6:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Cholesterol synthetic precursor levels in cortex tissue of R6/1 and WT littermates. Extracted 
sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A) Lathosterol and (B) lanosterol 
levels were significantly reduced early in R6/1 mice compared to WT. (C) Zymosterol was significantly 
reduced in R6/1 at the end time point. (D) 24,25 dihydro lanosterol  had a trend to be reduced however 
there was no significant difference between WT and R6/1 at any time point. Zymosterol and lanosterol 
decreased in R6/1 over time while WT levels remained unchanged (p < 0.01). Lathosterol levels decreased 
both in R6/1 and WT at a similar rate. 24,25 dihydro lanosterol levels were not detected to change over 
time. The rate of change in (E) desmosterol levels over time was not significantly different between R6/1 
and WT; however desmosterol was elevated in R6/1 mice at 28 weeks. (F) 7-Dehydrocholesterol did not 
significantly decline in R6/1 mice and no significant differences were detected between R6/1 and WT at 
any time point examined.  Each data point represents combined results from male and female mice, n = 
10-13 per group.  Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p < 0.05 **p < 0.01 
***p < 0.0001. t-test Ψp < 0.05 
A B 
C D 
E F 
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3.3.2.3 Cholesterol  
 
 Total cholesterol levels were not significantly altered between R6/1 and WT mice in this study. 
However, an increase in cholesterol levels over time was observed both in striatum and cortex 
of WT and R6/1 mice. Striatum WT (p = 0.0003), R6/1 (p = 0.0005). Cortex WT (p = 0.048), R6/1 
(p = 0.0075) (Figure 3.7). Analysis of the slope revealed the rate of change over time was not 
significantly different between R6/1 or WT mice in either striatum or cortex. The correlation 
coefficient of cholesterol levels over time is provided in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Cholesterol levels in cortex tissue of R6/1 and WT littermates. Extracted sterols were 
quantified using heavy isotope mass dilution GC-MS/MS. No difference between cholesterol levels was 
detected between WT and R6/1 mice. The absolute level of cholesterol did increase with time in cortex 
and striatum of both WT and R6/1 mice. [Striatum WT (p = 0.0003), R6/1 (p = 0.0005). Cortex WT (p= 
0.048), R6/1 (p=0.0075).] The rate of change over time was not significantly different between R6/1 or 
WT mice in either striatum or cortex. Each data point represents combined results from male and female 
mice, n = 10-13 per group.  Error bars represent ± SEM.  
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3.3.2.4 Cholesterol metabolites 
 
The brain specific cholesterol elimination product 24-OHC was significantly reduced in the 
striatum of R6/1 mice at the end time point of 28 weeks (p < 0.01, Figure 3.8). No other time 
point or brain region measured showed an effect of genotype on 24-OHC levels. 24-OHC levels 
increased in both striatum and cortex of WT and R6/1 mice over time (p < 0.01) however there 
was no difference between the rate of change between R6/1 and WT (linear regression slopes 
were not significantly different, Figures 3.8, 3.9) 
27-OHC, a predominantly peripheral metabolite of cholesterol was consistently depleted in R6/1 
striatum from the age of 12 weeks (p < 0.05) and in all later time points (20 weeks p < 0.01, 24 
weeks p < 0.05, 28 weeks p < 0.05, Figure 3.8). 27-OHC levels were not significantly altered in 
cortex tissue of R6/1 mice when compared to WT at any of the 5 time points examined. 27-OHC 
levels in both striatum and cortex showed a small increase over time in WT mice (p = 0.0288 and 
p = 0.0399 respectively) but not in R6/1 (Figures 3.8, 3.9). When comparing WT and R6/1 directly, 
no difference in rate of change was found in cortex or striatum. The correlation of 24-OHC and 
27-OHC changes over time is summarised in Table 3.1.  
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Figure 3.8: Cholesterol metabolites in striatum tissue of R6/1 and WT littermates. Extracted sterols were 
quantified using heavy isotope mass dilution GC-MS/MS. 24(S)-Hydroxycholesterol was significantly 
reduced in striatum of R6/1 mice compared to WT at the end stage of the study. A significant reduction 
in 27-hydroxycholesterol levels was detected early (12 weeks), and was consistently reduced until 28 
weeks. The level of 24-OHC increased during ageing in both WT and R6/1 mice (p < 0.01), the rate of 
change was not different between genotypes. Each data point represents combined results from male 
and female mice, n = 10-13 per group.  Error bars represent ± SEM. Bonferroni post-test *p < 0.05 **p < 
0.01  
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Figure 3.9: Cholesterol metabolites in cortex tissue of R6/1 and WT littermates. Extracted sterols were 
quantified using heavy isotope mass dilution GC-MS/MS. R6/1 cortex did not have significantly altered 
levels of 24-OHC or 27-OHC at any time point examined. 24-OHC levels increased in WT and R6/1 mice 
during ageing (p < 0.01), the rate of change was not different between genotypes. Each data point 
represents combined results from male and female mice, n = 10-13 per group.  Error bars represent ± 
SEM. 
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Table 3.1 Age/sterol correlation in R6/1 and WT mice. Sterols were analysed at five time points 
(6, 12, 20, 24 and 28 weeks) in striatum and cortex tissue of R6/1 and WT mice. Each time point 
consisted of combined male and female mice from both R6/1 and WT mice (n = 10-13 per group). 
 Striatum - correlation 
coefficient (r) 
Cortex - correlation 
coefficient (r) 
WT R6/1 WT R6/1 
Cholesterol synthetic precursors 
Lathosterol -0.63* -0.82* -0.31* -0.54* 
Lanosterol -0.31* -0.67* -0.047 -0.61* 
Zymosterol -0.63* -0.69* 0.22 -0.32* 
24, 25 Dihydro lanosterol -0.40* -0.44* -0.26 -0.42* 
Desmosterol -0.64* -0.26 0.0066 -0.047 
7-Dehydrocholesterol -0.30 0.076 0.022 0.083 
Cholesterol metabolites 
24(S)-Hydroxycholesterol 0.53* 0.36* 0.49* 0.33* 
27-Hydroxycholesterol 0.29* 0.060 0.28* 0.066 
 
Cholesterol 0.48* 0.47* 0.27* 0.36* 
*Indicates compounds with a significantly non-zero gradient (p < 0.05, linear regression analysis) 
3.3.2.5 Cholesterol oxidation products 
 
Free radical generated oxidation products of cholesterol were also measured over the course of 
the study. No significant differences in the level of 7-KC and 7β-OHC were detected between 
R6/1 and WT in any brain region or timepoint measured. The level of 7-KC and 7β-OHC were not 
significantly altered over time in cortex or striatum in either genotype (Appendix 1-3).  
3.3.2.6 Phytosterols 
 
Plant-synthesised sterols that are derived from the diet share a similar structure to cholesterol 
and can be measured in brain tissue. A small accumulation of phytosterols was observed in 
cortex and striatum during ageing in both WT and R6/1 (Appendix1-3). This reached significance 
in campesterol and brassicasterol. No effect of genotype on the on the level of phytosterols 
(campesterol, β-sitosterol, stigmasterol and brassicasterol) in cortex or striatum was detected 
in this study  
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3.4 Discussion 
 
Brain cholesterol homeostasis is maintained by de novo synthesis and brain-specific excretion 
pathways. Brain cholesterol is also isolated from peripheral cholesterol levels as the BBB is 
impermeable to cholesterol (Bjorkhem & Meaney, 2004). These regulatory mechanisms indicate 
that maintaining cholesterol levels is essential for normal brain function. This is indeed the case 
as cholesterol has essential functions involving synaptogenesis (Mauch et al., 2001), axon 
growth (Hayashi et al., 2004), membrane fluidity (Yeagle, 1985) and lipid raft structure relevant 
to cell signalling (Sheets et al., 1999; Zajchowski & Robbins, 2002; Kannan et al., 2007). Genetic 
defects in cholesterol synthetic enzymes also cause severe neurological impairment in diseases 
such as Smith-Lemli-Optitz (Wassif et al., 1998) and desmosterolosis (Waterham et al., 2001). 
A defect in cholesterol synthesis was first described in HD transgenic cells that identified several 
genes involved in cholesterol biosynthesis downregulated, including HMGCR and DHCR7 
(Sipione et al., 2002). Several HD mouse models have also been generated that express either: 
an expanded fragment of human HTT (Mangiarini et al., 1996), an expanded full-length human 
HTT (Hodgson et al., 1999; Slow et al., 2003), or an expanded mouse huntingtin (Wheeler et al., 
1999). A similar deficit in cholesterol biosynthesis has generally been reported in these models, 
identified through a reduction of cholesterol synthetic precursors (Valenza et al., 2005; Valenza 
et al., 2007a; Valenza et al., 2007b; del Toro et al., 2010; Valenza et al., 2010) and, in some cases, 
total cholesterol levels (Valenza et al., 2007a).  
The current literature has mostly used the R6/2 transgenic mouse model that expresses exon 1 
of human HTT with a 140-150 CAG repeat and has a rapid onset of symptoms. This mouse has 
been characterised in terms of phenotypic progression and potential changes in only a limited 
number of cholesterol synthetic precursors and metabolites. We have however, chosen to 
examine the R6/1 model which expresses a shorter CAG expansion (115-120) of exon 1 HTT. The 
R6/1 mouse has a later onset of motor dysfunction and a longer life span, therefore providing a 
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model that more accurately reflects the late onset and long timeline (15-30 years) of disease in 
human patients (Foroud et al., 1999). The R6/1 model has already been characterised in terms 
of behavioural phenotype and some molecular changes including, glycosphingolipid 
abnormalities (Denny et al., 2010), gene expression profile alterations (Hodges et al., 2008), 
cannabinoid receptor changes (Naver et al., 2003) and serotonin transporter deficits (Pang et 
al., 2009). Cholesterol synthesis and metabolism has not been comprehensively examined prior 
to experiments undertaken in this chapter. 
3.4.1 Cholesterol synthesis and metabolism  
 
Previous studies examining brain cholesterol changes in mouse models typically investigated a 
limited number of compounds at one or two time points during disease progression, in a single 
brain region or whole brain homogenate. In addition to this, potential differences between sexes 
have not been explored. A comprehensive analysis is required to assess whether alterations of 
cholesterol synthesis are a driving factor or a secondary event involved in HD pathogenesis. 
In this study we have analysed cortex and striatum in male and female R6/1 mice at 5 time points 
over the course of the disease, from a pre-symptomatic age (6 weeks) to end stage (28 weeks). 
Mass dilution GC-MS/MS analysis was used to quantify a larger number of cholesterol synthetic 
precursors, major metabolites, cholesterol oxidation products and phytosterols. This is the first 
study to comprehensively examine sterol changes in the R6/1 mouse, and the most 
comprehensive sterol analysis of any HD mouse model to date.  
3.4.1.1 Cholesterol synthetic precursors 
 
Significant differences between sexes were not detected in the sterol profile of either R6/1 or 
WT mice, and for simplicity the following discussion describes changes occurring when sexes 
were combined. Analysis of combined sexes also increased the statistical power, and detected 
significance in compounds exhibiting small changes. Although this study was not able to detect 
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differences between sexes in sterol levels of R6/1 mice, increasing the "n" number for future 
studies may identify small but significant differences that may explain the differences in the 
behavioural phenotype observed between sexes.  
Sterol analysis of R6/1 cortex and striatum showed a significant reduction in several cholesterol 
synthetic precursors over the course of the disease. The significant reduction of lathosterol and 
zymosterol in the striatum of R6/1 mice at 6 weeks of age represents the earliest detectable 
change in the R6/1 sterol profile, and appears before the onset of overt motor dysfunction 
measured on the RotaRod. Changes to zymosterol are more specific to the striatum compared 
to other precursors that decrease early in both cortex and striatum. This highlights zymosterol 
as a possible specific biomarker of early striatal changes in HD mice. 24,25 Dihydro lanosterol 
levels were not significantly altered between R6/1 and WT mice however the mean 
concentration in R6/1 mice was consistently lower than WT at all five time points. This sterol is 
found at low concentrations in the brain (0.1-0.4 ng/mg tissue), and while the GC-MS/MS 
method we have developed can sensitively detect this compound at these levels, it may be 
prone to greater concentration variation between individuals at any time, and statistically 
significant differences would therefore be difficult to detect with the current study size.  
Synthetic precursor levels were more severely affected in striatum compared to cortex in our 
study; changes occurred earlier and were of a greater magnitude in striatum (lathosterol 
decreased by 80% in striatum compared with 50% in cortex). This observation is consistent with 
previous studies in the YAC and R6/2 models (Valenza et al., 2007a; Valenza et al., 2007b), as 
well as the striatum in humans being the earliest and most severely affected brain region in HD 
(Vonsattel et al., 1985). Absolute cholesterol and cholesterol synthetic precursor levels were 
also previously shown to be higher in striatum compared to cortex (Zhang et al., 1996; Valenza 
et al., 2007b). For this reason it has been hypothesised that disturbed cholesterol homeostasis 
in HD may lead to specific vulnerability of the striatum (Valenza et al., 2007b). Significant sterol 
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changes early in the striatum of the R6/1 mouse suggest that alterations to the cholesterol 
biosynthetic pathway in the brain occur very early; with the possibility that these changes may 
even be present during embryonic development. This has implications for brain development as 
the majority of brain cholesterol is synthesised during prenatal life (Dietschy & Turley, 2004). If 
this is the case in HD, neurodegeneration may be seeded early with individuals only becoming 
symptomatic later in life. 
 A current hypothesis suggests that errors in myelination during development may be a factor 
in human HD, taking many years to manifest before onset due to compensatory mechanisms 
that function early but become overwhelmed in the aged brain (Bartzokis et al., 2007). 
Alternatively, early changes may be independent of the pathological processes in HD and 
investigating changes that occur during overt motor dysfunction may provide further insight into 
the involvement of altered cholesterol synthesis in the disease. 
This study has also examined 7-dehydrocholesterol and desmosterol; the immediate precursors 
to cholesterol in the Kandutsch-Russell and Bloch pathways respectively (Figure 1.2). Contrary 
to a previous finding that desmosterol decreases in YAC 128 mice (Valenza et al., 2007a), 
desmosterol levels were significantly elevated in R6/1 striatum and cortex by the end stage in 
our study. This may be an artefact of the different mouse models expressing different forms of 
mHTT, however it may also be due to the previous study using single quadrupole GC-MS (Valenza 
et al., 2007a), a technique that has lower specificity in discriminating between similar sterols 
(especially 7-dehydrocholesterol) compared to GC-MS/MS used in our study. However, it is 
unlikely that the elevated desmosterol levels we observe are due to a higher throughput of 
synthesis, as cholesterol levels did not increase in our study or in a previous study examining 
R6/1 mice (del Toro et al., 2010). A plausible explanation for this accumulation is the reduced 
activity of the enzyme (DHCR24) that catalyses the conversion of desmosterol to cholesterol.  
Previous studies in R6/2 mice do not report desmosterol levels and therefore it is unknown if 
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desmosterol accumulation also occurs in the longer exon 1 CAG repeat mouse model (Valenza 
et al., 2007b). 7-Dehydrocholesterol, similarly to desmosterol did not decrease over time as seen 
in upstream precursors, and the levels were not significantly altered between WT and R6/1 mice 
at any time point or brain region. Considering lathosterol levels are substantially reduced (the 
immediate precursor of 7-dehydrocholesterol) and 7-dehydrocholesterol levels were 
unchanged, we suggest that the enzyme that converts 7-dehydrocholesterol to cholesterol 
(DHCR7) may also be less active or at lower abundance in R6/1 mice. Our current study gives a 
novel insight into 7-dehydrocholesterol levels which have not been previously reported in HD 
mouse brain; most likely due to analytical difficulties in resolving the structures of desmosterol 
and 7-dehydrocholesterol, achieved only in this study by high resolution GC-MS/MS.  
 Previously it has been suggested that the absolute level of cholesterol synthetic precursors 
(lathosterol and lanosterol) in the brain are markers of cholesterol synthesis (Thelen et al., 2006; 
Valenza et al., 2007b), however our results which describe an accumulation of penultimate 
precursors suggest there is likely to be more complex regulation at various points of the 
synthetic pathway than previously believed. How this regulation affects lanosterol and 
lathosterol levels is unknown, and therefore the measurement of these precursors alone to 
interpret synthetic rate may be potentially confounding. The regulation of "post-squalene" 
cholesterol synthesis has been investigated recently showed that the two terminal enzymes in 
the pathway interact functionally, DHCR24 regulating the activity of DHCR7 (Luu et al., 2015). 
The idea of synthetic enzymes interacting physically supports the hypothesis of a 
"cholestesome" of cholesterol synthesis; which would involve a discrete group of enzymes 
acting on cholesterol synthetic precursors as they are converted to a final product (Sharpe & 
Brown, 2013). DHCR24 is also believed to have further regulatory roles upstream in the pathway 
(Luu et al., 2015), however these roles have not been fully established. It is clear that the 
cholesterol synthetic pathway has more complex regulation than previously believed, and while 
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recent studies have identified synthetic enzyme interactions in cells derived from the periphery, 
the specific details of cholesterol synthetic regulation remains to be fully understood in the 
brain.  
3.4.1.2 Age related changes to cholesterol synthetic precursors 
 
Cholesterol synthetic precursors lanosterol, lathosterol, zymosterol and 24, 25 dihydro 
lanosterol in the striatum decrease at a similar rate during ageing in WT and R6/1 mice. This was 
also evident in cortex however the correlation was weaker. Consistent with our results in mouse 
brain, a negative correlation in lathosterol and lanosterol levels has been observed in human 
brain tissue during ageing (r = -0.5) (Thelen et al., 2006). Whether this suggests an overall 
decrease in cholesterol levels with ageing is discussed below (3.4.1.4).  
 Interestingly 7-dehydrocholesterol levels did not decline over time in WT or R6/1 mice in cortex 
or striatum in our study. In contrast, desmosterol levels declined in WT striatum over 28 weeks, 
while remaining stable in R6/1. The regional specificity of this change highlights desmosterol 
accumulation (or reduction in DHCR24 levels or activity), as a more specific indicator of 
cholesterol synthetic alterations in the R6/1 mouse compared to upstream cholesterol synthetic 
precursor changes. Desmosterol, as measured in this study may also represent a reliable marker 
of DHCR24 activity in brain tissue of HD, or other neurodegenerative disorders.  
3.4.1.3 Cholesterol levels in the R6/1 mouse 
 
Our study did not detect any significant alterations in the cholesterol levels of the striatum and 
cortex of R6/1 mice compared to WT at any time point or brain region analysed. This is 
consistent with previous studies in the striatum of R6/1 (del Toro et al., 2010) and R6/2 mice 
(Valenza et al., 2007b). Previous studies also describes conflicting results; a small but significant 
decrease in cholesterol levels was measured in whole brain homogenates of YAC 128 mice at 10 
months of age (Valenza et al., 2007a), and a significant increase of striatal  cholesterol was 
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detected in HdhQ111 mice (del Toro et al., 2010). The apparent contradictions in cholesterol level 
changes previously reported could be explained by several factors. The different mouse models 
varying in the length and species of huntingtin expressed (YAC, R6 - human HTT, HdhQ111-mouse 
huntingtin), may cause different metabolic effects that alter total cholesterol in the brain. 
Detection and quantification methodologies (enzymatic, colorimetric, mass spectrometry) and 
sample preparation differs between studies, and have been shown to affect the result obtained 
(Marullo et al., 2012). Of these methods, mass spectrometry was previously found to be the 
most sensitive and reliable method for cholesterol quantification (Marullo et al., 2012). Tissue 
samples are also varied between studies; from discrete brain regions such as the striatum, to 
whole brain homogenates. Different brain regions vary in total volume and cholesterol content 
(10-30 µg/mg tissue) (Zhang et al., 1996; Valenza et al., 2007b). The use of whole brain 
homogenates may obscure changes in discrete regions as well as potentially giving a false 
positive if non-disease-specific changes occur in a large brain region. Analysis of brain 
cholesterol in HD models would benefit from the use of standardised methods in collecting 
discrete brain regions and using specific analytical methods such as a mass spectrometry 
method developed by our laboratory (Abbott et al., 2013). This would allow more accurate 
comparisons to be made between laboratories studying different HD models.  
Unchanged levels of cholesterol in the R6/1 brain compared to WT that we observe does not 
necessarily rule out an altered cholesterol synthetic rate in this tissue. The concentration of 
cholesterol in the brain is relatively high (μg.mg-1), and the rate of synthesis slow in the adult 
brain (ng.h-1.mg-1) (Spady & Dietschy, 1983), therefore significant alterations to total cholesterol 
levels may not take place during the short life span of these mice. This idea is consistent with 
total cholesterol changes only being observed in models with a longer lifespan (Valenza et al., 
2010).  
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 Metabolism of cholesterol to 24-OHC occurs mainly in neurons (Lund et al., 1999) and altered 
rates of metabolism may compensate for declining synthesis which is discussed in more detail 
in 3.4.1.5. It is also possible that although the concentration of cholesterol does not change in 
whole tissue samples, cholesterol is redistributed within the cell as previously observed in 
cultured striatal cells derived from the R6/2 mouse model (del Toro et al., 2010). The discrete 
cellular and regional pools of cholesterol in the brain are diverse and vary in concentration. 
Myelin contains 70-80% of cholesterol in the brain (Norton & Autilio, 1965; Snipes & Suter, 
1997); it is formed early in development and is possible that this is not greatly affected by the 
HD mutation. Neuronal cholesterol and that synthesised in astrocytes represents a smaller mass 
of cholesterol however is more dynamic (Bjorkhem et al., 1997). Small alterations in cholesterol 
formation and delivery between astrocyte and neuron may not be easily detected in whole 
tissue samples and is one limitation of examining whole tissue. Ideally, individual cell types could 
be examined from in vivo sources, however this is technically challenging. While in vitro cell 
culture experiments provide the ability to control cell types and the extracellular environment, 
essential cholesterol shuttling between astrocytes and neurons as well as ageing, cannot be 
accurately replicated. This is an important consideration when examining cholesterol 
homeostasis in vitro.  
3.4.1.4 Age related alteration to cholesterol levels in the brain 
 
Interestingly a small, but significant increase in cholesterol was observed over time in the 
striatum and cortex of WT and R6/1 mice over the 28 week study. Mice in this study are not 
significantly aged (28 weeks old, representing early adulthood) and therefore it is difficult to 
deduce the influence of further ageing on cholesterol levels in these mice. Striatal cholesterol 
levels have been reported to increase during ageing in rats; regional age-related differences 
were also noted with cerebellum and hippocampus remaining unchanged (Zhang et al., 1996). 
Whether cholesterol levels and the biosynthetic rate changes over time in the human brain has 
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not been established; too few studies have examined brain cholesterol during ageing, those that 
do have found unchanged levels (Soderberg et al., 1990; Thelen et al., 2006), or a decrease in 
cholesterol (Svennerholm et al., 1994). Cholesterol synthetic precursors have been shown to 
decrease with age, however a significant alteration of cholesterol levels was not detected due 
substantial variation between individuals (Thelen et al., 2006). Previous inconclusive findings are 
likely the result of brain regional differences, high variation within the human population and 
lower "n" numbers of post-mortem tissues studied in different publications. An association 
between cholesterol homeostasis and AD have been highlighted previously (Cutler et al., 2004; 
Gamba et al., 2011; Gamba et al., 2014) ; however, no consensus has been reached regarding 
cholesterol changes in these settings. Previous literature examining cholesterol changes in 
human HD brain is similarly inconclusive, probably due to low numbers of samples and the high 
variation between samples leading to a loss of statistical power (del Toro et al., 2010). While 
total cholesterol levels in tissue may be unchanged, altered distribution of cholesterol within 
the cell may have a very significant influence. Studies depleting cholesterol in cell membranes 
observe significant changes to cell signalling (Kabouridis et al., 2000). Primary striatal cultures of 
HD mice also show increased cholesterol concentration at the cell membrane while the overall 
concentration remains unaltered (del Toro et al., 2010). These findings are potentially important 
and require more investigation in the HD context.  
3.4.1.5 Cholesterol metabolite changes in ageing and Huntington’s disease 
 
24-OHC has been marked as a molecule of interest after being identified as a major and specific 
elimination product of cholesterol from the brain (Lutjohann et al., 1996; Bjorkhem et al., 1998). 
24-OHC is formed enzymatically from CNS cholesterol catalysed by CYP46A1, which is primarily 
expressed in neurons (Lund et al., 1999). 24-OHC levels in plasma have been suggested as a 
biomarker of several neurodegenerative diseases including AD (Bretillon et al., 2000b), PD 
(Bjorkhem et al., 2013), multiple sclerosis (Teunissen et al., 2003) and recently HD (Leoni et al., 
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2008; Leoni et al., 2013). Our study identified a significant (25%) reduction of 24-OHC levels in 
the R6/1 striatum at 28 weeks of age. We believe the relative decline of 24-OHC in R6/1 mice 
compared to WT is progressive over the course of the disease becoming more pronounced at 
later stages. Previous studies have also identified a reduction of this metabolite in the brain and 
plasma of several other HD mouse models (Valenza et al., 2007b; Valenza et al., 2010).  
Aside from differences between genotypes, 24-OHC levels increase in cortex and striatum of 
R6/1 and WT during ageing. This data supports the finding that CYP46A1 enzyme levels increases 
during ageing in the mouse brain (Lund et al., 1999). Human CYP46A1 does not show such a 
strong age related increase (Lund et al., 1999), this is consistent with plasma 24-OHC 
measurements in humans being independent of age after the 2nd decade (Lutjohann et al., 
1996). 24-OHC levels during ageing in the brain have not been measured extensively and our 
data constitutes the first evidence of age-related 24-OHC accumulation in HD mouse brain. 
Age-related changes during HD are important to examine, as measuring only a single time point 
can produce potentially misleading results. When examining one time point in our study, the 
reduction of 24-OHC  in R6/1 mice could be assumed to compensate for reduced levels of 
cholesterol synthetic precursors, therefore maintaining equal cholesterol levels between WT 
and R6/1 mice. However by examining multiple time points in our study we have identified that 
both 24-OHC and total cholesterol levels increase with age in both R6/1 and WT mice. This 
suggests a more complex system maintaining cholesterol levels, potentially involving another 
mechanism that regulates cholesterol excretion from the brain via ApoE (Pitas et al., 1987b). 
ApoE has been reported to be altered during neurodegeneration (Roses, 1996), and evidence 
from mouse models suggests that ApoE is reduced during HD pathology (Valenza et al., 2010). 
ApoE has been suggested to have neuroprotective properties (Pedersen et al., 2000; Horsburgh 
et al., 2002), with expression trending to increase during ageing (Masliah et al., 1996). Potential 
interactions of 24-OHC and ApoE have not been explored in HD, however this represents 
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another possible influence of altered cholesterol metabolism observed in the HD brain. Further 
investigation is required to elucidate the underlying mechanisms responsible for cholesterol 
metabolic changes during ageing; these studies will ultimately provide greater insight into lipid 
alterations occurring during neurodegeneration that typically takes place in the aged brain.  
A predominantly peripheral metabolite of cholesterol, 27-OHC, was also significantly reduced in 
R6/1 striatum by the age of 12 weeks, while cortex tissue had no significant alterations. 27-OHC 
has a net movement from circulation into the brain (Heverin et al., 2005) and reduced levels 
seen in R6/1 might be explained by a whole body metabolic dysfunction that is known to occur 
in HD (Lodi et al., 2000; Chen et al., 2007). However, this is unlikely as cortex did not exhibit the 
same reduction of 27-OHC levels observed in striatum. It is possible that enzymes that further 
metabolise 27-OHC are upregulated, or enzymes capable of forming 27-OHC in brain are 
downregulated in striatum, however we have no experimental evidence to support this, and 
requires further investigation.  
3.4.1.6 Cholesterol oxidation product changes in ageing and HD 
 
Oxidation of cholesterol in the 5,6 position generates 7β-OHC and 7-KC. These products 
represent stable and reliable markers of cholesterol oxidation, previously assayed in plasma 
(Iuliano et al., 2003). In contrast to our results that showed no change in COPs, a study in the 
striatum of R6/1 mice did observe a time dependant increase of lipid peroxidation (Perez-
Severiano et al., 2000). While the different methodology used (lipid soluble fluorescence vs GC-
MS/MS in our study) may derive a different result, we would expect that as cholesterol is highly 
abundant in the brain, the presence of oxidative stress would increase the formation of the COPs 
we have measured. Until multiple laboratories using reliable analytical techniques can 
consistently demonstrate the presence of oxidative stress in the brain of R6/1 mice, the role of 
lipid peroxidation in the HD pathogenesis of this mouse model is still in question.  
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3.4.1.7 Phytosterol changes during ageing and HD 
 
Phytosterols are derived from the diet and share a similar structure to cholesterol. They are 
known to slowly accumulate in brain and other peripheral tissues (Plat et al., 2008). Phytosterol 
levels were variable between R6/1 and WT over the course of the study and no significant effect 
of genotype was observed. A small accumulation of campesterol and brassicasterol over time in 
both WT and R6/1 mice was observed in both regions, consistent with previous studies in rats 
(Plat et al., 2008). As these compounds can only be taken up from the circulation, they may 
represent a useful post mortem indicator of a disturbed BBB that would result in higher 
phytosterols levels present in HD brain tissue.   
3.4.2 Physical phenotypic changes in the R6/1 mouse 
 
In this study we have also investigated the R6/1 phenotype in detail over the course of the 
disease, from 6 to 28 weeks of age. Previous literature has typically studied either male or female 
R6/1 mice, in separate studies. Here we have examined both sexes in parallel to more directly 
assess sex differences in the HD phenotype that have been previously reported. 
3.4.2.1 Weight loss 
 
Human and mouse metabolism is quite different yet the CAG expansion in transgenic R6/1 mice 
causes weight loss in line with observations in human HD patients (Sanberg et al., 1981; Morales 
et al., 1989). Weight loss may not be directly involved in neuronal dysfunction; however 
monitoring the effect of mHTT on peripheral metabolism may give an insight into relevant 
effects in the brain. Consistent with previous literature we have observed a milder weight loss 
phenotype in females compared to male R6/1 mice (Clifford et al., 2002; Naver et al., 2003). In 
our study female weight gain in R6/1 mice was significantly slower than WT mice prior to weight 
loss suggesting a metabolic abnormality from early life; however after a certain age a dramatic 
weight loss is seen. Due to a high variation in body weight of male R6/1 mice, a significant 
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difference in weight gain prior to weight loss was not detected. Food intake of R6/1 mice was 
not measured in this study to reduce stress on animals being isolated and reunited. We do not 
believe the primary cause of weight loss is a lack of feeding as it has been reported that R6/1 
mice have a similar food intake to WT mice however still exhibit a distinct weight loss profile 
(Mangiarini et al., 1996), similar to that described in our study.  
3.4.2.2 Hind paw clasping phenotype 
 
The hind paw clasping phenotype measures an involuntary clasping of the hind paws when R6/1 
and R6/2 mice are suspended by the tail (Mangiarini et al., 1996). Female mice had a later onset 
of hind paw clasping with a lower percentage of mice exhibiting the phenotype until the very 
end of the study where 60% of both male and female R6/1 mice showed a positive phenotype. 
Hind paw clasping has been described previously, however the onset is variable. Mangiarini et 
al. (1996) and Naver et al. (2003) observe hind paw clasping from 16-20 weeks in R6/1 mice, 
while other studies have observed the phenotype much later at 30 weeks (Clifford et al., 2002). 
In this study we have categorised hind paw clasping into a full clasp or half clasp. A half clasp is 
a less severe phenotype, where one or two hind paws are clasped in an interrupted manner. 
This behaviour was seen prior to full clasping (two paws clasped continuously) and was used to 
create a distinction between the severities of clasping. Although hind paw clasping is limited to 
producing binary data of 'positive' or 'negative', it is a fast and simple test that is able to examine 
a reflex response that is not measured by the RotaRod. 
3.4.2.3 Motor performance 
 
During the progression of disease in the R6/1 mouse, a progressive motor dysfunction was 
observed and this was quantified using data derived from the RotaRod experiments. Both male 
and female R6/1 mice showed progressive loss of motor skills that were quantified by the time 
taken to fall from a rotating, accelerating rod. While all mice were treated under the same 
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conditions, variation between mice of the same test group did exist, and therefore any sex 
differences in the progression of the motor phenotype could not be conclusively demonstrated. 
However, the impaired motor performance at the end time point was comparable between 
male and female R6/1 mice.  
The RotaRod provides an objective and quantitative measure of forced motor function, however 
comparison of data obtained in different laboratories can be difficult. Dependant on the 
manufacturer, the fundamental design of the apparatus can be slightly different. The RotaRod 
manufactured by Ugo Basile (Italy) [used in previous studies (Carter et al., 1999; Hockly et al., 
2003; Spires et al., 2004; Hodges et al., 2008)] and Panlab RotaRod (Barcelona, Spain) are open 
designs without an enclosed box around the apparatus. The RotaRod from TSE systems (Bad 
Homberg, Germany) and Sandigeo instruments (USA) are enclosed in a darkened box. The rod 
diameter for mice is usually 30 mm, however these specifications are not always defined in the 
literature. This specification will affect surface speed (as RotaRod is controlled in RPM) and also 
the available surface area for the animal to balance on. The material of which the rod is made 
can also potentially influence performance. A RotaRod made from hard plastic with longitudinal 
grooves has been used (Carter et al., 1999; Spires et al., 2004) and a modified version achieved 
by covering the rod with a bicycle inner tube (Hockly et al., 2002; Hodges et al., 2008), has also 
been described. The specific acceleration and speed protocol is another important variable that 
influences the difficulty of the task. A single standard protocol is not defined in the literature; 
past studies have used a range of acceleration profiles [3-44 RPM over 410 sec (Hodges et al., 
2008); 4-40 RPM over 570 sec (Hockly et al., 2002); 3.5-40 RPM over 110 sec (Spires et al., 2004); 
4-40 RPM over 180 sec (Lazic et al., 2006); 5-44 RPM with undefined acceleration (Carter et al., 
1999)]. These differences make it difficult to compare absolute run times of mice between 
studies. Even if the specific RPM at which a mouse fell, is known, the increased difficulty of faster 
acceleration must still be considered. Aside from comparisons between other studies, these 
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factors need to be considered when testing the effects of interventions. A slower accelerating 
rod with a rubber covering may be less challenging for HD mice at later stages and may be more 
sensitive to detect smaller improvements in motor function. Alternatively this may create a 
ceiling effect early in the disease progression, and subtle differences in the age of onset may be 
missed. Care should be taken when interpreting and comparing the result of RotaRod 
experiments from other laboratories, as well maintaining strict consistency within a particular 
experiment.  
3.4.2.4 Brain mass 
 
Both male and female R6/1 mice had a similar profile of brain mass changes during disease 
progression; being significantly reduced from 20 weeks of age until the 28 week time point, 
where both male and female R6/1 mice had a 17% reduction in brain mass compared to WT. 
This is similar to the 19% reduction in the brain mass of R6/2 mice that has been previously 
reported (Mangiarini et al., 1996). In this study no regionally specific atrophy was observed, 
rather an overall shrinkage of the brain was reported (Mangiarini et al., 1996). In a more recent 
study utilising MRI, specific shrinkage of the striatum and cortex was detected in R6/1 mice 
(Rattray et al., 2013), similar to the atrophy observed in human HD (Vonsattel et al., 1985; Rosas 
et al., 2003). Further investigation into specific cell loss and the striatal microenvironment of 
R6/1 mice is required to confirm that neuron loss and astrocytosis, as seen in human HD (Myers 
et al., 1991), also occurs in the mouse model.  
3.4.3 Correlation of phenotype and sterol changes during HD progression 
 
Marked changes in synthetic precursors (lanosterol, lathosterol, zymosterol) were detected at 6 
weeks, a point at which the behavioural tests we have performed did not distinguish between 
R6/1 and WT mice. A subtle, early difference between the exploratory behaviour of R6/1 and 
WT mice at 4 weeks of age has been shown (Bolivar et al., 2004), and suggests that other neural 
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changes are present at this early age. It is possible that the cholesterol synthetic changes we 
have detected are independent of HD pathology; however it must also be considered that 
progressive reduction in cholesterol synthesis has a cumulative effect that only becomes 
apparent after a threshold is reached. If precursor changes do reflect disease, they are 
potentially useful post mortem biomarkers for assessing the efficacy of intervention studies. 
Currently no studies exist that examine the modulation of the cholesterol synthetic deficit in HD 
models through therapeutic intervention. Changes to other synthetic precursors (desmosterol) 
and cholesterol metabolites 24-OHC and 27-OHC were detected later in the disease once motor 
symptoms were present in our current study. These compounds are potentially useful to assess 
the effect of therapy, specifically in preclinical animal trials as measurement of these compounds 
must be taken from brain tissue. Examining cholesterol synthetic rate in vivo in the brain is 
technically challenging, alterations to specific stages of the cholesterol synthetic pathway is 
more so difficult in vivo and has not been previously reported. After assessing the progression 
of the R6/1 model used in this study, future experiments examining progressive brain sterol 
changes would benefit from investigating a 15-16 week time point that marks the onset of (or 
just prior to) hind paw clasping and severe motor decline.  
3.4.4 Conclusion 
 
In this study we have comprehensively profiled cholesterol synthetic and metabolic changes in 
R6/1 mice using GC-MS/MS and found similar reductions in the limited cholesterol synthetic 
precursors previously reported in the R6/2 model. The novel measurement of desmosterol and 
7-dehydrocholesterol in this study has highlight that there may be more complex regulation of 
the cholesterol synthetic pathway, as not all "post-squalene" precursors were reduced equally 
in brain tissue. It has also highlighted the specific accumulation of desmosterol levels in R6/1 
mice that is potentially due to a reduced activity of DHCR24. Along with levels of the brain 
specific cholesterol metabolite, 24-OHC, being significantly reduced in striatum of R6/1 mice, we 
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have successfully quantified 27-OHC levels and identified a striatum specific depletion of this 
metabolite in R6/1 mice. This suggests that multiple pathways of cholesterol metabolism are 
perturbed in the R6/1 brain. Phytosterols and COPs were not altered between genotypes, 
suggesting an intact BBB and absence of lipid peroxidation in R6/1 mice. The multiple time points 
measured in this study have not only avoided potentially misleading conclusions that are 
possible in single time point studies, but also identified previously unreported age-related 
changes to many sterols in the brain. A milder weight loss and hind paw clasping phenotype was 
observed in female R6/1 mice compared to male R6/1 mice, however no significant difference 
in the loss of brain mass or motor dysfunction was detected between sexes. The physical 
phenotype in these mice did not correlate exactly to cholesterol synthetic and metabolic 
alterations, however it is possible that molecular changes are cumulative and reach a threshold 
before overt symptoms occur. Comprehensive and sensitive analysis of sterol compounds in the 
brain of R6/1 mice has given a new insight into synthetic and metabolic changes occurring in this 
model of HD. It has also provided novel data on age-related changes occurring in the brain, which 
are not only useful for further investigating HD, but also other neurodegenerative processes that 
typically manifest in the aged brain.  
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Chapter 4                                                 
The effect of environmental enrichment 
on cholesterol homeostasis and motor 
phenotype in the R6/1 HD mouse model 
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4.1 Introduction 
 
An active lifestyle is believed to be important in reducing the risk of many peripheral diseases 
including, cancers, cardiovascular diseases and diabetes (Duncan et al., 1997; Lee et al., 1999; 
Shephard & Balady, 1999). Several epidemiological studies have highlighted that increased 
cognitive use and physical activity also reduces the risk of AD, PD and other dementias (Stern et 
al., 1994; Evans et al., 1997; Lindsay et al., 2002). However, due to environmental and genetic 
heterogeneity in the human population, these studies are limited in their ability to discover 
specific aspects of the environment that cause beneficial effects in the brain and the 
mechanisms involved. Previous animal studies involving EE report similar findings to 
epidemiological studies, delaying disease onset and reducing the severity of neurological 
disorders (Kempermann et al., 2002; Jankowsky et al., 2005; Lazarov et al., 2005). Animals 
housed with EE exhibit improved memory and learning, and numerous neurophysiological 
changes including increased synaptic plasticity, neurogenesis and reduced oxidative stress in the 
brain (Jones et al., 1999; van Praag et al., 1999; Fernandez et al., 2004). The use of EE in HD 
mouse models has been reported to improve motor function and improve molecular deficits 
including amelioration of reduced levels of BDNF in the striatum (Spires et al., 2004). In addition 
to essential roles in neuronal growth and survival, BDNF is believed to play a role in cholesterol 
homeostasis in the brain, being potentially relevant to HD mouse models that exhibit a 
significant cholesterol synthetic and metabolic perturbation. Therefore in this study we have 
investigated the influence of EE on the cholesterol homeostatic alterations in the R6/1 mouse 
model. The influence of EE on the physical phenotype in R6/1 mice was also examined, which 
includes: motor dysfunction, the hind paw clasping phenotype, and brain and body weight loss.  
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4.2 Materials and Methods 
 
Materials: Materials used in this study are listed in 2.2.  
Mice: R6/1 mice were generated as outlined in 2.3.1. Mice were randomly assigned into cages 
of control or EE housing (4-5 animals per cage, 7-8 animals per group). Both male and female 
mice were used in this study. Control housing used a standard small mouse cage (30 cm x 12 cm 
x 13 cm) with a wire lid. Control cages contained sawdust, pine shavings and one PVC tube. EE 
housing used a larger cage with a wire lid (48 cm x 12 cm x 18cm), and contained novel objects 
with different textures and shapes. These included additional bedding material (tissue paper, 
wool, paper), cardboard tubes, wooden, metal and plastic objects (See Figure 4.1 for an 
example). Novel objects were replaced with new objects twice per week. Mice were provided 
with standard rodent diet (see 2.3.1 for details) and water available ad libitum in both housing 
conditions. Mice were housed with at least 2 of each genotype per cage.  
Body weight: Mouse weight was recorded every 4-5 days from 7 weeks of age until sacrifice. 
Hind paw clasping: Hind paw clasping was tested every 5-10 days following the procedure 
outlined in 2.3.3.   
RotaRod: Motor performance was measured using the RotaRod protocol outlined in 2.3.2. The 
RotaRod performance of mice was tested at 6, 11, 15, 19 and 23 weeks of age.  
Tissue collection: Mice were sacrificed at 26 weeks of age using slow flow CO2 asphyxiation. Brain 
tissue was dissected and collected as described in 2.3.4. 
Lipid extraction and GC-MS/MS analysis of sterols: Quantification of cholesterol synthetic 
precursors, metabolites, oxidation products and phytosterols was performed as outlined in 2.3.5 
and 2.3.6. 
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Statistical Analysis: Linear regression analysis was used to identify a difference in the rate of 
weight gain in mice. A 2-way ANOVA was used to analyse RotaRod performance and body 
weight. A student's t-test was used to compare means of brain mass, cholesterol synthetic 
precursors, metabolites, oxidation products and phytosterols between R6/1 and WT mice. All 
analyses were performed in Graphpad PRISM v5.0 (Graphpad Software Inc., USA). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Enriched and control housing conditions. (A) Control housing in a standard small mouse cage 
(30 cm x 12 cm x 13 cm) contained sawdust, pine shavings and a single PVC tube. (B) Environmentally 
enriched housing was provided in a larger cage (48 cm x 12 cm x 18cm) with the addition of novel objects 
replaced 2 times per week. 4-5 mice (at least 2 of each genotype) were housed per cage. 
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4.3 Results 
 
4.3.1 Phenotype 
 
The effect of EE on the progression of the HD phenotype in R6/1 mice was examined from 7-26 
weeks of age. Body weight, hind paw clasping and RotaRod performance was tested over this 
period (n = 7-8 per group). The brain mass of mice was measured at the completion of the study 
at 26 weeks of age when all mice were sacrificed.  
4.3.1.1 Weight loss 
 
Body weight was recorded every 4-5 days (Figure 4.2). Progressive weight loss is known to occur 
at 15 weeks in R6/1 mice (Mangiarini et al., 1996). 
 EE did not significantly alter weight gain between male WT and R6/1 mice, or have an overall 
effect on the weight loss phenotype although the baseline levels were higher in EE mice. Prior 
to weight loss, weight gain in both EE and control R6/1 males was significantly less than WT in 
both housing conditions (p < 0.001). EE had no effect on body weight in WT males when 
normalised to baseline measurements.  
Female R6/1 mice in EE housing had a significantly greater weight gain prior to weight loss (7-15 
weeks) when compared to control R6/1 and WT mice (p < 0.0001), and a similar weight gain to 
enriched WT female mice. Although the average bodyweight at baseline was higher in EE mice, 
when considering the full course of the experiment, the weight loss profile was not significantly 
altered between EE and control R6/1 mice. EE significantly increased the rate of weight gain in 
WT females compared to control WT female mice (p < 0.0001). 
80 
 
 
 
Figure 4.2 The effect of environmental enrichment on weight loss in R6/1 mice. Environmental 
enrichment (EE) did not significantly alter weight gain or weight loss in WT and R6/1 male mice. Female 
R6/1 mice housed with EE had a significantly greater weight gain prior to weight loss compared to control 
R6/1 female mice (7-15 weeks) (p < 0.0001), however there was no overall effect by the final time point. 
EE increased the weight gain in WT female mice compared to control WT females (p < 0.0001) n = 7-8 per 
group. Error bars represent + SEM 
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4.3.1.2 Hind paw clasping 
 
The percentage of male R6/1 mice housed with EE that exhibited a clasping phenotype was 
consistently lower than control R6/1 mice over the course of the study. At 26 weeks, 50% of EE 
male R6/1 and 80% of control R6/1 mice were positive for the clasping phenotype (Figure 4.3). 
Female R6/1 mice from both EE and control housing had a similar onset of hind paw clasping at 
22 weeks of age.  The percentage of EE female R6/1 mice exhibiting a clasping phenotype 
between 23-26 weeks was less than control mice, however, the difference was relatively small 
over this short period (35% vs 50%, Figure 4.3). No influence of housing was observed in WT 
mice with several mice from both enriched and control housing showing a half clasp phenotype 
at various time points during the study (Figure 4.3).  
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Figure 4.3 The effect of environmental enrichment on the hind paw clasping phenotype in R6/1 mice. 
R6/1 mice develop a phenotype where the hind paws are clasped to the body when suspended by the 
tail. Environmental enrichment (EE) did not alter the onset of hind paw clasping in male R6/1 mice, 
however the percentage of mice showing positive for the phenotype was consistently lower than control 
R6/1 mice during disease progression. Hind paw clasping at 22 weeks in female R6/1 mice and the small 
attenuation of hind paw clasping in the EE female R6/1 mice was not considered significant. A small 
proportion of WT mice appeared to exhibit a half clasp during the course of the study independent of 
housing treatment. n = 7-8 per group. 
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4.3.1.3 RotaRod 
 
A small but statistically significant improvement in motor performance was detected in EE male 
R6/1 mice compared to control R6/1 males (p = 0.0032). While R6/1 males kept in both housing 
conditions did show significant motor decline over the entire study, R6/1 mice housed with EE 
had a delayed motor decline and a consistently higher average RotaRod time compared to 
control R6/1 mice (Figure 4.4). EE housing did not have a significant effect on the RotaRod 
performance of female R6/1 mice; both EE control mice had a similar motor decline over the 
course of the study (Figure 4.4). A small improvement in the average RotaRod time of EE R6/1 
females at 20 and 24 weeks was observed, however this did not reach statistical significance. 
The RotaRod performance of WT animals was not influenced by the housing treatment in either 
male or female mice.  
4.3.1.4 Brain mass 
 
The reduction of brain mass previously observed in R6/1 mice (Chapter 3) was not altered by EE 
housing. Male and female R6/1 mice housed in EE or control housing had a highly significant 
brain mass reduction of 17-18% compared to WT mice of the same sex and housing treatment 
(p < 0.0001). Absolute brain mass values can be found in Table 4.1.  
 
Table 4.1 Brain mass of R6/1 and WT mice with environmentally enriched or control housing.  Values 
represent mg ± SEM. n = 7-8 per group. EE = environmental enrichment 
 
 
 
 Control housing EE 
WT R6/1 WT R6/1 
Male 476 ± 6 391 ± 7 493 ± 6 401 ± 5 
Female 480 ± 5 399 ± 7 483 ± 8 402 ± 8 
84 
 
 
Figure 4.4 The influence of environmental enrichment on RotaRod motor performance of R6/1 mice. 
Environmental enrichment (EE) caused a delay in the onset of motor dysfunction in male R6/1 mice 
compared to control R6/1, and improved the average latency to fall from the RotaRod over the course of 
the study (p = 0.0032). No effect of housing treatment was detected between female EE and control R6/1 
mice. The RotaRod performance of WT animals was not influenced by the housing treatment in either 
male or female mice.  n = 7-8 per group. Error bars represent + SEM. 
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4.3.2 Sterol analysis of R6/1 brain tissue 
 
All mice were sacrificed at 26 weeks of age and solvent extracted lipids from the cortex and 
striatum were analysed using GC-MS/MS for cholesterol synthetic precursors, metabolites, 
oxidation products and phytosterols. Sterol compounds examined in this study included; 
[cholesterol synthetic precursors (lathosterol, lanosterol, zymosterol, 24,25 dihydro lanosterol, 
desmosterol, 7-dehydrocholesterol), metabolic products (24-OHC, 27-OHC), oxidation products 
(7-KC, 7β-OH), phytosterols (campesterol, β-sitosterol, stigmasterol, brassicasterol)]. Quantified 
values for all sterols measured can be found in Appendix 4-6. 
4.3.2.1 Cholesterol oxidation products 
 
Male R6/1 mice housed with EE had significantly reduced levels of 7β-OH in cortex tissue 
compared to control R6/1 mice (p = 0.0343) (Figure 4.5). Male R6/1 and WT control mice did not 
significantly differ in 7β-OH levels (Figure 4.5). Although the effect of EE was not statistically 
significant in male WT mice, a similar profile to that of R6/1 male mice was observed. No 
difference in the level of cholesterol oxidation products was detected between housing 
treatments in female R6/1 mice. Combining the sexes in WT mice revealed a significant 
reduction of 7β-OH levels in cortex tissue (p = 0.0389) (Figure 4.6). Significant alterations to 7β-
OH or 7-KC were not detected in any other brain region in either genotype or sex.  
4.3.2.2 Cholesterol synthetic precursors, metabolic products and phytosterols 
 
EE had no detectable influence on the level of cholesterol synthetic precursors, metabolic 
products or phytosterols in cortex or striatum of male and female R6/1 mice. No differences in 
these compounds were detected between EE and control WT mice. The sterol profile of R6/1 vs 
WT mice was consistent to the results obtained in Chapter 3 at a similar time-point of 24 weeks.  
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Figure 4.5 The influence of environmental enrichment on cholesterol oxidation products in male cortex. 
Environmental enrichment (EE) significantly decreased the level of the cholesterol oxidation product 7β-
hydroxy cholesterol (7β-OHC) in the male R6/1 cortex when compared to control R6/1 males (p = 0.0343). 
No difference was detected between WT or R6/1 mice in either housing condition. n = 7-8 per group. Error 
bars represent +SEM. *p < 0.05 
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Figure 4.6 The influence of environmental enrichment on cholesterol oxidation products in cortex of WT 
mice. When sexes were combined there was a small but significant decrease in the cholesterol oxidation 
product 7β-hydroxy cholesterol (7β-OHC) in cortex tissue of WT mice housed with environmental 
enrichment (EE) (p = 0.0389). n = 14-16 per group.  Error bars represent +SEM. *p < 0.05 
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4.4 Discussion 
 
Previous studies investigating EE in R6 mice have reported several neurophysiological 
changes, including, increased neurogenesis (Lazic et al., 2006) and neurotrophin 
expression (Spires et al., 2004) in EE mice. In this study we have examined the effect of 
EE on R6/1 mice by characterising physical phenotypic changes as well as molecular 
changes to cholesterol homeostasis and oxidative stress.  
4.4.1 Motor performance 
 
In this study we have detected improved motor performance in R6/1 male mice housed with EE.  
The improvement observed was in conjunction with a milder hind paw clasping phenotype over 
the course of the study. A similar finding was reported where EE delayed the onset and overall 
severity of the clasping phenotype in R6/1 mice (van Dellen et al., 2000). Since then, several 
studies have found improved motor co-ordination (RotaRod) and grip strength in both R6/1 and 
R6/2 mice housed with EE (Hockly et al., 2002; Spires et al., 2004). In the past, studies testing 
motor performance using the RotaRod have reported varying results in the latency to fall from 
the rod (Spires et al., 2004; Lazic et al., 2006). These differences may result from different 
RotaRod protocols (as previously discussed in 3.4.2.3), or differences in husbandry protocols 
between laboratories that have been demonstrated to influence animal behaviour (Logge et al., 
2014; Sorge et al., 2014). It may also be the result of different enrichment protocols, where the 
type of environment (toys, tunnels, and nesting materials), cage size, and presence of exercise 
equipment may result in different outcomes (van Praag et al., 1999; Zajac et al., 2010). This then 
poses the question, what is environmental enrichment? It has been defined as 'a sustained 
increase in daily, cognitive and sensory-motor and physical activity' by Mattson et al. (2001), 
however we also consider that EE could involve increased sensory and cognitive stimulation in 
the absence of high levels of physical activity. This is consistent with human epidemiology that 
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finds increased cognitive function (by measure of education level and occupational status) 
reduces risk of dementia (Stern et al., 1994; Evans et al., 1997). This question also highlights the 
idea that various aspects of EE may have different effects in specific brain regions. This is evident 
in a study where the presence of a running wheel alone improved brain neurogenesis 
differentially to a large cage containing novel object stimuli (van Praag et al., 1999). Wheel 
running and EE have also been reported to modify gene expression differentially in R6/2 mice 
(Zajac et al., 2010). Apart from increasing physical fitness, running wheels may provide motor 
skill practise and potentially confound RotaRod results when assessing motor performance. In 
the current study we have provided enrichment in the absence of a running wheel to examine 
whether degeneration of the brain controlling motor function in HD can be achieved by sensory 
and cognitive stimulation.  
The age of exposure and duration of EE is also likely to play a role in the brain changes. Due to 
mice being bred in a separate facility in the current study, EE was started at 7 weeks of age, 
while previous studies implemented enrichment at 4 weeks of age (van Dellen et al., 2000; 
Hockly et al., 2002; Spires et al., 2004). The difference of several weeks early in development 
may be significant as it has been found that early handling (pre-weaning) of rodents alters 
behavioural phenotypes (Levine et al., 1967) and age-related brain deficits (Meaney et al., 1991) 
compared to later handled (post-weaning) animals (Levine & Otis, 1958). Therefore, in the R6/1 
mouse model where biochemical changes are evident at 6 weeks (Chapter 3), we postulate that 
earlier exposure to EE would result in the greatest benefit. Several mechanisms have been 
proposed to explain the various benefits of EE seen in animal disease models, many of these 
being specifically relevant to HD pathology.    
4.4.2 Mechanisms of environmental enrichment changes in the brain 
 
EE has been demonstrated to improve behavioural phenotypes in animal studies including, 
improved spatial memory, motor function and reduced anxiety (Kempermann et al., 2002; 
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Benaroya-Milshtein et al., 2004; Spires et al., 2004). Neurophysiological changes that occur 
alongside these behavioural improvements include; increased dendritic branching (Kolb & Gibb, 
1991) and synaptic density (Saito et al., 1994), reduced spontaneous apoptosis (Young et al., 
1999), and increased expression of neurotrophic factors (Turner & Lewis, 2003; Lazarov et al., 
2005). Studies incorporating EE prior to a damaging insult in the brain demonstrate that EE builds 
a 'protective' environment that confers resistance to damage (Kolb & Gibb, 1991; Johnson et al., 
2013), while implementing EE after brain damage also demonstrates the potential for  repair 
and growth (Wainwright et al., 1993; Rampon et al., 2000; Shin et al., 2013). 
A simplified hypothesis suggests that neuronal activation leads to increased expression of 
neurotrophic factors that promote neurogenesis, plasticity and cell survival (Mattson et al., 
2001). Previous studies have focused on BDNF which is elevated in a variety of rodent models 
housed with EE (Ickes et al., 2000; Turner & Lewis, 2003; Lazarov et al., 2005). BDNF has 
functions involving in cell survival, differentiation and growth (Binder & Scharfman, 2004), and 
is believed to play a role in HD pathology since it is reduced in human HD brain (Zuccato et al., 
2001) as well as several HD mouse models (Spires et al., 2004; Zuccato et al., 2005). BDNF 
knockout mice also show a similar gene expression profile to human HD (Strand et al., 2007). 
The relevance of BDNF and EE has been highlighted by studies that report rescued BDNF levels 
in HD mice exposed to EE, accompanied by improved RotaRod performance (Duan et al., 2003; 
Spires et al., 2004). EE restored BDNF levels in the striatum of HD mice and caused a milder 
motor phenotype (Spires et al., 2004). As cortical levels of BDNF are unaffected in these HD 
mice, it is hypothesised that the corticostriatal transport of BDNF is impaired in HD, which is 
ameliorated by EE (Spires et al., 2004). Specific elevation of BDNF in striatum of HD mice housed 
with EE, suggests that EE may be specifically beneficial to HD pathology which involves early and 
severe striatal atrophy (Vonsattel et al., 1985).  
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Another aspect of EE may also involve increased cognitive activity through more complex social 
interactions. Rats housed in isolation have forebrain atrophy and significantly reduced levels of 
neurotrophins compared to rats housed in groups (Pham et al., 1999; Ickes et al., 2000). 
Enrichment protocols using a larger number of animals in a large cage (10-15) (van Praag et al., 
1999; Hockly et al., 2002), enables more complex social hierarchies and interactions compared 
to a small cage of 4 animals. These increased social interactions have been shown to modulate 
the endocrine system in rodents (Blanchard et al., 1995; Hardy et al., 2002), and induce 
neurological changes (Chao et al., 1993). Benefits through increased social interaction may be 
of relevance to HD pathology that has well established neuroendocrine alterations (Popovic et 
al., 2004; Wood et al., 2008; Saleh et al., 2009). While the beneficial effects of EE on behaviour 
and brain physiologies are evident in previous literature, including our current study, further 
work is required to elucidate the specific aspects of an enriched environment that actively confer 
health benefits to the CNS.  
4.4.3 Cholesterol synthesis and metabolism 
 
Previously we have characterised the progression of the cholesterol synthetic and metabolic 
defects in the R6/1 mouse model of HD (Chapter 3). In our current study EE had no detectable 
effect in altering the levels of lipid species measured, when compared to control mice. The levels 
of all sterol compounds measured were consistent with the later time points (24-28 weeks) in 
our previous study (Chapter 3). Cholesterol homeostatic alterations were investigated in this 
study since previous literature reports improved BDNF levels in EE HD mice (Spires et al., 2004). 
BDNF is believed to influence cholesterol homeostasis in the brain, increasing cholesterol 
content and gene expression of cholesterol synthetic enzymes in cultured neurons (Suzuki et al., 
2007). This neurotrophin also promotes DHCR24 expression (Sarchielli et al., 2014), the enzyme 
responsible for catalysing desmosterol conversion to cholesterol at the end of the cholesterol 
synthetic pathway. In this study (and in Chapter 3) we observed an accumulation of desmosterol 
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in the striatum, which is likely attributed to loss of DHCR24 levels or activity (as discussed in 
3.4.1.1). However, EE did not alter desmosterol levels in R6/1 mice. It is possible that EE did not 
restore BDNF levels early enough to attenuate the severe cholesterol synthetic deficit in R6/1 
mice. The mechanisms behind altered cholesterol homeostasis in HD are still largely undefined 
in vivo; it is possible other factors may also play a significant role. Specifically mHTT, which may 
diminish the effect of BDNF by interfering with sterol regulatory binding proteins (SREBPs) 
(Valenza et al., 2005) that also regulate cholesterol synthesis (Yokoyama et al., 1993). 
Further investigation into BDNF and cholesterol homeostasis is required in HD models. A 
potentially useful model to investigate whether BDNF can rescue the cholesterol deficit in vivo 
is a transgenic HD mouse crossed to overexpress BDNF (Canals et al., 2004; Xie et al., 2010). As 
cholesterol synthetic precursors are present in concentrations as low as 0.1 ng/mg in brain 
tissue, sensitive analytical tools such as GC-MS/MS are essential to detect the full extent of any 
potential changes.  
4.4.4 Cholesterol oxidation products 
 
The cholesterol oxidation product 7β-OHC was reduced in the cortex of R6/1 male mice housed 
with EE. The difference in oxidation markers observed between EE and control housing is likely 
to be a combination of EE reducing oxidative stress in the brain and a control or "non-enriched 
environment" promoting it. This is supported by studies reporting reduced markers of oxidative 
stress (nitrotyrosine, glutathione) in the brain of rodents housed with EE (Fernandez et al., 2004; 
Herring et al., 2010), and studies describing elevated brain lipid peroxidation in rodents under 
environmental stress (Liu et al., 1996; Lucca et al., 2009). In our current study mice housed 
without EE may have increased levels of stress due to having fewer places to find shelter, while 
EE mice have many places to hide and therefore reduced environmental stress. 
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Although WT and R6/1 mice in control housing had comparable levels of 7β-OH, the HD brain 
may have diminished capacity to cope with an increased oxidative environment, enhancing the 
deleterious effects of a "non-enriched” environment. This was previously observed in the R6/2 
HD mouse model which was highly susceptible to an artificially induced oxidative insult while 
basal levels of oxidative markers were unaltered between genotypes (Bogdanov et al., 1998).  
Interestingly oxidative stress was not significantly elevated in the striatum of R6/1 mice, 
consistent with previous analysis in 3.3.2.5. While the pathological hallmark of HD is striatal 
atrophy, the cortex does undergo neurodegeneration in later stages of human HD (Vonsattel et 
al., 1985; Rosas et al., 2003), and may explain why oxidative stress may be present in this region 
of R6/1 mice late in the disease progression (25 weeks). Although oxidative stress in R6/1 mice 
has been reported in a previous study (Perez-Severiano et al., 2000), our data suggests that 
oxidative stress may not be a primary driving factor in R6/1 HD pathology as it is not specific to 
regions that are most susceptible to early degeneration. 
4.4.5 Weight loss and brain mass 
 
EE of R6/1 mice in this study did not have significant effects on the overall weight loss and the 
reduction in brain mass that is characteristic of these transgenic mice (Mangiarini et al., 1996). 
This is consistent with previous findings where weight loss or brain masses were not significantly 
altered with EE in the R6/1 mouse (Spires et al., 2004). EE has been shown to increase brain 
mass in WT rodents, however subtle differences were found to be regionally specific and only 
detectable with very large cohorts (La Torre, 1968; Bennett et al., 1969; Henderson, 1970). 
Specific to HD models, EE in R6/2 mice was associated with a small increase in peristriatal volume 
(6%) (Hockly et al., 2002), suggesting that any brain mass changes due to EE are most likely small 
in magnitude, and only detectable using complex and sensitive brain volume analytical 
techniques.  
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4.4.6 Conclusion 
 
EE had a measureable effect on attenuating motor decline and involuntary clasping in male R6/1 
mice in this study. Although motor symptoms were delayed, significant and progressive motor 
dysfunction was still observed by the end stage of disease in EE mice. Improvements to 
perturbed cholesterol homeostasis were not detected at 25 weeks of age once the disease 
phenotype was fully present in both EE and control R6/1 mice.  Although lipid peroxidation was 
reduced in male R6/1 mice housed with EE, a substantial alteration in oxidative stress markers 
was not observed when comparing R6/1 and WT mice in our study, and may be a secondary 
event associated with HD neurodegeneration (Browne & Beal, 2006). However, it is possible that 
although basal levels of oxidative stress were not elevated in R6/1 mice, the HD brain is more 
susceptible to damage by stressful stimuli and this is ameliorated by EE. While the main 
hypothesis surrounding the benefits of EE in HD involve upregulation of neurotrophic factors, 
the benefit of specific aspects of EE on brain function are not fully understood. Previous EE 
studies in HD models, and the study described here have provided further insight into HD 
pathology, not only to extend the understanding of molecular mechanisms in HD 
neurodegeneration, but also highlight a potentially significant suppressor of disease progression 
and severity that may be applied to human HD patients.   
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Chapter 5                                              
Berry extract supplementation in the R6/1 
transgenic mouse model of Huntington's 
disease 
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5.1 Introduction 
 
In recent years sensitive analytical techniques have highlighted many classes of compounds 
present in foods that have potentially potent health benefits. Many of these compounds were 
previously believed to exert beneficial effects primarily through their antioxidant properties, 
however more complex biochemical interactions have been recently highlighted which suggest 
that plant derived phytochemicals may alter cell signalling, invoke a hormetic response or inhibit 
protein misfolding.  
 Many plants produce secondary metabolites that are concentrated in fruit, among these are 
phenolic compounds that contain multiple aromatic rings in their structure. Recent studies using 
berry extract (BE) supplementation have discovered that berries such as blueberries, 
blackberries and blackcurrants have potent effects to reduce brain deficits associated with aging 
in animal models (Joseph et al., 1998; Casadesus et al., 2004; Galli et al., 2006). Anthocyanins 
are a major phenolic component of berries, and are believed to be the main active component 
of these fruits. Dietary supplementation of phenolic fruit extracts have also been applied to 
neurodegenerative disease, and in the case of HD, several compounds have been identified that 
attenuate disease pathology in animal and cell models (Ehrnhoefer et al., 2006; Maher et al., 
2011). 
In this chapter we have investigated BE extract supplementation on the R6/1 HD mouse model 
and tracked the progression and severity of symptoms. We have assessed the effects of BE 
extract supplementation on biochemical changes involved in altered cholesterol homeostasis 
and oxidative stress as well as several established phenotypic changes that occur in these mice.  
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5.2 Materials and Methods 
 
Mice: R6/1 mice were generated as outlined in 2.3.1. Equal numbers of male and female R6/1 
and WT mice (6 per group) were caged in standard housing (30 cm x 12 cm x 13 cm) containing 
a single PVC tube, saw dust and pine shavings. Four mice were housed per cage, two of each 
genotype. All procedures that were undertaken conformed to the standards of the University of 
Wollongong ethics committee (ethics approval number: AE 13/20). 
Diet: Control and BE diets were manufactured by Speciality Feeds Pty Ltd. (Glen Forrest, W.A, 
Australia). Control diet comprised of the standard rodent growth diet (AIN-93G) (Reeves et al., 
1993). BE diet contained [control diet + 0.2% blackcurrant extract (NutriPhy Blackcurrant 100, 
Chr. Hansen pty. Ltd., Australia)]. Control and BE diet were equal in caloric content. BE diet was 
calculated to be equivalent to one serving of whole berries in humans (100-150 g) (Prior et al., 
2001; Scalzo et al., 2008; Tabart et al., 2011; Milivojevic et al., 2012), corrected to body surface 
area as described in Reagan-Shaw et al. (2008). The consumption of anthocyanins by mice in this 
study (when corrected for body surface area) was similar to previous studies investigating 
anthocyanin supplementation in rats (Joseph et al., 1999; Youdim et al., 2000). Both diets were 
kept a 4oC in a light sealed box prior to being dispensed for feeding. Food and water was 
available ad libitum. Unconsumed diet was removed and replenished from cages every 2 days. 
Body weight: Mouse weight was recorded every 4-5 days from 7 weeks of age until sacrifice. 
Hind paw clasping: Hind paw clasping was tested every 5-10 days following the procedure 
outlined in 2.3.3.   
RotaRod: Motor performance was measured using the RotaRod protocol outlined in 2.3.2. The 
RotaRod performance of mice was tested at 6, 11, 15, 19 and 23 weeks of age.  
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Tissue collection: Mice were sacrificed at 25 weeks of age using slow flow CO2 asphyxiation. Brain 
tissue was dissected and collected as described in 2.3.4. 
Lipid extraction and GC-MS/MS analysis of sterols: Quantification of cholesterol synthetic 
precursors, metabolites, oxidation products and phytosterols was performed as outlined in 2.3.5 
and 2.3.6. 
Statistical analysis: Linear regression analysis was used to identify differences in the rate of 
weight gain between mice. 2-way ANOVA was used to test for an effect of BE extract 
supplementation on RotaRod performance and weight loss. A student's t test was used to 
compare mean values of sterol analysis and brain mass. All analyses were performed in 
Graphpad PRISM v5.0 (Graphpad Software Inc., USA). 
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5.3 Results 
 
5.3.1 Phenotype 
 
5.3.1.1 Body weight 
 
Supplementation of BE had no effect on the weight loss phenotype in either male or female R6/1 
mice when body weight was normalised to baseline levels (Figure 5.1). Both male and female 
R6/1 mice had significant weight loss independent of diet when compared to WT mice (p < 0.01). 
A significant difference in weight gain prior to weight loss was observed between control and BE 
R6/1 males, the control fed mice gaining weight more rapidly (p = 0.004). No other significant 
differences in weight gain were detected in WT or female R6/1 mice.  
5.3.1.2 Hind paw clasping 
 
A small delay in the onset of the hind paw clasping phenotype was observed in male R6/1 mice 
fed a BE supplemented diet (12 vs. 14 weeks of age in control and BE fed mice respectively) 
(Figure 5.2). After the initial onset of clasping the percentage of R6/1 control mice showing 
positive for clasping was higher on average, however there was variability between time points 
and a clear difference in hind paw clasping between diet treatments was not observed. In female 
R6/1 mice the hind paw clasping phenotype progressively increased after 19 weeks of age 
independent of diet treatment (Figure 5.2). A small percentage of WT mice from both diet 
treatments were positive for a half clasp phenotype at various stages of the study.  
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Figure 5.1 The effect of berry extract supplementation on weight loss in R6/1 mice. The weight loss 
phenotype in male and female R6/1 mice was not altered by berry extract (BE) supplementation when 
compared to control fed R6/1 mice. Prior to weight loss (at age 15 weeks) the weight gain of BE fed R6/1 
males was significantly less than control fed R6/1 mice (p = 0.004). Diet treatment had no effect on the 
weight gain of WT mice or female R6/1 mice. Over the entire study R6/1 mice had significant weight loss 
compared to WT independent of diet treatment (p < 0.01). n = 6 per group. Error bars represent + SEM. 
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Figure 5.2 The effect of berry extract supplementation on the hind paw clasping phenotype in R6/1 
mice. R6/1 mice develop a phenotype where the hind paws are clasped to the body when suspended by 
the tail. A small delay in the onset of hind paw clasping was observed in berry extract (BE) supplemented 
R6/1 male mice (2 week delay) however the overall severity was not consistently reduced after onset. No 
effect of diet was observed in female R6/1 mice. A small proportion of WT mice appeared to exhibit a half 
clasp during the course of the study independent of diet treatment. n = 6 per group. 
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5.3.1.3 RotaRod 
 
The average RotaRod time for female R6/1 mice fed a BE diet was consistently higher than 
control fed mice over the course of the study, and a small but significant overall improvement 
was detected (p = 0.0349). Male R6/1 mice fed a BE diet did not have a detectable improvement 
in performance compared to control fed R6/1 mice. BE supplementation did not alter the 
RotaRod performance of male or female WT mice (Figure 5.3). 
5.3.1.4 Brain mass 
 
Dietary intervention had no effect in altering the brain mass reduction seen in R6/1 mice (R6/1 
male BE vs control p = 0.587, R6/1 female BE vs control p = 0.738) (Table 5.1). Both male and 
female R6/1 mice fed control and BE supplemented diets had significantly reduced brain mass 
when compared to WT mice (p < 0.001), with a mean reduction of 10-15%. 
 
 
 
 
 
 
 
 
 
 
 Control diet BE 
WT R6/1 WT R6/1 
Male 467 ± 8 397 ± 14 465 ± 8 388 ± 5 
Female 460 ± 6 405 ± 13 458 ± 5 410 ± 5 
Table 5.1 Brain mass of R6/1 and WT mice fed a berry extract supplemented diet.  Values represent 
mg ± SEM. n = 6 per group. BE = Berry extract 
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Figure 5.3 The effect of berry extract supplementation on the RotaRod motor performance of R6/1 mice. 
Berry extract (BE) supplementation attenuated the motor function decline in R6/1 females when 
compared to control fed R6/1 mice (p = 0.0349). No detectable improvement in RotaRod performance 
was observed in male R6/1 mice fed a BE diet. Diet treatment did not influence RotaRod performance of 
WT mice over the course of the study. n = 6 per group. Error bars represent + SEM. 
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5.3.2 Sterol analysis of R6/1 brain tissue 
 
At the age of 25 weeks all mice were sacrificed for brain lipid analysis. Striatum and cortex was 
dissected from the brain and sterols were analysed using GC-MS/MS. Dietary supplementation 
with BE had no detectable influence in WT or R6/1 mice when examining the level of cholesterol 
synthetic precursors, metabolic products, oxidation products and phytosterols quantified in this 
study. No significant sex differences were observed in WT or R6/1 mice. The sterol profile of 
R6/1 vs WT mice was consistent to the results obtained in Chapter 3 and 4 at a similar time-
point of 24 weeks. Sterol compounds examined in this study included; [cholesterol synthetic 
precursors (lathosterol, lanosterol, zymosterol, 24,25 dihydro lanosterol, desmosterol, 7-
dehydrocholesterol), metabolic products (24-OHC, 27-OHC), oxidation products (7-KC, 7β-OH), 
phytosterols (campesterol, β-sitosterol, stigmasterol, brassicasterol) and cholesterol]. 
Quantified values for all sterols measured can be found in Appendix 7-9.  
 
 
 
 
 
 
 
 
 
 
105 
 
5.4 Discussion 
 
The R6 mouse models of HD have been previously used to examine a variety of therapeutic 
strategies targeting multiple aspects of HD pathology that is manifested in these mice. These 
include studies addressing: metabolic impairment, protein misfolding, inflammation, 
excitotoxcity and oxidative stress through strategies such as drug treatments, gene therapies, 
tissue transplantation, environmental enrichment and dietary interventions (Ferrante et al., 
2000; van Dellen et al., 2000; van Dellen et al., 2001; Ferrante et al., 2002; Wang et al., 2005; 
Maher et al., 2011). These interventions have typically generated small improvements in motor 
dysfunction and survival of mice, and have increased the current understanding of mechanisms 
involved in HD pathology. Novel therapeutics are likely to take many years to develop and test 
for safety, hence many studies in animals have trialled already approved drugs (lithium chloride, 
remacemide, riluzole) with some success, reducing the severity of motor phenotypes and 
increasing survival of animals (Ferrante et al., 2002; Schiefer et al., 2002; Wood & Morton, 2003). 
An advantage of dietary supplementation is that the active compounds used to treat disease are 
safe and already consumed on a daily basis. A large number of foods containing phytochemicals 
believed to have health benefits have been identified recently, among these are anthocyanins, 
phenolic compounds that are highly concentrated in berries. BE has been used to reduce age-
related cognitive deficits and improve memory and cognition in rats (Joseph et al., 1999; 
Casadesus et al., 2004; Galli et al., 2006; Duffy et al., 2008). The dosing of anthocyanins 
consumed by rats in these studies is equivalent to the consumption of approximately 100-150g 
of fresh berries (blueberry, blackberry, blackcurrant) per day in humans. Several other plant 
derived phenolic compounds have been trailed in animal models of neurodegeneration 
including HD (Ehrnhoefer et al., 2006; Maher et al., 2011). Prior to experimentation in this 
chapter, BE has not been investigated in HD models. Here we discuss the benefits, and possible 
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protective mechanisms, of phytochemical supplementation in brain related disorders, 
specifically in HD and the R6/1 HD mouse model.  
5.4.1 Motor performance in R6/1 transgenic mice and possible protective mechanisms of 
dietary phenolics in the brain 
 
In this study we describe the novel use of BE to improve motor function in the R6/1 HD mouse 
model. Our study was able to identify a significant improvement in the RotaRod performance of 
female R6/1 mice. Although there is a trend for improved function in the later stages of disease 
in male R6/1 mice, this did not reach statistical significance. It is possible that due to the more 
rapid onset of symptoms in male R6/1 mice as reported in Chapter 3, we have not been able to 
detect a significant level of improvement in male mice. This is consistent with the greatest effect 
of BE supplementation in females occurring at the onset of symptoms at 11-15 weeks, delaying 
the onset of motor dysfunction by several weeks. Improvements in motor function have also 
been observed in aged rats fed a BE supplemented diet (Shukitt-Hale et al., 2009). Several other 
studies using BE supplementation in rats have seen improvements in memory and 
neurolophysiological deficits associated with aging in the brain (Joseph et al., 1999; Goyarzu et 
al., 2004; Ramirez et al., 2005; Galli et al., 2006; Duffy et al., 2008). In many studies using dietary 
phenolic supplementation, young and healthy WT controls do not show the same level of 
improvement in brain biochemistry or motor and cognitive performance when compared to 
aged or disease models (Duffy et al., 2008; Wang et al., 2010; Willis et al., 2010). This suggests 
that phenolic supplementation specifically attenuates disease pathology (or ageing) rather than 
an overall improvement of neurological function. 
The dose of BE and the anthocyanins contained in this diet is also an important consideration 
when conducting and comparing studies, or assessing the feasibility of dietary berry 
consumption for therapeutic purposes. Our current study has used a commercially available 
blackcurrant anthocyanin extract with a known concentration of anthocyanins. The dose of 
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anthocyanins equated to the consumption of approximately 100-150 g of berries per day in 
humans (300 mg total anthocyanins) assuming a daily intake of 3 g of diet in mice. Total 
anthocyanin content of berries varies between species; blueberries, blackberries and 
blackcurrants contain approximately 1.5-2 mg, 2 mg and 3 mg total anthocyanins per gram fresh 
weight respectively (Scalzo et al., 2008). Previous studies in rats have used lyophilised extracts 
by homogenising whole blueberries (Joseph et al., 1999; Youdim et al., 2000; Andres-Lacueva et 
al., 2005), however the exact anthocyanin content has not been described. Assuming no 
anthocyanins have been lost in this process, the dosing is similar to that used in our study; 
approximately equal to the consumption of 100-150 g of fresh berries per day in humans. One 
aspect that has been overlooked however is the potential loss of anthocyanins during the 
extraction process. Oven drying and lyophilisation has been demonstrated to reduce the total 
anthocyanin content of blueberries and grape skin (Lohachoompol et al., 2004; de Torres et al., 
2010). It is therefore important to quantify total anthocyanins in extracts to identify the exact 
quantity of the active molecule being utilised in diet treatments. 
Due to the heterogeneity of phytochemical structures found in food, it is likely that different 
classes of compounds or even different compounds of similar structure act through diverse 
mechanisms. Several hypothesised mechanisms have been suggested to explain the 
neuroprotective properties of BE supplementation.  One hypothesis focuses on the antioxidant 
properties of BE containing anthocyanins and other phenolic compounds. Several studies using 
a BE supplemented diet describe reduced levels of oxidative stress markers in rat brain (Joseph 
et al., 1999; Elks et al., 2011). In vitro studies have also reported cells treated with BE and grape 
seed extract as having enhanced survival against oxidative stress (Duffy et al., 2008; Wang et al., 
2010). However, the physiological relevance of the dose of phytochemicals used in these cell 
culture studies is unknown. Our study did not detect altered lipid peroxidation in the brain of BE 
supplemented R6/1 or WT mice when quantifying the cholesterol oxidation products 7-KC and 
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7β-OHC. Lipid peroxidation was not previously identified as being altered in R6/1 compared to 
WT mice (Chapter 3) and therefore antioxidant effects by suppressing lipid peroxidation is 
unlikely to confer a strong protective effect towards the HD mice in our study. 
Hormesis has been suggested as a mechanism through which phytochemicals such as 
anthocyanins may confer health benefits. A hormetic response involves a low dose of a toxin (or 
stressor) promoting or upregulating protective survival factors in an organism, which then have 
enhanced survival prospects against future toxic insults such as increased oxidative stress in 
aging or that caused by mHTT in HD. Dietary phytochemicals have been shown to increase the 
immune response (Feng et al., 2002), expression of cytoprotective proteins (McWalter et al., 
2004) and have anti-inflammatory properties (Willis et al., 2010). Attenuated age-related 
neurological deficits also suggests the upregulation of prosurvival mechanisms by these 
compounds (Casadesus et al., 2004; Goyarzu et al., 2004; Galli et al., 2006). However, high 
concentrations of phytochemicals can also be toxic as demonstrated by in vitro studies (Liontas 
& Yeger, 2004; Fimognari et al., 2005). A previous study feeding BE to rats describes a similar 
hormetic response when reactive oxygen and nitrogen species were elevated in short fed 
animals term (2 days), while the same markers where significantly decreased in chronic fed 
animals (6 and 12 weeks) (Elks et al., 2011). A future study into the survival of BE fed HD mice 
would be useful to identify if this supplementation can delay death in R6/1 mice. In the current 
study, lipid analysis of brain tissue required all mice to be sacrificed at a predetermined time 
point and therefore a survival study could not be conducted. 
There is substantial evidence to suggest that BE and anthocyanins also influence cellular 
signalling pathways in the brain that may result in neuroprotection and promote proliferation. 
BE supplementation has been shown to increase extracellular signal-related kinase (ERK) 
phosphorylation in aged rat brains (Williams et al., 2008). The ERK signalling cascade has a role 
in altering synaptic plasticity and dendritic morphology relevant to memory (Bailey et al., 1997; 
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Wu et al., 2001), and essential neuronal transcriptional events (Sweatt, 2004). A recent study in 
a HD cell and fly model identified increased ERK phosphorylation with supplementation of fisetin 
(a flavonoid found in fruit) (Maher et al., 2011). Fisetin was able to reduce photoreceptor 
degeneration pathology and increase survival in a dose dependant manner in a HD fly model 
(Maher et al., 2011). Fisetin was also supplemented in the diet of R6/2 HD mice that exhibited 
improved motor performance and also increased survival (Maher et al., 2011). In addition to 
modification of ERK phosphorylation by BE anthocyanins in rats, Williams et al, (2008) found 
increased cAMP response element-binding protein (CREB) phosphorylation. CREB is involved 
with gene transcriptional regulation (Carlezon et al., 2005), including that of BDNF (Tao et al., 
1998; Yu et al., 2012). The BDNF gene codes for the neurotrophin BDNF, that has functions in 
cell survival, differentiation and growth (Binder & Scharfman, 2004), and is significantly reduced 
in HD (Zuccato et al., 2001; Zuccato et al., 2005). BDNF levels have not been reported in 
phytochemical supplemented HD mouse models, however the current literature on HD 
pathophysiology suggests rescued BDNF levels may be one mechanism by which BE 
supplementation improves the HD phenotype described.  
There is evidence to suggest that mHTT aggregation plays a significant role in HD pathogenesis 
(Gutekunst et al., 1999; Yang et al., 2002), and therefore the inhibition of aggregation has been 
the target of therapies to reduce HD severity. Dietary supplementation of a green tea-derived 
phenolic compound reduced the disease phenotype of a HD fly model (increased movement and 
reduced photoreceptor degeneration), and reduced mHTT aggregates in a HD cell model 
(Ehrnhoefer et al., 2006). It was therefore proposed that the protective effects of this phenolic 
compound are conveyed through inhibition of mHTT aggregation (Ehrnhoefer et al., 2006). 
Further evidence from a study using a grape seed extract reported decreased mHTT aggregation 
in a HD cell model, increased survival of a HD fly model and improved RotaRod performance of 
the R6/2 HD mouse model (Wang et al., 2010). Interestingly the same cell model treated with 
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fisetin did not prevent mHTT aggregation (Maher et al., 2011). Although our current study, or 
previous studies in phytochemical supplementation in HD mice have not examined mHTT 
aggregation, the available evidence suggests that the beneficial effects of different phenolics 
may work through multiple different mechanisms to result in an improved phenotype. Future 
investigation into a cocktail of phytochemical supplements would support this idea further and 
possibly highlight a supplementation regime that has more potent therapeutic effects than 
single compounds or extracts alone. 
5.4.2 Cholesterol homeostasis and BE supplementation in R6/1 mice 
 
In this study we also investigated alterations to cholesterol homeostasis in R6/1 mice receiving 
BE supplementation. BE supplementation did not result in significant alterations to the sterol 
profile (alteration of synthetic and metabolic products of cholesterol) previously identified in 
the R6/1 mouse model (Chapter 3). Previously BE supplementation improved ERK 
phosphorylation (Williams et al., 2008) and this may influence BDNF levels, and in turn alter 
cholesterol homeostasis. However, the cholesterol synthetic deficits began early in the R6/1 
model (6 weeks of age, Chapter 3) and therefore the age at which supplementation is initiated 
in HD models may significantly affect the relative benefits of the treatment. Several past dietary 
studies in HD animal models began supplementation at the embryonic development stage, by 
feeding the P1 generation and continuing supplementation after birth (Clifford et al., 2002; 
Ehrnhoefer et al., 2006; Wang et al., 2010). Another possible strategy for future dietary studies 
is intermittent supplementation; this has been suggested to potentially enhance a hormetic 
response that may be caused by these phytochemicals (Mattson, 2008).  
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5.4.3 The influence of BE on hind paw clasping in R6/1 mouse 
 
A small delay in the onset of the hind paw clasping phenotype was observed in BE supplemented 
male R6/1 mice, however an overall improvement during the later stages of the study was not 
observed in either male or female R6/1 mice. It is possible that the hind paw clasping phenotype 
is controlled by a brain region or neurological process that is not specifically improved through 
dietary anthocyanin intervention. Hind paw clasping represents a reflex response in contrast to 
motor co-ordination measured by the RotaRod apparatus. The idea that different brain regions 
control different functions is well established, and the manifestation of broad behavioural 
symptoms in HD is likely to be the result of neurodegeneration in multiple brain regions. HD 
brain pathology is indeed widespread, following early striatal degeneration, atrophy is found in 
the globus pallidus, accumbens, amygdala, thalmus and cerebral cortex (Vonsattel et al., 1985; 
Rosas et al., 2003). Tissue transplant studies in the anterior cingulate cortex of R6/1 mice have 
identified an improvement in hind paw clasping but no change in RotaRod performance (van 
Dellen et al., 2001). Similarly hind paw clasping and several involuntary phenotypes (sniffing, 
rearing, grooming) were improved in fatty acid fed R6/1 mice without rescuing striatal pathology 
(Clifford et al., 2002). The same fatty acid supplementation has proved effective in mouse 
models of dyskinesia (involuntary movement disorder) (Vaddadi et al., 2006), possibly acting to 
rescue a similar region involved with choreic movements in HD mice. Although sensitive and 
specific volumetric analysis of R6 mouse brain has been conducted to investigate gross cell loss 
(Sawiak et al., 2009), future work investigating molecular alterations in HD mouse brain may 
benefit from analysing tissue samples derived from micro dissection techniques that facilitates 
high resolution sampling.   
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5.4.4 Body weight loss and brain mass of R6/1 mice receiving a BE diet 
 
 The weight loss phenotype was not attenuated in male or female R6/1 mice fed a BE 
supplemented diet. The only detectable effect was a reduced weight gain in BE male R6/1 mice 
when compared to control R6/1 males. However, due to the baseline difference in body weight 
of control and BE fed animals (resulting form randomisation), the difference in weight gain is 
likely to be a chance event. Previous literature also reports that BE supplementation does not 
modify the body weight of rodents (Sweeney et al., 2002; Goyarzu et al., 2004; Duffy et al., 2008; 
Rashid et al., 2014). The majority of therapeutic interventions in the R6 mouse models target 
brain alterations and therefore do not restore the peripheral metabolic deficit that is a classical 
symptom of HD. Studies addressing HD metabolic deficits in R6 mice using dietary restriction 
(Duan et al., 2003) or creatine supplementation (Ferrante et al., 2000) have reported a small 
improvement in weight loss, however it is not completely rescued. Total food consumption is 
also a consideration for dietary invention studies; in the present study it is unlikely that average 
food consumption per cage was influenced by diet, similar to a previous BE study in rats (Elks et 
al., 2011) and a preliminary study in WT mice (Jenner, A.M., pers. comm. 2015). In this study the 
specific food intake of WT and R6/1 mice could not be determined due to equal distribution of 
WT and R6/1 genotypes within cages. Separation of mice to measure food consumption was not 
performed to prevent potential stress and uncontrolled factors of social hierarchy and 
aggression between reunited mice. Previously, feeding habits have been shown to be unaltered 
by the mHTT transgene in R6 mice; however the typical weight loss profile is still observed 
(Mangiarini et al., 1996). This is consistent with the human HD symptomatology where weight 
loss is observed with equal or higher caloric intake (Sanberg et al., 1981; Morales et al., 1989). 
This suggests that food intake was most likely not a factor contributing to R6/1 weight loss in 
our current study. 
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Previous studies have approached phytochemical supplementation by either feeding animals a 
concentrated plant extract (Papandreou et al., 2009; Wang et al., 2010; Maher et al., 2011) 
similar to our current study, or a purified phytochemical compound (Ehrnhoefer et al., 2006; Ho 
et al., 2010). Experimental designs that supplement fruit extracts containing a mixture of 
phytochemicals do not have the specificity required to identify a single molecular mechanism of 
action, however fruit extracts are more relevant in a dietary context as they represent the 
phytochemical mixture readily available for human consumption.  
In this study there was no detectable effect of BE supplementation on the brain mass of R6/1 
mice. Improved motor and cognitive performance independent of improved brain mass in R6 
mice has been observed in several studies (Spires et al., 2004; van Dellen et al., 2008), and 
suggests that significant recovery of the brain mass phenotype in these mice may not be 
necessary to improve the symptomatic outcome of HD.   
5.4.5 Therapeutic intervention and bioavailability of phytochemicals 
 
Delivery of active molecules and compounds to the site of action is a major challenge to treat 
many diseases, and is one factor that explains why many improvements in vitro are not exactly 
matched in vivo. Compounds must remain stable and un-modified until the target site is 
reached; oral delivery must also survive the low pH in the stomach and be absorbed into the 
bloodstream. Addressing neurological disorders and neurodegenerative diseases present 
additional complications as therapeutic agents must pass the BBB. Permeability of the BBB is 
dependent on several factors including active transport across the membrane, molecular weight 
and lipid solubility (Banks, 2009). Phytochemical compounds previously investigated in HD are 
relatively small molecules, and in the case of anthocyanins contained in BE, are able to cross the 
BBB and penetrate regions which have improved with treatment (Andres-Lacueva et al., 2005; 
Kalt et al., 2008). As many phytochemicals, including anthocyanins are consumed daily in a 
normal diet, the process of assessing potential toxicity in humans is simplified compared to 
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newly developed drugs. These features make phytochemicals such as anthocyanins potentially 
useful therapeutic agents that can be easily implemented to treat disease within the brain.  
5.4.6 Conclusion 
 
Dietary phytochemicals, specifically anthocyanins in BE are reported to have substantial 
protective effects in the aged and diseased brain. The motor phenotype of R6/1 HD mouse 
model was attenuated in female mice through dietary supplementation of BE in our study. 
Several mechanisms may be responsible for improvements seen in HD models treated with BE 
supplementation. These include; rescued cell signalling, anti-aggregation, antioxidant and anti-
inflammatory mechanisms that may be stimulated by a hormetic response. Different 
phytochemicals are likely to work through different mechanisms, and specifically in BE 
supplemented HD, may deliver therapeutic benefits to address a dysfunction of motor co-
ordination, but not involuntary reflex movement such as hind paw clasping as seen in this study. 
The progressive weight loss and brain mass reduction observed in HD mouse models was not 
rescued by BE supplementation; however these phenotypes are not necessarily rescued in 
conjunction with motor and cognitive improvements. Our study was unable to detect an 
alteration of the cholesterol homeostatic deficit that is observed in R6/1 mice. Nevertheless, 
previous findings that consistently demonstrate ameliorated age-related brain deficits with BE 
supplementation, and our current finding of improved motor function in R6/1 mice, indicates 
this dietary supplement should be investigated more thoroughly in HD. 
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Chapter 6                                          
Cholesterol metabolism in Huntington's 
disease post-mortem brain tissue 
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6.1 Introduction 
 
HD is an autosomal dominant, progressive neurodegenerative disease characterised by the 
expansion of a glutamine repeat on the N-terminus of HTT. Classic symptoms include involuntary 
movement and cognitive dysfunction. The classical neuropathological hallmark of HD is the 
severe atrophy of the striatum (caudate and putamen) (Vonsattel et al., 2011), with substantial 
volume loss in the order of 50% in late stages of the disease. While these brain regions are most 
severely affected, MRI techniques have highlighted that the hippocampus, cerebral cortex, 
globus pallidus and amygdala also have reduced volume in HD patients (Rosas et al., 2003). 
Despite the genotypic identification of mHTT carriers, there is a lack of reliable biomarkers to 
predict HD progression or effectiveness of therapies. The mutation of HTT has been reported to 
alter HTT-phospholipid interactions (Kegel et al., 2009), membrane organisation (del Toro et al., 
2010) and gene transcription of lipid metabolic enzymes (Sipione et al., 2002). Several studies 
have also identified that cholesterol synthesis and metabolism in HD cell lines and animal models 
is significantly disturbed (Valenza et al., 2005; Valenza et al., 2007b; Valenza et al., 2010), 
however the current literature contains very limited data obtained from human tissue, which is 
required for greater understanding of human HD pathophysiology. In this chapter we have 
investigated for the first time the level of cholesterol metabolites, synthetic precursors and 
oxidation products in 13 cases of human HD and 13 matched healthy controls across 5 brain 
regions, to comprehensively profile sterol changes in human brain. This study also investigated 
the levels of two key cholesterol synthetic and metabolic enzymes in HD putamen.  
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6.2 Materials and methods 
 
Materials: Materials used in this study are listed in 2.2.  
Human brain tissue: Frozen brain tissues from five brain regions (putamen, caudate, cerebellum, 
grey and white frontal cortex) were received from the Victorian Brain Bank Network. The cohort 
contained 13 cases of HD and 13 controls from each brain region. Tissue was transported on dry 
ice and stored at -80°C until analysis. Demographic and basic clinical data are presented in Table 
6.1. The mean age of control cases was 68.9 ± 1.9 y which was not significantly different from 
the HD cases with mean age of 67.3 ± 2.2 y. Post mortem interval (PMI) of control cases (41.5 ± 
4 h) and tissue pH (6.4 ± 0.1) was not significantly different to HD PMI (37.5 ± 6.2 h) or tissue pH 
(6.4 ± 0.04). All brain tissue was from the left hemisphere of Caucasian donors. Ethics approval 
was from the University of Wollongong Human Research Ethics Committee (HE10/327). Control 
tissue was screened with a full neuropathology examination to determine the absence of 
degenerative pathologies. The research was carried out in accordance with the Declaration of 
Helsinki (2008) of the World Medical Association.  
Western Blotting: Brain tissue (~20 mg) was added to 250 µL ice cold radio-immunoprecipitation 
assay (RIPA; 50 mM Tris, 150 nM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 100) 
buffer containing 1% protease inhibitor (P8340, Sigma) and homogenised at 4°C using a Precellys 
24 homogeniser (Bertin Technologies) (2 x 20 s, 6000 rpm). The homogenate was centrifuged at 
14 000 x g and the soluble fraction taken for SDS-PAGE. Homogenates were incubated at 95°C 
for 10 min with 5x loading dye containing β-mercaptoethanol. Equal amounts of protein (90 µg, 
determined by a BCA assay) were loaded onto a 12% acrylamide gel and electrophoresed for 1 
h at 150V. Proteins were then transferred onto a 0.4 µm nitrocellulose membrane (BIO-RAD, 
Gladesville, NSW, Australia) for 35 min at 100V. To improve antigen detection, boiling phosphate 
buffered saline + tween 20 (PBST) (50 mL) was added to the membrane and left to cool to room 
temperature. The membrane was blocked with a 10 mL solution of PBST containing 5% skim milk 
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powder, rocking for 1 h at room temperature. Membranes were probed with antibodies 
detecting CYP46A1 1:100 (1F11, Santa Cruz Biotechnology) and DHCR24 1:1000 (ab137845, 
Abcam). Antibodies were diluted in 10 mL PBST 5% skim milk powder and incubated with 
membranes overnight, rocking at 4°C. Membranes were washed 3 x 10 min with PBST at room 
temperature before being incubated for 1 h at room temperature with a species specific IgG-
HRP conjugated secondary antibody (1:3000). Membranes were washed 3 x 10 min with PBST 
before chemiluminescent detection of signal. Membranes were stripped, washed and re-probe 
for β-actin (1:10 000) following the protocol outlined above. Signal intensity was quantified using 
ImageJ software V1.46r (National Institutes of Health, USA), and normalised for β-actin. 
qPCR: The quantitative PCR of human brain tissue was performed as previously described 
(Abbott et al., 2014) with minor modifications. Briefly, human tissue (~30mg) was added to 10 
volumes of TRIzol reagent (wt:vol) and homogenised in a Precellys 24 homogeniser at 2 x 20 s at 
5500 rpm. The RNA concentration and purity was determined spectrophotometrically with a 
Nanodrop 1000 (Thermo Scientific). Following the manufacturer’s protocol, 2 µg of total RNA 
was used to synthesise cDNA using a Tetro cDNA synthesis kit (Oligo dT18) (Bioline, Sydney, 
Australia). Quantitative PCR was performed using a Roche Lightcycler 480 using SensiFAST SYBR 
No-ROX kit (Bioline) following the manufacturer’s instructions. Analyses were carried out in 
triplicate and gene of interest mRNA was normalised to GAPDH mRNA levels. Gene expression 
was calculated using the comparative threshold cycle (Ct) value method using the formula 2-ΔΔCt 
(ΔΔCt = ΔCt sample – ΔCt reference) as described (Li et al., 2012). All primers were purchased 
from Sigma Aldrich (Sydney, Australia). The primer sequences used were as follows: CYP46A1 (F: 
TTCTAGGACACCTCCCCTGC and R: CAGGTCCATACTTCTTAGCCCAAT) DHCR24 (F: 
TGTTCGTGTGCCTCTTCCTC and R: ATTCCCGCACCTGCTTCTG) GAPDH (F: 
GAGCACAAGAGGAAGAGAGAGACCC and R: GTTGAGCACAGGGTACTTTATTGATGGTACATG) 
RNU6-6P (F: CTCGCTTCGGCAGCACA and R: AACGCTTCACGAATTTGCGT). 
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Lipid extraction and GC-MS/MS analysis of sterols: Quantification of cholesterol synthetic 
precursors, metabolites, oxidation products and phytosterols was performed as outlined in 2.3.5 
and 2.3.6. 
Statistical Analysis: All results are expressed as mean ± SEM with a P < 0.05 considered 
significant. An unpaired t-test was used to test for significantly different means, an F-test was 
used to determine if variances were significantly different. Welch’s correction for unequal 
variances was used when variances were found to be significantly different. All analyses were 
performed in Graphpad PRISM v5.0 (Graphpad Software Inc., USA). 
 
Table 6.1 Demographic details of control and HD cohorts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case# Gender Age (y) PMI (h) pH HD Grade 
stage(0-
IV) 
Con 1 M 78.3 46 6.54 - 
Con 2 M 69.1 34 6.31 - 
Con 3 M 63.9 54.5 6.51 - 
Con 4 M 81 36.5 6.56 - 
Con 5 M 64.1 24 6.56 - 
Con 6 F 59 30 6.84 - 
Con 7 F 67.3 30 6.23 - 
Con 8 F 74.8 61.5 6.24 - 
Con 9 F 68.3 71.5 6.34 - 
Con 10 F 60.4 49 6.23 - 
Con 11 M 63.9 32 6.47 - 
Con 12 M 69.4 24 6.27 - 
Con 13 M 75.6 46 6.57 - 
HD 1 M 77 8.5 6.57 IV 
HD 2 M 68.7 72 6.32 IV 
HD 3 M 61.1 17 6.54 IV 
HD 4 M 81.1 50.5 6.23 IV 
HD 5 M 66.6 37 6.26 IV 
HD 6 F 57.2 22 6.22 IV 
HD 7 F 66.7 18.5 6.21 IV 
HD 8 F 72.2 22 6.43 IV 
HD 9 F 70.7 70 6.16 IV 
HD 10 F 51.5 63.5 6.54 IV 
HD 11 M 62.3 21.5 6.62 IV 
HD 12 M 65.9 58 6.33 IV 
HD 13 M 73.9 26.5 6.31 IV 
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6.3 Results 
 
6.3.1 Sterol analysis 
 
Human HD post mortem brain tissue from putamen, caudate, frontal cortex (grey and white) 
and cerebellum was analysed using heavy isotope dilution GC-MS/MS. Cholesterol metabolites, 
oxidation products and synthetic precursors are presented as percent relative change compared 
to control (Figure 6.1). Absolute values of sterols measured are provided in Appendix 10. 
6.3.1.1 Cholesterol metabolites 
 
The most significant changes were detected in HD putamen, a region that is severely affected in 
HD (Vonsattel et al., 1985). The brain specific cholesterol metabolite 24-OHC, was reduced 59% 
(p < 0.0001) in HD putamen (Figure 6.1A). Caudate was the only other region to show changes 
in this metabolite with a 66% reduction (p = 0.0009) of 24-OHC in HD tissue compared to control 
tissue (Figure 6.1A). 27-OHC, a peripheral cholesterol metabolite was significantly increased by 
3-fold in HD putamen (p = 0.0107).  27-OHC was also significantly increased 3-fold in grey frontal 
cortex (p = 0.0117) and 2-fold in cerebellum (p = 0.0281) (Figure 6.1A). 
6.3.1.2 Cholesterol oxidation products 
 
HD putamen was the only brain region to show evidence of oxidative stress, with a 53% and 69% 
increase in the cholesterol oxidation products 7β-OHC (p = 0.0226) and  7-KC (p = 0.0009) 
respectively (Figure 6.1B). 
6.3.1.3 Cholesterol synthetic precursors 
 
Altered cholesterol synthesis was evident in HD putamen which exhibited an increase in the 
cholesterol synthetic precursors, desmosterol (3-fold, p = 0.0046), lathosterol (2-fold, p = 
0.0405), zymosterol (3-fold, p = 0.0066) and 24, 25 dihydro lanosterol (2-fold, p = 0.0051) (Figure 
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6.1C). Total cholesterol levels were also significantly increased by 31% in HD putamen (p = 
0.0342) (Figure 6.1D). No other brain regions were found to have significant changes in 
cholesterol precursors, or cholesterol levels. 
6.3.2 Cholesterol metabolic and synthetic enzymes 
 
To further investigate pathways that may contribute to changes in brain cholesterol metabolism 
and synthesis observed in putamen, we examined two major enzymes involved by western 
blotting. The protein level of CYP46A1 in HD was reduced 90% compared to control (p = 0.0027) 
(Figure 6.2A). We also detected a significant (91%) reduction (p = 0.0014) of DHCR24 protein 
levels (Figure 6.2B), which is in agreement with the accumulation of desmosterol seen in HD 
putamen (Figure 6.1B). 
The mRNA levels of the genes CYP46A1 and DHCR24 were also measured in putamen using 
quantitative PCR. mRNA levels did not reflect protein levels and were not significantly changed 
between HD and control tissue in both CYP46A1 and DHCR2 (Figure 6.3). 
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Figure 6.1 Sterol levels in human HD putamen, caudate, grey cortex, white cortex and cerebellum. (A) 
Cholesterol metabolites (B) Cholesterol oxidation products (C) Cholesterol synthetic precursors (D) 
Cholesterol were measured by GC-MS/MS.  Levels are expressed as a percentage change against control 
tissue. n = 12-13 per group, error bars represent +SEM *** p < 0.0001, **p < 0.005, *p < 0.05 
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Figure 6.2 Protein level of cholesterol synthetic and metabolic enzymes in human HD putamen. Brain 
tissue homogenates from HD and control were probed for (A) cholesterol 24-hydroxylase (CYP46A1) and 
(B) delta(24)-sterol reductase (DHCR24) by western blotting. Representative blots are shown (n = 3 per 
group). Integrated optical density for all blots (n = 9 per group) is represented as relative abundance 
compared to control (assigned a value of 1.0). Blots were normalised to β-actin level. Error bars represent 
+SEM. **p < 0.005 
Figure 6.3 mRNA levels of genes coding for cholesterol synthetic and metabolic enzymes in human HD 
putamen. The level of CYP46A1 (coding for cholesterol 24-hydroxylase) and DHCR24 (coding for delta(24)-
sterol reductase) in brain tissue was determined by qPCR (n = 9 for control and HD). The genes of interest 
were normalised to GAPDH and RNU6-6P mRNA levels and expressed relative to control (assigned a value 
of 1.0). Error bars represent +SEM 
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6.4 Discussion 
 
Alteration of cholesterol metabolism has been recently linked to several neurodegenerative 
diseases including AD, PD and HD (Sipione et al., 2002; Puglielli et al., 2003; Cheng et al., 2011). 
In particular, the elimination pathway where 24-OHC is formed by the hydroxylation of 
cholesterol has been suggested as a contributing factor in neurodegeneration (Bjorkhem et al., 
2006). Neuronal 24-OHC has a major role in the turnover of cholesterol in the brain (Bjorkhem 
et al., 1998), and the level of 24-OHC in plasma has been suggested as a measure of CYP46A1 
enzymatic activity and thus metabolically active neurons (Bjorkhem, 2006).  
6.4.1 Alteration of cholesterol metabolism in human Huntington’s disease brain 
 
Previous studies have found that the plasma levels of 24-OHC in HD patients correlate with 
disease severity and brain volume measured by MRI (Leoni et al., 2008; Leoni et al., 2013). Here 
for the first time we report the levels of 24-OHC in human HD post-mortem brain tissue. A 
significant reduction of 24-OHC was found in HD putamen accompanied by a large (90%) 
reduction in the protein level of CYP46A1, the enzyme responsible for 24-OHC formation. 
Reduced enzyme levels may be due to neuron loss, where CYP46A1 is primarily located. 
Alterations in post-transcriptional regulation may also play a role since no change in mRNA 
expression was detected between control and HD. This is potentially relevant as protein 
turnover is known to be dysregulated in HD cell models (Hatters, 2008). Caudate (another 
striatal region affected in HD) also had reduced levels of 24-OHC, while grey and white frontal 
cortex and cerebellum showed no change. Although the cerebral cortex is affected in later stages 
of HD (de la Monte et al., 1988; Rosas et al., 2003), the degree of volume loss and astrocytosis 
is substantially less compared to the striatum (Sotrel et al., 1991; Vonsattel & DiFiglia, 1998; 
Rosas et al., 2003). Reduced 24-OHC levels in HD striatum supports previous human studies that 
reported reduced plasma levels of this metabolite in HD patients (Leoni et al., 2008; Leoni et al., 
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2013). Our data indicates that decreased circulating 24-OHC levels are likely the result of 
reduced 24-OHC production in affected regions and not an aberration of BBB 24-OHC flux. In the 
mature brain, delivery of cholesterol synthesised in the astrocyte is required for normal 
neuronal function (Posse de Chaves et al., 1997; Mauch et al., 2001; Hayashi et al., 2004).  It has 
been hypothesised that 24-OHC production in neurons acts as a signalling molecule to initiate 
the delivery of cholesterol from astrocytes to neurons therefore maintaining homeostasis 
(Pfrieger, 2003). There is also evidence to suggest that CYP46A1 may have neuroprotective 
properties, being upregulated near plaques (Brown et al., 2004) and in glia of the human AD 
brain (Bogdanovic et al., 2001). Whether reduced levels of CYP46A1 in HD is a secondary event 
reflecting active neuron loss, or is a pathogenic factor altering cholesterol metabolism and 
synthesis remains to be established. 
27-Hydroxycholesterol, a metabolite of cholesterol that is produced predominantly in peripheral 
tissue, was increased in several regions of human HD brain as compared to controls. While an 
increased flux of 27-OHC into the brain may be caused by a disrupted BBB, we believe this is not 
the case in this tissue since sterols that are present in higher peripheral abundance such as 
campesterol (a dietary derived phytosterol) were not significantly different between HD and 
control brain tissues (Appendix 10). As there is a net movement of 27-OHC from circulation into 
the brain (Heverin et al., 2005), 27-OHC accumulation may be the result of a decrease in the 
activity of enzymes in the brain (such as CYP27A1) that further metabolise this oxysterol to 
cholestenoic acids (Meaney et al., 2007). Accumulation of 27-OHC is potentially important in 
neurodegeneration since in vitro studies have shown 27-OHC promotes β-amyloidogenesis 
(Gamba et al., 2014) as well as being elevated in human AD brain and transgenic mice (Heverin 
et al., 2004; Shafaati et al., 2011). While there is little direct in vivo physiological evidence that 
cholesterol metabolites promote neuronal damage, further studies are required to investigate 
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the hypothesis that preventing the accumulation of 27-OHC in the brain reduces 
neurodegeneration in AD and HD. 
6.4.2 Alteration of cholesterol synthesis in human Huntington’s disease brain 
 
A defect in cholesterol synthesis has been previously described in several cell and mouse models 
of HD. Specifically; a reduction in the cholesterol synthetic precursors lathosterol and lanosterol 
as well as cholesterol in the YAC128 mouse (Valenza et al., 2007a), reduced levels of lathosterol 
and lanosterol, but not cholesterol, in the R6/2 mouse model (Valenza et al., 2007b), reduced 
mRNA levels of cholesterol synthetic enzymes in R6/2 mouse and human HD fibroblasts (Valenza 
et al., 2005) and reduced cholesterol synthetic enzymes in a transgenic HD cell model (Sipione 
et al., 2002). In contrast to these findings, our data on end stage human HD putamen shows an 
increase in cholesterol synthetic precursors from both the Bloch (desmosterol and 24,25 dihydro 
lanosterol) and Kandutsch-Russell (lathosterol and zymosterol) pathways and an increase in 
total cholesterol levels. No significant changes in squalene levels were observed (Appendix 10) 
suggesting that alterations in the upstream mevalonate pathway had no influence on the 
changes that we measured in the Kandutsch-Russell and Bloch pathways. The increase in 
cholesterol and synthetic precursors was only observed in the putamen; a region that 
degenerates early and severely in the human disease (Vonsattel et al., 1985). In contrast to 
macro and microscopic classification of disease pathology, which shows the caudate 
degenerates in parallel with the putamen (Vonsattel et al., 1985; Vonsattel & DiFiglia, 1998), we 
did not observe any cholesterol synthetic alterations in this region. While the cholesterol 
synthetic changes observed in the putamen may suggest an overall increase of cholesterol 
synthesis utilising both pathways, we believe this is not the case for the Bloch pathway. In our 
study, HD putamen had significantly higher levels of desmosterol, an immediate synthetic 
precursor of cholesterol (Bloch pathway) and a substrate of DHCR24. Significantly depleted 
protein levels of DHCR24 in human HD putamen (91% reduction) are consistent with the reduced 
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conversion of desmosterol to cholesterol and its subsequent accumulation. Unaltered mRNA 
levels of DHCR24 in putamen again suggests enzyme levels are being affected post-
transcriptionally. Previous in vitro examination of cholesterol synthesis in specific cell types 
found astrocytes utilise the Bloch pathway via desmosterol, while neurons primarily utilised 7-
dehydro cholesterol and other precursors from the Kandutsch-Russell pathway (Nieweg et al., 
2009). This suggests that in late stage human HD, desmosterol accumulates in astrocytes due to 
down regulated DHCR24. An increased density of oligodendrocytes and activated astrocytes is 
known to be present in HD (Myers et al., 1991) and is believed to be a compensatory response 
to demyelination in HD (Bartzokis et al., 2007). While the specific cell type/s exhibiting elevated 
Kandutsch-Russell synthetic precursors is yet to be determined, increased oligodendrocyte 
activity attempting remyelination in affected tissue may contribute to this.  
Previous studies in HD mouse brain reported a significant reduction of the cholesterol precursor 
lathosterol (Valenza et al., 2007a; Valenza et al., 2007b), which is found in the Kandutsch-Russell 
pathway. In contrast, the Bloch pathway precursor desmosterol, was either unchanged (Valenza 
et al., 2007a) or not reported (Valenza et al., 2007b) in these previous HD mouse studies. 
Examining precursors from both arms of the cholesterol synthetic pathway in these mouse 
models enables greater insight into the alterations occurring in different cell types, and their 
possible response to HD pathology / neurodegeneration. The differences seen between HD 
mouse models, in vitro cell models, and human post-mortem tissue may reflect a difference in 
the homeostatic response to mutant HTT between organisms and cell types. There is also a 
difference between the relative ages of mice being in early adulthood compared to end stage 
human HD tissue where the mean age was 67 years old. The differences in the data derived from 
our current study and previous mouse models and cell culture models may also reflect that in 
this human tissue study we examined end stage HD where a significant number of vulnerable 
neurons are predicted to have been lost. Examining earlier stages of the disease in brain tissue 
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is therefore important to consolidate the role of cholesterol synthesis and metabolism in the 
early stages of HD in humans. 
6.4.3 Cholesterol oxidation products in human Huntington’s disease brain 
 
Along with measuring cholesterol metabolites and precursors, our GC-MS/MS method was able 
to sensitively detect COPs, and use these as markers of oxidative stress in HD brain tissue. 
Oxidative stress has been previously shown in HD (Browne et al., 1999), and in several other 
neurodegenerative diseases (Subbarao et al., 1990; Ferrante et al., 1997; Cheng et al., 2011). 
Similar to changes seen in other sterols, significant increases in 7-KC and 7β-OHC were only 
observed in putamen. The specific increase in oxidation products in the putamen is consistent 
with this region being affected early and severely in HD (Vonsattel et al., 1985). 7-KC and 7β-
OHC have been shown to be stable, and previously used as markers of oxidative stress in plasma 
(Iuliano et al., 2003) and CSF (Leoni et al., 2005). Measurement of COPs in HD plasma together 
with other sterols may represent a convenient tool to follow progression, quantify severity, and 
assess therapeutic effectiveness in patients. Importantly, these markers can be measured 
sensitively and reliably by GC-MS/MS techniques. 
6.4.4 Consequences of altered cholesterol homeostasis in human Huntington’s disease brain 
 
Homeostasis of cholesterol is essential for neurological function however the precise role of 
cholesterol in HD neurodegeneration is still debated. Evidence suggests that cholesterol 
accumulation in HD alters membrane organisation and cell signalling, enhancing the 
susceptibility of striatal neurons to excitotoxicity (del Toro et al., 2010). Another hypothesis 
suggests that impaired cholesterol synthesis drives neurodegeneration by limiting the supply of 
cholesterol to neurons (Valenza et al., 2007a). As a result synaptogenesis and dendrite 
outgrowth is impaired (Mauch et al., 2001; Fan et al., 2002), and neurotransmission is disrupted 
(Koudinov & Koudinova, 2005). It is also believed that a reduction of BDNF in HD (Zuccato et al., 
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2001) may play a significant role in neurodegeneration (Zuccato & Cattaneo, 2009). BDNF is a 
neurotrophin expressed by neurons that promotes cell survival, differentiation and growth 
(Binder & Scharfman, 2004). Among these properties, BDNF has been shown to promote 
DHCR24 expression (Sarchielli et al., 2014). Therefore, a loss of BDNF action may also contribute 
to a reduction in DHCR24, and the cholesterol homeostatic imbalance we have detected in HD 
putamen. 
6.4.5 Conclusion 
 
Our study reveals for the first time that several cholesterol synthetic and metabolic pathways 
are disturbed in multiple brain regions of human HD. This disturbance was identified to be most 
severe in the putamen, a region that degenerates early and severely in HD.  These data provide 
evidence to support previous studies that link altered cholesterol synthesis, metabolism and 
oxidative stress with the neuropathological process involved in HD. Since HD shares similar 
sterol disturbances as other late-onset neurodegenerative diseases, we believe these changes 
represent potential biomarkers for neurodegenerative disease and elucidating cholesterol 
related mechanisms of neuropathology may provide targets for therapeutic intervention. The 
key finding of reduced CYP46A1 in human HD brain confirms previous studies in HD patient 
plasma that indicate 24-OHC as a promising peripheral biomarker to monitor the development 
of HD neuropathology. 
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Chapter 7                                             
General discussion 
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7.1 Cholesterol homeostasis alterations in Huntington's disease 
 
The functions of cholesterol biosynthesis and metabolism, although not fully understood in the 
brain, have been demonstrated to be essential for proper brain function (Kabouridis et al., 2000; 
Mauch et al., 2001; Hayashi et al., 2004); mutations in enzymes of the cholesterol synthetic 
pathway having severe neurological consequences in humans (Wassif et al., 1998; Waterham et 
al., 2001). The mutation of the HTT protein in HD is associated with alterations to cholesterol 
homeostasis and has been demonstrated consistently in multiple rodent and cell models 
(Sipione et al., 2002; Valenza et al., 2005; Valenza et al., 2007a; Valenza et al., 2007b; del Toro 
et al., 2010). Thorough investigation of cholesterol synthetic and metabolic alterations in human 
HD brain has not been conducted prior to the experiments in this thesis. Using sensitive GC-
MS/MS analytical techniques we have identified several alterations that are consistent between 
the R6/1 mouse model and human post mortem tissue. We have also identified several 
alterations that are not consistent, and require further investigation to determine the relevance 
of these changes to HD pathology. Here we discuss our data derived from the R6/1 mouse model 
in comparison to that obtained from human HD post-mortem tissue, and highlight HD specific 
alterations to cholesterol homeostasis and other pathways that require more detailed 
investigation in the HD brain. 
 
7.2 Brain cholesterol synthesis and metabolism in human and mouse models of HD 
 
Although many animal models of neurodegenerative disease are able to replicate some 
pathological hallmarks of a disease, they rarely replicate precisely the condition observed in 
humans. This is due to fundamental differences between species in; diet, metabolism, ageing as 
well as the physical size of the brain. Aside from some of these limitations, mice have been 
genetically manipulated to model several neurodegenerative diseases including AD, PD, MND 
132 
 
and MS (Mucke et al., 2000; Bettelli et al., 2003; Laird et al., 2008; Gispert et al., 2009).  In the 
case of HD, generation of several mouse models expressing forms of mutated human HTT 
(Mangiarini et al., 1996; Hodgson et al., 1999; Slow et al., 2003) as well as knock-in expanded 
mouse huntingtin (Wheeler et al., 1999), have allowed for in vivo study of the mechanisms that 
underlie HD. In this study we have investigated the R6/1 mouse model, expressing a CAG 
expanded (115-120 repeats) exon 1 of human HTT, similar to the R6/2 model that expresses a 
longer CAG repeat (Mangiarini et al., 1996). Multiple aspects of HD pathology have been 
investigated in the R6 models as they show many of the molecular and physical phenotypes of 
human HD. These include similarities in gene expression changes (Strand et al., 2007), reduced 
levels of BDNF (Spires et al., 2004; Zuccato et al., 2005), nuclear inclusions (Hansson et al., 2001; 
Meade et al., 2002) and cannabinoid receptor downregulation (Denovan-Wright & Robertson, 
2000; Naver et al., 2003; Horne et al., 2013). A physical phenotype indicative of human HD is 
also observed in these mice that includes, a progressive motor and cognitive dysfunction, weight 
loss, striatal atrophy and chorea (Mangiarini et al., 1996; Hansson et al., 1999; Murphy et al., 
2000; Naver et al., 2003). 
In this study we have focused on characterising cholesterol synthetic and metabolic alterations 
in HD. Based on several studies in mouse and cell models, cholesterol synthesis (by measure of 
cholesterol synthetic precursors lathosterol and lanosterol) is believed to be reduced in HD 
(Sipione et al., 2002; Valenza et al., 2005; Valenza et al., 2007a; Valenza et al., 2007b). Prior to 
our study, cholesterol homeostasis has not been sufficiently examined in human HD brain tissue, 
with three previous studies using a maximum of 3 cases of HD post-mortem tissue (Valenza et 
al., 2005; del Toro et al., 2010; Samara et al., 2014). Our study, and previous studies examining 
cholesterol levels in aged human brain have shown cholesterol levels to be variable (Thelen et 
al., 2006), and studies using small samples may therefore lack statistical power to identify 
changes, or are susceptible to identifying false positives. Analysis of 5 regions in 13 cases of late 
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stage human HD post mortem brain tissue in our study has revealed an increase in cholesterol 
synthetic precursors of the Kandutsch-Russell pathway (such as lathosterol), and increased total 
cholesterol levels, contrary to that demonstrated in previous mouse model studies (Valenza et 
al., 2007a; Valenza et al., 2007b), and our study of R6/1 mice (Chapter 3). Several factors may 
underlie these differences in cholesterol biosynthetic alterations between the R6 mice and 
humans, including the CAG length, HTT protein length (truncated vs full length) and the intact 
expression of endogenous murine huntingtin.   
The duration of HD in humans compared to the mouse is also likely to be a factor resulting in 
differences in cholesterol homeostasis. Although we have used the R6/1 mouse which develops 
symptoms slower than the R6/2 model, the onset of disease and disease timeline is rapid 
compared to that in humans that manifests over decades (Foroud et al., 1999). The relative age 
of affected R6/1 mice is comparable to humans in early adulthood and therefore the effects of 
an aged brain may be less apparent in the mouse.  A slower disease timeline in humans is likely 
to result in some cellular changes in the brain that do not have time to manifest in the mouse 
model, and may explain the absence of lipid peroxidation in the R6/1 mice we examined. 
Massive neuron loss through apoptosis is not observed in the R6 models, rather a shrinkage of 
neurons is a common neuropathological feature in these mice (Hansson et al., 1999; Iannicola 
et al., 2000; Klapstein et al., 2001; Petersen et al., 2002). A degenerative process reported to be 
'dark cell degeneration' has also been previously reported in R6/1 mice and juvenile human HD 
(Iannicola et al., 2000; Turmaine et al., 2000). This process is believed to occur over weeks and 
may not manifest completely in the lifespan of these mice (Turmaine et al., 2000). The lack of 
significant astrocytosis and increased oligodendrocyte density in R6 mice (Mangiarini et al., 
1996; Hansson et al., 1999; Turmaine et al., 2000), compared to that seen in human HD (Myers 
et al., 1991), is potentially relevant to the level Kandutsch-Russell cholesterol synthetic 
precursors we observe between human and R6/1 mice. Oligodendrocytes have a high capacity 
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for cholesterol synthesis, and the increased density of these cells believed to be attempting 
remyelination in HD (Bartzokis et al., 2007), may explain increased cholesterol levels and 
synthetic precursors that we observe in human HD putamen.  
Although this difference in Kandutsch-Russell precursors does exist between mouse and human, 
we believe the increase of desmosterol (the penultimate sterol of the Bloch pathway) in both 
species describes a HD specific dysfunction of the cholesterol synthetic regulation. Desmosterol 
levels are likely to reflect the level or activity of DHCR24 (as shown in chapter 6), which is 
believed to have regulatory roles in cholesterol synthesis beyond converting desmosterol to 
cholesterol at the end of the synthetic pathway (Luu et al., 2015). DHCR24 expression levels 
have also been reported to be mediated by BDNF, a trophic factor that is depleted in both human 
and animal models of HD (Zuccato et al., 2001; Spires et al., 2004; Zuccato et al., 2005). The 
current literature has not investigated brain levels of DHCR24 in detail, and further examination 
into desmosterol levels and DHCR24 activity in HD may explain the cholesterol homeostatic 
perturbation beyond simply describing the level of Kandutsch-Russell cholesterol synthetic 
intermediates.   
Human and mouse HD brain tissues we have investigated also exhibited some important 
similarities in cholesterol metabolic alterations. Formation of 24-OHC by the enzyme CYP46A1 
is a major route of cholesterol elimination from the brain. In our study, the level of 24-OHC is 
reduced in the striatum of human and R6/1 mice, this is consistent with previous studies in 
rodent brain (Valenza et al., 2010) and human plasma (Leoni et al., 2008). 24-OHC levels were 
previously suggested as a biomarker of metabolically active neurons in the brain (Bjorkhem, 
2006), however the relevance of this suggestion in a diseased brain state is not fully understood. 
Although in human HD, where significant neuron loss occurs, it is unknown whether reduced 24-
OHC levels are simply a reflection of neuron loss, or if a cholesterol metabolic deficit precedes 
neurodegeneration. Previously it has been hypothesised that cholesterol metabolism in neurons 
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and delivery from astrocytes may be regulated by feedback from 24-OHC (Pfrieger, 2003; 
Bjorkhem, 2006),however a precise mechanisms by which 24-OHC regulates cholesterol 
synthesis in the brain has not been identified. Until further investigation is undertaken, it is 
unknown if synthetic, or metabolic dysfunction is the primary cause of cholesterol homeostatic 
dysfunction in HD.  
Our study of human HD tissue has highlighted that the metabolic pathway involving 27-OHC 
formation and further metabolism is not consistent with the R6/1 mouse striatum. 27-OHC has 
a net movement into the brain from the periphery, where it is quickly metabolised to 
cholestenoic acids that diffuse back into the bloodstream (Heverin et al., 2005; Meaney et al., 
2007). It was previously suggested that the cell-rich grey matter in the human brain is the major 
site of 24-OHC formation and further metabolism of 27-OHC (Bjorkhem, 2006). Degeneration in 
these areas would therefore result in the decrease of 24-OHC levels and increased 27-OHC, as 
we observed in human caudate and putamen, and previously described in human AD brain 
(Heverin et al., 2004). In the R6/1 mouse model we investigated, a striatum specific decrease in 
27-OHC levels contradicts findings in humans. It is possible that faster cholesterol turnover in 
the brain of mice compared to humans (Dietschy & Turley, 2004), and lower absolute levels of 
27-OHC in this region (0.05ng/mg in mouse vs 0.3 ng/mg in human), causes greater fluctuation 
and variation in absolute levels. Interestingly, previous examination of a mouse AD model 
revealed a consistent increase of 27-OHC in mouse brain tissue as well as in human AD brain 
tissue (Heverin et al., 2004). Previously levels of 27-OHC levels have not been reported in studies 
examining cholesterol metabolism in HD mouse models (Valenza et al., 2007a; Valenza et al., 
2007b); further work to identify if this change occurs in other models may clarify if 27-OHC 
formation or further metabolism has a role in HD pathogenesis. Future studies of CSF and plasma 
may also identify 27-OHC, or further metabolites of 27-OHC, as potential biomarkers of CYP7B1 
and CYP27A1 activity in HD brain.  
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7.3 Localisation of cholesterol synthetic and metabolic changes in Huntington's 
disease 
 
Neurodegeneration in human HD begins in the striatum, affecting neighbouring regions such as 
the globus pallidus, hippocampus, amygdala and cerebral cortex (Vonsattel et al., 1985; Rosas 
et al., 2003). The end stage tissue we have examined specifically exhibit a cholesterol metabolic 
deficit in the striatum (caudate and putamen), and altered synthesis was only observed in the 
putamen. This suggests that these changes may be associated with early events in HD, where 
specific degeneration of medium spiny neurons occurs in the striatum (Vonsattel et al., 1985). 
Interestingly in the R6/1 and R6/2 HD mouse model, the cholesterol synthetic defect is more 
widespread, detected in the striatum and cortex in our study, and the hippocampus in a previous 
study (Valenza et al., 2007b). Although changes to Kandutsch-Russell synthetic precursors are 
more pronounced in the striatum of R6/1 mice compared to other regions, the early occurrence 
of changes suggests these alterations may not be as specific to HD as the reduction of 24-OHC 
and accumulation of desmosterol. Both these changes are present in the striatum at later stages 
of the disease, and we hypothesise these alterations are not as widespread in the brain of R6/1 
mice, similar to our observations in human brain.  
 
7.4 Sex differences in Huntington's disease 
 
In this thesis we have also examined interventions of HD in the R6/1 model. It is of interest that 
different interventions had differential effects on the motor phenotype of male and female R6/1 
mice. EE improved the motor co-ordination of male R6/1 mice but did not influence females. 
The opposite occurred with BE supplementation, where female R6/1 mice had improved motor 
co-ordination compared to controls, however males did not improve. We have also previously 
identified a sex difference in the progression of the physical phenotype in R6/1 mice (Chapter 
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3). Previous studies examining the R6/1 model typically use males or females in separate studies 
(Clifford et al., 2002; Naver et al., 2003), and it is likely that any sex differences have not been 
previously observed in the more studied R6/2 model as the progression is more rapid 
(Mangiarini et al., 1996). On a molecular level, we have not detected any significant difference 
in brain sterols between male and female R6/1 mice with our current study size; it is possible a 
larger study may identify potential alterations between mice that reflect phenotypic changes. 
Few studies have examined sex-specific changes in HD models, one study reported 
neuroprotective effects of a sex hormone (17β-estradiol) in HD transgenic rats (Bode et al., 
2008), another identified sex-dependant alterations to BDNF expression in R6/1 mice when 
exposed to environmental enrichment (Zajac et al., 2010). These findings suggest further 
investigation into sex differences is warranted in HD models, an area which has been largely 
ignored in the past. In human HD patients, a significant influence of sex in the progression and 
severity of HD has not been previously identified. Assessing the age of onset, and disease 
severity between patients is complex as symptoms can be highly variable between people 
(Foroud et al., 1999). Even if overt differences between sexes have not been identified in human 
HD patients, it is possible that the response to certain treatments may be sex dependant as 
previously identified in mice (Zajac et al., 2010). It is therefore an important consideration to 
assess both sexes in studies, not only in mouse models but also in humans.  
 
7.5 Future directions studying cholesterol homeostasis in HD 
 
Our findings constitute the first comprehensive sterol analysis in human HD brain tissue, and we 
have identified several alterations to cholesterol homeostasis that were previously not 
identified in mouse models of HD. We have examined late stage human PM tissue (grade IV) and 
therefore the current understanding of cholesterol homeostasis in human HD would benefit 
from analysis of earlier stage HD tissue. However, due to the relatively early onset of HD, and 
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long timeline (Foroud et al., 1999), sufficient early stage cases for a statistically powerful analysis 
are very difficult to obtain (McLean, C. A. 2015, pers. comm., 27 July), and is reflected in the past 
literature where the majority of analyses are carried out in late stage tissue (Augood et al., 1996; 
Arzberger et al., 1997; Petersen et al., 2005; Zuccato et al., 2008; Silvestroni et al., 2009) . 
Measurements of peripheral sterols may therefore be required to confirm these cholesterol 
homeostatic alterations also occur early in HD. 
Currently, methods to directly measure in vivo brain cholesterol synthesis without post-mortem 
tissue examination have not been reported. 24-OHC levels in plasma, which originate from the 
brain, may be an indirect marker of brain cholesterol synthesis. Formation of 24-OHC constitutes 
a major route of cholesterol elimination from the brain (Bjorkhem et al., 1997; Bjorkhem et al., 
1998), and the formation of 24-OHC is believed to be coupled to cholesterol synthesis (Lund et 
al., 2003). The reduction of plasma 24-OHC levels in HD patients has been described in the past 
(Leoni et al., 2008; Leoni et al., 2013), however naturally high variability in 24-OHC plasma 
concentrations between individuals limits the ability of a single time point to fully describe the 
changes occurring over disease progression. A very useful future study would be the 
examination of HD patient plasma in a longitudinal study beginning in the pre-symptomatic 
stage. Tracking changes on an individual basis would help normalise baseline variability in 24-
OHC levels, and improve the power of detection. With highly sensitive analytical techniques, 
only low volumes of plasma are required for analysis (maximum 250 µL) (Leoni et al., 2008); 
plasma measurements of 24-OHC may therefore be a useful biomarker in a prospective 
longitudinal study such as Enroll-HD (CHDI Foundation Inc, 2015).  
Another future direction for cholesterol homeostasis in HD is to carry out an even more 
comprehensive analysis in animal models of HD. Transgenic large animal models with a larger 
brain, may provide an alternative insight into early cholesterol perturbations occurring in human 
HD. However, until these transgenic models that have been generated in sheep (Jacobsen et al., 
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2010), pig (Yang et al., 2010) and rhesus monkey (Yang et al., 2008), are consistently established 
and validated, a closer look at mouse models may be more feasible in the short term. Here we 
have examined a transgenic mouse expressing truncated human HTT. It would therefore be of 
great interest to more closely examine the progression of cholesterol homeostasis in other 
models expressing truncated human HTT [N171-82Q (Schilling et al., 1999)], full length human 
HTT [YAC128 (Slow et al., 2003)], as well as knock-in HD mice [hdhQ92, hdhQ111 (Wheeler et 
al., 1999)] to identify if alterations in cholesterol synthesis and metabolism progress consistently 
across these models. Future studies would also benefit from examining several key synthetic 
and metabolic enzymes we have highlighted as potentially important in our lipid analysis. These 
include CYP27A1, CYP7B1, DHCR24 and CYP46A1. Investigating protein levels in addition to 
mRNA expression would produce additional valuable results as we have previously shown that 
CYP46A1 and DHCR24 protein levels do not reflect mRNA expression in human HD (Chapter 6).  
 
7.6 Conclusion 
 
Due to HTT having multiple roles in a variety of cellular compartments, it is not surprising that 
the HD mutation has been associated with neurodegenerative pathology acting through 
multiple mechanisms. The mutation has also been associated with a cholesterol homeostatic 
perturbation, causing cholesterol synthetic and metabolic dysfunction in multiple rodent and 
cell models. In this study we report the novel reduction of DHCR24 and CYP46A1 in the human 
HD putamen. Measurement of cholesterol synthetic precursors and metabolites in human HD 
post mortem brain tissue also confirms the cholesterol homeostatic perturbation in animal 
models also occurs in human HD. It is not surprising that the R6/1 model and the human HD 
brain do not share all disturbances of cholesterol synthesis and metabolism, however 
predominant changes to the brain specific metabolic product 24-OHC, and accumulation of 
desmosterol are consistent between species and we suggest are important pathways for future 
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investigation. The specific localisation of cholesterol synthetic and metabolic dysfunction to the 
putamen in the human HD brain suggests this may be an early event in HD pathogenesis. 
Similarly, these alterations were also detected earliest and most severely in the striatum of R6/1 
mice. Although we were unable to detect an alteration in the brain sterol profile of R6/1 mice 
treated with EE and dietary BE supplementation, a sex-dependant improvement in motor 
function was seen in both intervention studies, supporting a growing body of evidence that has 
identified sex differences in HD. Both mouse and human tissue have proved valuable in 
identifying cholesterol homeostatic alterations in HD. In addition to this, the mouse model has 
enabled us to identify fundamental age-related changes in both WT and HD mice, adding to the 
currently sparse knowledge of cholesterol synthetic and metabolic changes in the brain during 
ageing. Although investigation of isolated compounds and enzymes tells part of the story, 
further investigation of the fundamental mechanisms surrounding cholesterol synthesis and 
metabolism in the brain will help identify the relevance of these pathways in HD pathogenesis, 
and most likely an array of other neurodegenerative diseases.  
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 Appendices 
 
 
Appendix 1a Absolute values of sterols in male R6/1 and WT cortex and striatum. GC-MS/MS was used 
to analyse lipids extracted from mouse brain tissue at various stages of the disease. Values represent 
ng/mg tissue ± SD. 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 Male 
6 week 12 week 20 week 
WT R6/1 WT HD WT R6/1 
St
ri
at
u
m
 
Lathosterol 54.8 ± 5.6 41.7 ± 6.7 43.2 ± 6.2 20.0 ± 4.8 41.6 ± 5.7 17.8 ± 6.1 
Lanosterol 13.6 ± 3.8 13.1 ± 3.6 10.8 ± 1.7 8.3 ± 2.5 13.6 ± 2.7 8.7 ± 3.4 
Zymosterol 5.0 ± 1.3 4.0 ± 0.9 3.2 ± 0.4 2.2 ± 0.4 2.9 ± 0.63 2.2 ± 0.83 
24,25 diH 0.34 ± 0.22 0.39 ± 0.19 0.33 ± 0.09 0.24 ± 0.18 0.26 ± 0.05 0.19 ± 0.06 
Desmosterol 57.0 ± 9.1 57.7 ± 3.8 31.1 ± 9.6 39.7 ± 17.2 35.8 ± 5.1 41.7 ± 12.6 
7-DHC 63.0 ± 15.9 59.0 ± 4.9 43.5 ± 22.4 48.4 ± 21.8 54.3 ± 16.8 46.7 ± 14.6 
24-OHC 48.5 ± 8.7 42.3 ± 4.8 46.8 ± 4.1 39.7 ± 4.1 57.6 ± 11.2 48.6 ± 15.1 
27-OHC 0.039 ± 0.02 0.034 ± 0.01 0.078 ± 0.02 0.051 ± 0.01 0.083 ± 0.03 0.052 ± 0.02 
7-KC 0.67 ± 0.26 0.66 ± 0.29 0.65 ± 0.18 0.65 ± 0.15 0.30 ± 0.003 0.28 ± 0.009 
7β-OHC 0.36 ± 0.12 0.36 ± 0.17 0.45 ± 0.19 0.54 ± 0.27 0.26 ± 0.005 0.26 ± 0.010 
β-Sitosterol 2.8 ± 1.3 2.3 ± 0.19 2.4 ± 0.79 2.7 ± 0.53 2.0 ± 0.23 2.0 ± 0.48 
Campesterol 18.2 ± 2.7 17.9 ± 3.6 16.7 ± 3.1 19.2 ± 1.4 18.7 ± 3.8 18.5 ± 5.7 
Stigmasterol 0.40 ± 0.23 0.31 ± 0.10 0.12 ± 0.08 0.14 ± 0.11 0.24 ± 0.12 0.26 ± 0.11 
Brassicasterol 0.13 ± 0.06 0.11 ± 0.06 0.14 ± 0.08 0.18 ± 0.06 0.15 ± 0.007 0.16 ± 0.006 
Cholesterola 15.1 ± 1.1 13.6 ± 4.3 17.8 ± 3.1 19.9 ± 1.4 21.5 ± 2.6 21.7 ± 6.0 
C
o
rt
ex
 
Lathosterol 33.5 ± 8.7 27.7 ± 11.2 34.7 ± 14.8 14.8 ± 4.1 34.5 ± 10.8 19.5 ± 3.1 
Lanosterol 7.9 ± 1.4 8.3 ± 2.9 7.9 ± 2.7 5.7 ± 1.4 12.3 ± 4.7 7.4 ± 1.7 
Zymosterol 2.4 ± 0.66 2.9 ± 1.1 2.9 ± 0.6 2.5 ± 0.6 2.7 ± 0.6 2.0 ± 0.3 
24,25 diH  0.33 ± 0.06 0.40 ± 0.17 0.32 ± 0.11 0.22 ± 0.07 0.37 ± 0.18 0.32 ± 0.17 
Desmosterol 32.8 ± 14.9 36.8 ± 9.2 34.6 ± 16.3 42.4 ± 16.4 41.9 ± 12.9 47.3 ± 7.3 
7-DHC 39.5 ± 17.2 41.2 ± 9.9 39.9 ± 6.0 40.5 ± 12.0 44.1 ± 6.4 44.5 ± 13.2 
24-OHC 28.4 ± 9.5 27.3 ± 7.5 29.7 ± 7.8 33.5 ± 7.5 40.3 ± 7.7 37.4 ± 9.0 
27-OHC 0.038 ± 0.02 0.030 ± 0.008 0.037 ± 0.01 0.038 ± 0.01 0.099 ± 0.06 0.071 ± 0.03 
7-KC 0.27 ± 0.12 0.32 ± 0.13 0.51 ± 0.04 0.50 ± 0.09 0.37 ± 0.11 0.58 ± 0.16 
7β-OHC 0.14 ± 0.07 0.18 ± 0.10 0.40 ± 0.11 0.35 ± 0.14 0.12 ± 0.03 0.16 ± 0.12 
β-Sitosterol 0.92 ± 0.22 1.56 ± 0.80 1.7 ± 0.33 2.0 ± 0.31 1.7 ± 0.43 2.1 ± 0.44 
Campesterol 14.0 ± 3.5 13.9 ± 4.5 12.8 ± 2.7 14.1 ± 1.8 23.1 ± 7.2 25.2 ± 3.6 
Stigmasterol 0.11 ± 0.03 0.15 ± 0.09 0.11 ± 0.04 0.12 ± 0.08 0.35 ± 0.13 0.42 ± 0.12 
Brassicasterol 0.067 ± 0.02 0.067 ± 0.03 0.13 ± 0.05 0.17 ± 0.04 0.15 ± 0.06 0.16 ± 0.04 
Cholesterola 9.5 ± 2.6 9.2 ± 2.8 13.8 ± 1.8 14.6 ± 2.0 10.5 ± 2.0 12.8 ± 1.4 
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Appendix 1b Absolute values of sterols in male R6/1 and WT cortex and striatum. GC-MS/MS was used 
to analyse lipids extracted from mouse brain tissue at various stages of the disease. Values represent 
ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Male 
24 week 28 week 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 43.8 ± 10.7 12.6 ± 3.5 31.4 ± 6.0 8.7 ± 2.7 
Lanosterol 12.2 ± 4.0 4.5 ± 1.3 8.9 ± 2.5 4.7 ± 1.7 
Zymosterol 3.5 ± 0.88 1.8 ± 0.36 2.7 ± 0.4 1.5 ± 0.6 
24,25 diH  0.31 ± 0.07 0.20 ± 0.07 0.19 ± 0.09 0.13 ± 0.08 
Desmosterol 39.8 ± 8.1 42.0 ± 4.6 33.0 ± 5.9 40.1 ± 7.3 
7-DHC 37.9 ± 7.0 42.5 ± 12.6 57.3 ± 15.3 68.7 ± 15.3 
24-OHC 53.3 ± 8.5 45.5 ± 5.2 53.7 ± 3.4 40.5 ± 8.3 
27-OHC 0.075 ± 0.012 0.051 ± 0.014 0.043 ± 0.02 0.024 ± 0.01 
7-KC 0.58 ± 0.19 0.52 ± 0.11 0.65 ± 0.29 0.41 ± 0.17 
7β-OHC 0.21 ± 0.06 0.22 ± 0.06 0.28 ± 0.13 0.23 ± 0.11 
β-Sitosterol 2.6 ± 0.31 3.1 ± 0.83 3.3 ± 1.0 3.0 ± 0.47 
Campesterol 21.6 ± 3.1 18.2 ± 2.6 38.1 ± 4.6 33.5 ± 3.9 
Stigmasterol 0.18 ± 0.04 0.25 ± 0.13 0.31 ± 0.17 0.32 ± 0.14 
Brassicasterol 0.27 ± 0.05 0.25 ± 0.05 0.23 ± 0.08 0.27 ± 0.08 
Cholesterola 19.1 ± 1.8 18.9 ± 1.9 19.2 ± 3.0 19.8 ± 3.2 
C
o
rt
ex
 
Lathosterol 32.1 ± 11.9 14.8 ± 3.3 28.8 ± 5.5 14.6 ± 3.1 
Lanosterol 6.7 ± 2.3 4.2 ± 1.2 8.4 ± 1.3 4.6 ± 1.2 
Zymosterol 3.0 ± 1.2 2.7 ± 0.85 2.9 ± 0.30 2.0 ± 0.42 
24,25 diH  0.22 ± 0.07 0.14 ± 0.04 0.32 ± 0.03 0.25 ± 0.09 
Desmosterol 27.0 ± 9.5 33.1 ± 9.4 32.0 ± 8.1 38.0 ± 2.1 
7-DHC 31.0 ± 7.0 30.6 ± 9.9 45.6 ± 7.4 49.7 ± 6.2 
24-OHC 23.6 ± 5.7 26.2 ± 6.7 46.3 ± 6.7 42.4 ± 6.7 
27-OHC 0.034 ± 0.007 0.032 ± 0.011 0.051 ± 0.008 0.044 ± 0.01 
7-KC 0.31 ± 0.08 0.22 ± 0.04 0.86 ± 0.50 1.0 ± 1.05 
7β-OHC 0.12 ± 0.02 0.15 ± 0.07 0.43 ± 0.30 0.20 ± 0.09 
β-Sitosterol 1.8 ± 0.25 2.1 ± 1.2 1.7 ± 0.68 2.0 ± 0.69 
Campesterol 13.6 ± 4.1 11.3 ± 2.6 27.3 ± 5.9 30.0 ± 6.2 
Stigmasterol 0.11 ± 0.02 0.11 ± 0.03 0.27 ± 0.15 0.29 ± 0.16 
Brassicasterol 0.18 ± 0.05 0.17 ± 0.04 0.16 ± 0.05 0.19 ± 0.03 
Cholesterola 11.0 ± 2.1 10.4 ± 1.9 15.4 ± 1.9 17.6 ± 2.9 
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Appendix 2a Absolute values of sterols in female R6/1 and WT cortex and striatum. GC-MS/MS was used 
to analyse lipids extracted from mouse brain tissue at various stages of the disease. Values represent 
ng/mg tissue ± SD. 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 Female 
6 week 12 week 20 week 
WT R6/1 WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 58.5 ± 13.7 36.4 ± 8.3 46.6 ± 14.8 19.7 ± 6.6 48.3 ± 4.1 18.7 ± 6.4 
Lanosterol 17.1 ± 6.7 10.2 ± 3.3 14.8 ± 5.9 7.9 ± 2.8 15.2 ± 4.3 8.3 ± 3.4 
Zymosterol 5.1 ± 1.2 3.6 ± 0.93 3.6 ± 1.3 2.1 ± 0.8 3.1 ± 0.74 1.9 ± 0.43 
24,25 diH  0.44 ± 0.22 0.20 ± 0.14 0.51 ± 0.26 0.33 ± 0.20 0.30 ± 0.03 0.21 ± 0.05 
Desmosterol 53.7 ± 9.1 42.9 ± 8.2 47.8 ± 9.1 40.4 ± 6.8 33.0 ± 5.0 41.3 ± 6.5 
7-DHC 70.9 ± 13.2 46.9 ± 5.3 56.8 ± 21.0 52.3 ± 10.6 45.3 ± 16.8 44.0 ± 13.2 
24-OHC 38.1 ± 7.5 34.8 ± 3.6 45.1 ± 4.2 43.1 ± 3.1 56.5 ± 4.7 49.5 ± 7.9 
27-OHC 0.034 ± 0.02 0.030 ± 0.01 0.067 ± 0.01 0.046 ± 0.02 0.071 ± 0.007 0.049 ± 0.12 
7-KC 0.84 ± 0.57 0.33 ± 0.06 0.60 ± 0.21 0.70 ± 0.16 0.33 ± 0.008 0.32 ± 0.008 
7β-OHC 0.35 ± 0.28 0.20 ± 0.05 0.44 ± 0.12 0.57 ± 0.18 0.23 ± 0.004 0.23 ± 0.005 
β-Sitosterol 2.3 ± 0.55 2.1 ± 0.50 2.2 ± 0.60 2.9 ± 0.77 1.9 ± 0.48 1.9 ± 0.27 
Campesterol 15.9 ± 3.3 15.0 ± 2.4 17.1 ± 0.95 17.5 ± 2.6 17.9 ± 5.3 16.5 ± 2.9 
Stigmasterol 0.36 ± 0.15 0.30 ± 0.09 0.13 ± 0.10 0.24 ± 0.09 0.22 ± 0.13 0.26 ± 0.12 
Brassicasterol 0.09 ± 0.05 0.05 ± 0.02 0.12 ± 0.06 0.15 ± 0.03 0.15 ± 0.012 0.018 ± 0.009 
Cholesterola 14.5 ± 1.5 13.1 ± 1.4 19.5 ± 3.5 20.3 ± 1.5 23.3 ± 4.4 24.8 ± 4.1 
C
o
rt
ex
 
Lathosterol 40.2 ± 10.3 26.3 ± 10.4 43.9 ± 9.9 21.2 ± 6.1 41.6 ± 8.8 15.5 ± 6.3 
Lanosterol 9.4 ± 3.5 7.4 ± 1.1 10.4 ± 3.3 7.0 ± 1.5 10.9 ± 2.6 5.5 ± 1.6 
Zymosterol 2.6 ± 0.44 2.7 ± 0.69 3.2 ± 0.6 2.8 ± 0.4 2.4 ± 0.5 1.9 ± 0.6 
24,25 diH  0.45 ± 0.16 0.35 ± 0.08 0.35 ± 0.15 0.24 ± 0.11 0.32 ± 0.08 0.17 ± 0.11 
Desmosterol 29.6 ± 5.1 36.8 ± 10.0 33.6 ± 16.7 47.6 ± 18.6 26.1 ± 7.3 44.0 ± 2.9 
7-DHC 40.6 ± 4.9 39.1 ± 9.4 38.1 ± 6.1 41.8 ± 15.1 42.5 ± 7.3 46.0 ± 16.6 
24-OHC 26.6 ± 4.8 30.9 ± 7.6 30.4 ± 4.8 32.6 ± 2.5 38.7 ± 17.4 37.2 ± 3.6 
27-OHC 0.034 ± 0.008 0.033 ± 0.008 0.044 ± 0.02 0.047 ± 0.01 0.021 ± 0.006 0.017 ± 0.005 
7-KC 0.49 ± 0.18 0.33 ± 0.11 0.49 ± 0.17 0.46 ± 0.18 0.46 ± 0.22 0.51 ± 0.25 
7β-OHC 0.24 ± 0.12 0.22 ± 0.14 0.37 ± 0.17 0.37 ± 0.12 0.15 ± 0.06 0.16 ± 0.04 
β-Sitosterol 1.6 ± 0.79 1.2 ± 0.54 1.9 ± 0.45 1.9 ± 0.62 1.4 ± 0.21 1.5 ± 0.52 
Campesterol 13.4 ± 2.1 11.7 ± 1.7 15.5 ± 3.3 12.9 ± 2.7 26.0 ± 8.4 21.5 ± 4.6 
Stigmasterol 0.29 ± 0.20 0.20 ± 0.12 0.17 ± 0.10 0.18 ± 0.08 0.27 ± 0.07 0.30 ± 0.14 
Brassicasterol 0.058 ± 0.009 0.049 ± 0.005 0.14 ± 0.05 0.11 ± 0.02 0.14 ± 0.05 0.13 ± 0.03 
Cholesterola 10.9 ± 2.1 9.1 ± 2.4 16.6 ± 2.7 15.3 ± 2.3 12.2 ± 2.9 10.9 ± 1.9 
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Appendix 2b Absolute values of sterols in female R6/1 and WT cortex and striatum. GC-MS/MS was used 
to analyse lipids extracted from mouse brain tissue at various stages of the disease. Values represent 
ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 Female 
24 week 28 week 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 33.5 ± 8.9 17.7 ± 6.8 36.4 ± 7.8 5.7 ± 1.9 
Lanosterol 9.8 ± 4.3 6.4 ± 1.9 13.3 ± 3.0 2.7 ± 1.4 
Zymosterol 3.0 ± 1.2 2.3 ± 0.98 2.7 ± 0.3 1.1 ± 0.8 
24,25 diH  0.33 ± 0.012 0.23 ± 0.05 0.21 ± 0.12 0.04 ± 0.03 
Desmosterol 37.0 ± 6.7 45.1 ± 5.4 33.4 ± 5.1 39.4 ± 4.0 
7-DHC 42.9 ± 14.0 47.7 ± 16.6 56.5 ± 10.8 55.4 ± 16.1 
24-OHC 46.5 ± 5.6 43.6 ± 7.4 61.9 ± 6.8 49.3 ± 4.6 
27-OHC 0.078 ± 0.02 0.056 ± 0.008 0.058 ± 0.02 0.028 ± 0.009 
7-KC 0.49 ± 0.18 0.57 ± 0.19 0.38 ± 0.05 0.57 ± 0.19 
7β-OHC 0.20 ± 0.07 0.24 ± 0.06 0.20 ± 0.07 0.25 ± 0.13 
β-Sitosterol 2.4 ± 0.62 3.4 ± 0.79 2.6 ± 0.31 3.3 ± 0.31 
Campesterol 15.7 ± 2.3 21.1 ± 4.5 30.1 ± 8.4 31.6 ± 4.7 
Stigmasterol 0.19 ± 0.07 0.29 ± 0.1 0.31 ± 0.09 0.55 ± 0.27 
Brassicasterol 0.18 ± 0.03 0.27 ± 0.04 0.20 ± 0.02 0.23 ± 0.09 
Cholesterola 16.4 ± 1.5 18.0 ± 2.8 20.67 ± 1.7 20.4 ± 1.6 
C
o
rt
ex
 
Lathosterol 31.8 ± 7.9 15.6 ± 1.7 30.6 ± 6.1 15.3 ± 4.0 
Lanosterol 9.5 ± 2.2 4.6 ± 0.99 9.6 ± 0.94 5.3 ± 1.7 
Zymosterol 3.8 ± 0.94 2.7 ± 0.65 2.8 ± 0.50 2.0 ± 0.48 
24,25 diH  0.27 ± 0.07 0.14 ± 0.05 0.32 ± 0.05 0.23 ± 0.04 
Desmosterol 34.8 ± 12.5 39.5 ± 12.2 32.8 ± 7.9 38.5 ± 4.3 
7-DHC 24.1 ± 7.5 31.3 ± 11.3 49.2 ± 5.5 50.4 ± 9.6 
24-OHC 38.5 ± 9.5 32.9 ± 5.8 45.8 ± 10.9 37.8 ± 3.7 
27-OHC 0.060 ± 0.03 0.039 ± 0.01 0.055 ± 0.007 0.033 ± 0.007 
7-KC 0.33 ± 0.10 0.35 ± 0.11 0.91 ± 0.62 0.78 ± 0.68 
7β-OHC 0.11 ± 0.02 0.18 ± 0.06 0.35 ± 0.35 0.23 ± 0.11 
β-Sitosterol 2.0 ± 0.75 1.9 ± 0.36 1.5 ± 0.40 1.4 ± 0.28 
Campesterol 12.1 ± 3.6 13.9 ± 2.0 23.1 ± 7.8 23.1 ± 3.8 
Stigmasterol 0.19 ± 0.08 0.13 ± 0.07 0.24 ± 0.09 0.21 ± 0.06 
Brassicasterol 0.14 ± 0.05 0.16 ± 0.01 0.14 ± 0.05 0.14 ± 0.03 
Cholesterola 11.8 ± 3.04 10.9 ± 1.7 15.5 ± 1.8 15.2 ± 3.1 
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Appendix 3a Absolute values of sterols measured in combined sexes R6/1 and WT cortex and striatum. 
GC-MS/MS was used to analyse lipids extracted from mouse brain tissue at various stages of the disease. 
Values represent ng/mg tissue ± SD. 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 Combined sexes 
6 week 12 week 20 week 
WT R6/1 WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 56.5 ± 9.6 38.8 ± 7.8 45.0 ± 11.3 19.8 ± 5.6 44.6 ± 6.0 18.3 ± 5.9 
Lanosterol 15.2 ± 5.4 11.5 ± 3.6 12.9 ± 4.8 8.1 ± 2.5 14.3 ± 3.4 8.5 ± 3.2 
Zymosterol 5.0 ± 1.2 3.8 ± 0.88 3.5 ± 0.9 2.2 ± 0.6 3.0 ± 0.65 2.0 ± 0.65 
24,25 diH 0.38 ± 0.21 0.29 ± 0.19 0.44 ± 0.22 0.29 ± 0.19 0.28 ± 0.05 0.20 ± 0.05 
Desmosterol 55.5 ± 8.9 49.6 ± 9.9 40.2 ± 12.4 40.1 ± 11.9 34.5 ± 5.0 41.5 ± 9.5 
7-DHC 66.6 ± 14.7 52.2 ± 7.8 50.8 ± 21.6 50.5 ± 15.8 50.2 ± 16.6 45.2 ± 13.2 
24-OHC 43.7 ± 9.5 38.2 ± 5.6 45.5 ± 4.1 41.0 ± 3.6 57.1 ± 8.5 49.1 ± 11.4 
27-OHC 0.037 ± 0.02 0.033 ± 0.01 0.071 ± 0.02 0.047 ± 0.01 0.77 ± 0.02 0.51 ± 0.15 
7-KC 0.74 ± 0.40 0.48 ± 0.26 0.59 ± 0.17 0.67 ± 0.15 0.032 ± 0.006 0.030 ± 0.008 
7β-OHC 0.36 ± 0.19 0.27 ± 0.14 0.42 ± 0.15 0.54 ± 0.22 0.24 ± 0.005 0.025 ± 0.007 
β-Sitosterol 2.6 ± 1.0 2.2 ± 0.39 2.2 ± 0.66 2.7 ± 0.62 1.9 ± 0.35 1.9 ± 0.37 
Campesterol 17.2 ± 3.1 16.3 ± 3.2 16.9 ± 2.2 18.4 ± 2.3 18.3 ± 4.3 17.5 ± 4.4 
Stigmasterol 0.38 ± 0.19 0.31 ± 0.09 0.12 ± 0.09 0.18 ± 0.11 0.23 ± 0.12 0.26 ± 0.12 
Brassicasterol 0.11 ± 0.06 0.079 ± 0.05 0.14 ± 0.06 0.17 ± 0.05 0.15 ± 0.010 0.17 ± 0.007 
Cholesterola 14.8 ± 1.3 13.3 ± 2.9 18.5 ± 3.4 19.9 ± 1.3 22.3 ± 3.5 23.3 ± 5.2 
C
o
rt
ex
 
Lathosterol 36.6 ± 9.7 27.0 ± 10.2 39.7 ± 9.3 18.3 ± 6.1 35.8 ± 9.5 17.5 ± 5.1 
Lanosterol 8.6 ± 2.6 7.8 ± 2.0 9.2 ± 3.2 6.4 ± 1.5 7.7 ± 2.4 4.5 ± 1.3 
Zymosterol 2.5 ± 0.55 2.8 ± 0.84 3.0 ± 0.6 2.7 ± 0.5 2.5 ± 0.4 1.9 ± 0.4 
24,25 diH 0.39 ± 0.12 0.37 ± 0.12 0.34 ± 0.13 0.23 ± 0.09 0.32 ± 0.12 0.25 ± 0.15 
Desmosterol 31.3 ± 11.2 36.6 ± 9.2 34.1 ± 15.7 45.3 ± 17.0 35.3 ± 14.0 45.7 ± 5.5 
7-DHC 40.0 ± 12.6 40.1 ± 9.2 42.8 ± 6.4 45.3 ± 14.4 43.3 ± 6.5 45.3 ± 14.4 
24-OHC 27.5 ± 7.5 29.3 ± 7.5 30.1 ± 6.0 33.0 ± 5.1 39.6 ± 13.0 37.3 ± 6.5 
27-OHC 0.036 ± 0.01 0.032 ± 0.007 0.041 ± 0.01 0.043 ± 0.01 0.047 ± 0.04 0.044 ± 0.03 
7-KC 0.37 ± 0.18 0.33 ± 0.11 0.50 ± 0.12 0.48 ± 0.14 0.41 ± 0.17 0.54 ± 0.20 
7β-OHC 0.19 ± 0.11 0.20 ± 0.12 0.38 ± 0.14 0.36 ± 0.13 0.13 ± 0.045 0.16 ± 0.033 
β-Sitosterol 1.2 ± 0.63 1.1 ± 0.45 1.85 ± 0.40 1.94 ± 0.49 1.5 ± 0.34 1.8 ± 0.57 
Campesterol 13.7 ± 2.8 12.7 ± 3.3 14.3 ± 3.2 13.5 ± 2.3 23.6 ± 7.4 23.3 ± 4.3 
Stigmasterol 0.19 ± 0.16 0.18 ± 0.11 0.14 ± 0.08 0.15 ± 0.08 0.30 ± 0.12 0.36 ± 0.14 
Brassicasterol 0.063 ± 0.01 0.057 ± 0.02 0.14 ± 0.05 0.14 ± 0.04 0.14 ± 0.07 0.15 ± 0.05 
Cholesterola 10.1 ± 2.4 9.2 ± 2.5 15.4 ± 2.7 15.0 ± 2.1 11.0 ± 2.5 11.9 ± 1.7 
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Appendix 3b Absolute values of sterols measured in combined sexes R6/1 and WT cortex and striatum. 
GC-MS/MS was used to analyse lipids extracted from mouse brain tissue at various stages of the disease. 
Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH  = 24, 
25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-hydroxycholesterol; 27-OHC = 27-
hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-hydroxycholesterol. aValues expressed as 
µg/mg tissue. 
 
 
 
 
 
 
 
 
 Combined sexes 
24 week 28 week 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 38.6 ± 10.7 14.9 ± 5.6 33.9 ± 7.0 7.2 ± 2.7 
Lanosterol 11.0 ± 4.1 5.4 ± 1.9 11.1 ± 3.5 3.7 ± 1.8 
Zymosterol 3.7 ± 1.0 2.0 ± 0.71 2.7 ± 0.33 1.3 ± 0.72 
24,25 diH  0.32 ± 0.09 0.21 ± 0.06 0.20 ± 0.10 0.090 ± 0.08 
Desmosterol 38.4 ± 7.2 43.4 ± 5.0 33.2 ± 5.2 39.8 ± 5.6 
7-DHC 40.4 ± 10.8 44.9 ± 14.0 56.9 ± 12.8 62.2 ± 16.4 
24-OHC 49.9 ± 7.7 44.6 ± 6.0 57.8 ± 6.7 44.9 ± 7.8 
27-OHC 0.076 ± 0.02 0.053 ± 0.01 0.051 ± 0.02 0.026 ± 0.01 
7-KC 0.53 ± 0.18 0.54 ± 0.15 0.52 ± 0.24 0.49 ± 0.19 
7β-OHC 0.21 ± 0.06 0.23 ± 0.06 0.24 ± 0.11 0.24 ± 0.11 
β-Sitosterol 2.5 ± 0.47 3.2 ± 0.78 2.9 ± 0.77 3.1 ± 0.40 
Campesterol 18.7 ± 4.0 19.5 ± 3.7 34.1 ± 7.6 32.6 ± 4.2 
Stigmasterol 0.19 ± 0.05 0.26 ± 0.12 0.31 ± 0.13 0.44 ± 0.24 
Brassicasterol 0.22 ± 0.06 0.26 ± 0.05 0.22 ± 0.06 0.25 ± 0.08 
Cholesterola 17.8 ± 2.1 18.5 ± 2.3 20.0 ± 2.4 20.1 ± 2.4 
C
o
rt
ex
 
Lathosterol 31.9 ± 9.5 15.2 ± 2.6 29.7 ± 5.6 15.0 ± 3.5 
Lanosterol 8.1 ± 2.6 4.4 ± 1.1 9.0 ± 1.2 5.0 ± 1.4 
Zymosterol 3.4 ± 1.1 2.7 ± 0.73 2.9 ± 0.39 2.0 ± 0.42 
24,25 diH  0.24 ± 0.06 0.14 ± 0.04 0.32 ± 0.04 0.24 ± 0.07 
Desmosterol 30.9 ± 11.2 36.0 ± 10.7 32.4 ± 7.5 38.3 ± 3.2 
7-DHC 27.6 ± 7.7 30.9 ± 10.0 47.4 ± 6.4 50.0 ± 7.6 
24-OHC 31.0 ± 10.8 29.2 ± 6.9 46.1 ± 8.5 40.1 ± 5.6 
27-OHC 0.047 ± 0.02 0.035 ± 0.01 0.053 ± 0.007 0.039 ± 0.01 
7-KC 0.32 ± 0.08 0.29 ± 0.11 0.88 ± 0.53 0.90 ± 84 
7β-OHC 0.11 ± 0.02 0.16 ± 0.07 0.40 ± 0.30 0.22 ± 0.09 
β-Sitosterol 1.9 ± 0.55 2.0 ± 0.90 1.6 ± 0.54 1.7 ± 0.57 
Campesterol 12.9 ± 3.7 12.5 ± 2.6 25.2 ± 6.9 26.6 ± 6.1 
Stigmasterol 0.15 ± 0.07 0.12 ± 0.05 0.25 ± 0.12 0.25 ± 0.12 
Brassicasterol 0.16 ± 0.05 0.16 ± 0.03 0.15 ± 0.05 0.16 ± 0.03 
Cholesterola 11.4 ± 2.5 10.7 ± 1.7 15.5 ± 1.7 16.4 ± 3.1 
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Appendix 4 Absolute concentration of sterols measured in the cortex and striatum of male 
R6/1 and WT mice treated with environmental enrichment.  GC-MS/MS was used to analyse 
lipids extracted from mouse brain tissue. Mice were house in either standard (control) or 
environmentally enriched (EE) housing.  Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Male 
Control EE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 32.1 ± 5.3 9.1 ± 2.2 27.4 ± 3.8 9.5 ± 3.4 
Lanosterol 13.9 ± 1.7 4.4 ± 1.6 12.1 ± 3.7 4.9 ± 2.3 
Zymosterol 2.4 ± 0.29 1.3 ± 0.32 2.4 ± 0.24 1.4 ± 0.47 
24,25 diH  0.23 ± 0.03 0.11 ± 0.02 0.25 ± 0.05 0.14 ± 0.04 
Desmosterol 40.1 ± 3.2 45.9 ± 6.0 40.0 ± 7.1 46.5 ± 8.6 
7-DHC 43.4 ± 12.7 47.2 ± 20.3 37.3 ± 9.7 47.3 ± 13.7 
24-OHC 61.0 ± 1.2 60.7 ± 6.6 60.3 ± 7.3 57.1 ± 8.1 
27-OHC 0.067 ± 0.005 0.051 ± 0.01 0.061 ± 0.006 0.050 ± 0.006 
7-KC 0.55 ± 0.06 0.67 ± 0.40 0.73 ± 0.36 0.61 ± 0.16 
7β-OHC 0.22 ± 0.05 0.31 ± 0.09 0.23 ± 0.07 0.26 ± 0.06 
β-Sitosterol 2.5 ± 0.51 2.8 ± 0.46 2.0 ± 0.36 2.5 ± 0.52 
Campesterol 33.9 ± 4.3 37.5 ± 5.7 27.6 ± 6.7 33.2 ± 7.4 
Stigmasterol 0.21 ± 0.08 0.27 ± 0.08 0.15 ± 0.03 0.20 ± 0.07 
Brassicasterol 0.33 ± 0.06 0.35 ± 0.04 0.28 ± 0.05 0.35 ± 0.06 
Cholesterola 21.5 ± 3.6 24.4 ± 3.8 16.9 ± 2.4 21.3 ± 2.8 
C
o
rt
ex
 
Lathosterol 25.2 ± 3.6 14.9 ± 4.5 29.3 ± 7.3 13.7 ± 3.6 
Lanosterol 10.9 ± 2.2 7.9 ± 2.3 12.6 ± 3.2 6.7 ± 1.7 
Zymosterol 3.3 ± 0.70 2.7 ± 0.35 3.3 ± 0.66 2.3 ± 0.34 
24,25 diH  0.19 ± 0.15 0.095 ± 0.079 0.21 ± 0.076 0.069 ± 0.031 
Desmosterol 34.8 ± 13.1 41.7 ± 9.6 40.7 ± 11.4 38.4 ± 3.6 
7-DHC 36.2 ± 9.7 50.1 ± 8.0 50.0 ± 34.1 48.6 ± 21.3 
24-OHC 37.5 ± 10.2 34.2 ± 5.1 44.1 ± 8.4 33.1 ± 4.3 
27-OHC 0.029 ±  0.016 0.035 ±  0.007 0.059 ±  0.017 0.028 ±  0.017 
7-KC 0.50 ± 0.16 0.67 ± 0.19 0.48 ± 0.12 0.46 ± 0.17 
7β-OHC 0.36 ± 0.12 0.42 ± 0.10 0.28 ± 0.09 0.27 ± 0.09 
β-Sitosterol 2.3 ± 0.45 3.1 ± 0.77 2.6 ± 0.72 2.7 ± 0.66 
Campesterol 20.2 ± 5.6 28.1 ± 8.2 24.4 ± 9.1 23.2 ± 2.9 
Stigmasterol 0.25 ± 0.10 0.38 ± 0.15 0.29 ± 0.11 0.27 ± 0.10 
Brassicasterol 0.18 ± 0.06 0.24 ± 0.13 0.24 ± 0.07 0.22 ± 0.06 
Cholesterola 13.7 ±  4.1 18.1 ±  2.8 16.5 ±  1.8 15.8 ±  2.3 
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Appendix 5 Absolute concentration of sterols measured in the cortex and striatum of female 
R6/1 and WT mice treated with environmental enrichment.  GC-MS/MS was used to analyse 
lipids extracted from mouse brain tissue. Mice were house in either standard (control) or 
environmentally enriched (EE) housing.  Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Female 
Control EE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 31.8 ± 11.4 10.4 ± 3.3 36.7 ± 10.8 12.6 ± 3.7 
Lanosterol 15.1 ± 5.6 7.8 ± 4.0 16.5 ± 8.1 7.8 ± 2.8 
Zymosterol 2.9 ± 1.0 1.9 ± 0.79 2.8 ± 0.68 1.7 ± 0.65 
24,25 diH  0.35 ± 0.14 0.20 ± 0.07 0.34 ± 0.17 0.12 ± 0.02 
Desmosterol 42.6 ± 4.6 50.0 ± 12.4 42.4 ± 6.2 50.3 ± 5.6 
7-DHC 50.1 ± 21.1 45.4 ± 12.8 46.4 ± 20.7 50.8 ± 12.5 
24-OHC 65.7 ± 4.9 65.7 ± 13.1 69.2 ± 7.7 61.0 ± 5.1 
27-OHC 0.070 ± 0.01 0.055 ± 0.01 0.077 ± 0.02 0.053 ± 0.009 
7-KC 0.62 ± 0.18 0.55 ± 0.14 0.52 ± 0.08 0.57 ± 0.09 
7β-OHC 0.25 ± 0.09 0.26 ± 0.07 0.26 ± 0.06 0.31 ± 0.05 
β-Sitosterol 2.2 ± 0.46 2.6 ± 0.45 2.4 ± 0.69 2.7 ± 0.37 
Campesterol 32.7 ± 5.4 35.7 ± 4.2 30.7 ± 8.3 37.6 ± 5.9 
Stigmasterol 0.18 ± 0.06 0.27 ± 0.09 0.22 ± 0.1.2 0.28 ± 0.09 
Brassicasterol 0.30 ± 0.07 0.34 ± 0.04 0.28 ± 0.04 0.33 ± 0.05 
Cholesterola 21.9 ± 3.9 24.5 ± 2.9 23.8 ± 3.1 24.3 ± 3.4 
C
o
rt
ex
 
Lathosterol 31.9 ± 11.2 11.9 ± 1.5 29.0 ± 9.3 12.0 ± 3.2 
Lanosterol 13.7 ± 5.3 7.6 ± 1.9 10.8 ± 3.2 6.8 ± 2.3 
Zymosterol 3.1 ± 0.44 2.1 ± 0.55 3.0 ± 0.66 2.0 ± 0.51 
24,25 diH  0.21 ± 0.16 0.036 ± 0.010 0.20 ± 0.11 0.093 ± 0.10 
Desmosterol 32.0 ± 7.1 35.5 ± 8.8 30.6 ± 7.9 39.4 ± 2.8 
7-DHC 46.7 ± 23.6 38.3 ± 17.6 34.9 ± 6.9 46.9 ± 21.1 
24-OHC 38.9 ± 5.4 34.0 ± 5.2 38.7 ± 10.5 37.7 ± 5.3 
27-OHC 0.038 ±  0.02 0.031 ±  0.02 0.037 ±  0.01 0.038 ±  0.01 
7-KC 0.66 ± 0.06 0.41 ± 0.12 0.43 ± 0.09 0.54 ± 0.22 
7β-OHC 0.31 ± 0.04 0.19 ± 0.02 0.24 ± 0.08 0.29 ± 0.11 
β-Sitosterol 2.4 ± 0.22 2.6 ± 0.31 2.7 ± 0.80 2.7 ± 0.30 
Campesterol 20.1 ± 4.9 20.3 ± 4.1 18.6 ± 7.3 26.4 ± 6.4 
Stigmasterol 0.26 ± 0.03 0.26 ± 0.06 0.27 ± 0.13 0.027 ± 0.04 
Brassicasterol 0.21 ± 0.08 0.25 ± 0.06 0.18 ± 0.09 0.21 ± 0.05 
Cholesterola 15.3 ±  1.3 14.7 ±  1.4 15.4 ±  2.8 14.8 ±  1.6 
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Appendix 6 Absolute concentration of sterols measured in the cortex and striatum of 
combined sexes R6/1 and WT mice treated with environmental enrichment.  GC-MS/MS was 
used to analyse lipids extracted from mouse brain tissue. Mice were house in either standard (control) 
or environmentally enriched (EE) housing.  Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Combined sexes 
Control EE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 32.0 ± 9.1 9.6 ± 2.7 32.1 ± 8.4 11.0 ± 3.8 
Lanosterol 14.5 ± 6.4 6.1 ± 3.4 14.3 ± 4.1 6.4 ± 2.9 
Zymosterol 2.7 ± 0.52 1.6 ± 0.65 2.6 ± 0.73 1.5 ± 0.57 
24,25 diH  0.29 ± 0.13 0.16 ± 0.07 0.30 ± 0.11 0.13 ± 0.03 
Desmosterol 41.7 ± 6.4 47.9 ± 9.4 41.2 ± 3.9 48.4 ± 7.2 
7-DHC 47.0 ± 18.1 46.3 ± 13.0 41.9 ± 18.2 49.0 ± 16.0 
24-OHC 63.4 ± 4.2 63.2 ± 10.1 64.8 ± 8.6 59.1 ± 6.8 
27-OHC 0.069 ± 0.008 0.053 ± 0.01 0.069 ± 0.02 0.051 ± 0.008 
7-KC 0.59 ± 0.13 0.60 ± 0.27 0.62 ± 0.27 0.60 ± 0.13 
7β-OHC 0.24 ± 0.07 0.29 ± 0.08 0.25 ± 0.06 0.28 ± 0.06 
β-Sitosterol 2.3 ± 0.51 2.7 ± 0.44 2.2 ± 0.57 2.6 ± 0.43 
Campesterol 33.3 ± 4.7 36.6 ± 4.8 29.2 ± 7.4 35.5 ± 6.8 
Stigmasterol 0.19 ± 0.07 0.27 ± 0.08 0.19 ± 0.09 0.24 ± 0.08 
Brassicasterol 0.32 ± 0.06 0.34 ± 0.04 0.28 ± 0.04 0.34 ± 0.05 
Cholesterola 21.7 ± 3.6 24.5 ± 3.2 20.3 ± 4.4 22.8 ± 3.4 
C
o
rt
ex
 
Lathosterol 28.6 ± 8.7 13.4 ± 3.5 29.2 ± 7.9 12.9 ± 3.4 
Lanosterol 12.3 ± 4.2 7.8 ± 2.0 11.8 ± 3.2 6.7 ± 1.9 
Zymosterol 3.2 ± 0.58 2.4 ± 0.52 3.2 ± 0.66 2.2 ± 0.44 
24,25 diH  0.20 ± 0.15 0.066 ± 0.06 0.21 ± 0.09 0.080 ± 0.068 
Desmosterol 33.4 ± 10.1 38.6 ± 9.3 35.6 ± 10.8 38.9 ± 3.2 
7-DHC 41.4 ± 18.0 44.2 ± 14.3 42.4 ± 24.7 47.8 ± 20.2 
24-OHC 38.2 ± 7.8 34.1 ± 4.9 41.4 ± 9.6 35.4 ± 5.2 
27-OHC 0.033 ±  0.02 0.033 ±  0.013 0.047 ±  0.017 0.033 ±  0.014 
7-KC 0.57 ± 0.15 0.55 ± 0.20 0.45 ± 0.10 0.49 ± 0.19 
7β-OHC 0.33 ± 0.09 0.32 ± 0.14 0.26 ± 0.08 0.28 ± 0.09 
β-Sitosterol 2.3 ± 0.34 2.9 ± 0.62 2.6 ± 0.73 2.7 ± 0.50 
Campesterol 20.1 ± 5.0 24.2 ± 7.4 21.5 ± 8.4 24.8 ± 5.1 
Stigmasterol 0.25 ± 0.07 0.32 ± 0.12 0.28 ± 0.12 0.27 ± 0.07 
Brassicasterol 0.19 ± 0.07 0.25 ± 0.10 0.21 ± 0.08 0.21 ± 0.05 
Cholesterola 14.5 ±  3.0 16.4 ±  2.7 15.9 ±  2.4 15.3 ±  1.9 
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Appendix 7 Absolute concentration of sterols measured in the cortex and striatum of male 
R6/1 and WT mice receiving dietary supplementation.  GC-MS/MS was used to analyse lipids 
extracted from mouse brain tissue. Mice received either control or berry extract (BE) supplemented 
diets. Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Male 
Control BE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 33.9 ± 7.7 12.2 ± 5.2 34.1 ± 11.9 9.7 ± 2.7 
Lanosterol 13.8 ± 4.6  7.1 ± 2.8 13.1 ± 5.9 4.5 ± 1.9 
Zymosterol 2.2 ± 0.7 1.4 ± 0.6 2.5 ± 0.6 1.1 ± 0.6 
24,25 diH  0.25 ± 0.11 0.11 ± 0.05 0.21 ± 0.01 0.13 ± 0.07 
Desmosterol 41.6 ± 5.4 40.9 ± 8.9 43.4 ± 8.1 42.2 ± 5.9 
7-DHC 49.5 ± 21.9 68.4 ± 31.4 65.5 ± 15.4 72.5 ± 16.1 
24-OHC 64.5 ± 3.3 55.5 ± 13.8 67.5 ± 5.5 58.5 ± 3.8 
27-OHC 0.078 ± 0.009 0.044 ± 0.017 0.078 ± 0.013 0.048 ± 0.010 
7-KC 0.56 ± 0.31 1.36 ± 1.1 1.04 ± 0.57 1.60 ± 0.97 
7β-OHC 0.32 ± 0.13 0.52 ± 0.20 0.59 ± 0.26 0.87 ± 0.45 
β-Sitosterol 3.8 ± 0.7 4.5 ± 0.9 4.3 ± 0.8 4.5 ± 1.2 
Campesterol 40.9 ± 7.7 39.4 ± 5.3 42.2 ± 11.9 41.5 ± 12.0 
Stigmasterol 0.48 ± 0.13 0.59 ± 0.16 0.50 ± 0.08 0.59 ± 0.18 
Brassicasterol 0.44 ± 0.09 0.42 ± 0.08 0.45 ± 0.11 0.44 ± 0.07 
Cholesterola 15.5 ± 1.2 15.8 ± 1.8 16.6 ± 2.3 16.8 ± 1.6 
C
o
rt
ex
 
Lathosterol 36.6 ± 5.2 16.9 ± 3.5 27.4 ± 5.0 14.8 ± 4.4 
Lanosterol 11.8 ± 1.5 7.8 ± 1.9 10.1 ± 2.7 7.1 ± 3.1 
Zymosterol 2.0 ± 0.7 2.5 ± 1.4 1.7 ± 0.9 3.0 ± 1.3 
24,25 diH  0.22 ± 0.12 0.10 ± 0.05 0.16 ± 0.04 0.09 ± 0.03 
Desmosterol 32.0 ± 7.2 34.0 ± 5.7 39.2 ± 11.1 42.5 ± 11.2 
7-DHC 49.8 ± 17.1 53.8 ± 15.7 46.4 ± 12.0 50.3 ± 9.7 
24-OHC 53.3 ± 11.2 49.8 ± 10.9 57.7 ± 15.8 47.9 ± 8.1 
27-OHC 0.051 ± 
0.015 
0.031 ± 
0.010 
0.047 ± 
0.010 
0.027 ± 
0.008 7-KC 0.42 ± 0.11 0.36 ± 0.10 0.41 ± 0.14 0.37 ± 0.13 
7β-OHC 0.21 ± 0.08 0.22 ± 0.08 0.21 ± 0.07 0.19 ± 0.04 
β-Sitosterol 2.4 ± 0.58 2.4 ± 0.31 1.9 ± 0.38 2.0 ± 0.17 
Campesterol 39.7 ± 5.2 36.9 ± 8.0 35.1 ± 7.4 37.0 ± 8.8 
Stigmasterol 0.26 ± 0.13 0.26 ± 0.05 0.20 ± 0.08 0.23 ± 0.05 
Brassicasterol 0.40 ± 0.06 0.39 ± 0.21 0.38 ± 0.12 0.40 ± 0.13 
Cholesterola 12.7 ± 1.8 13.0 ± 2.0 13.6 ± 1.4 13.8 ± 1.8 
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Appendix 8 Absolute concentration of sterols measured in the cortex and striatum of female 
R6/1 and WT mice receiving dietary supplementation.  GC-MS/MS was used to analyse lipids 
extracted from mouse brain tissue. Mice received either control or berry extract (BE) supplemented 
diets. Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Female 
Control BE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 32.3 ± 9.2 11.3 ± 3.9 32.6 ± 8.9 11.6 ± 3.4 
Lanosterol 11.8 ± 5.1 5.7 ± 2.7 11.5 ± 4.2 6.6 ± 2.7 
Zymosterol 2.4 ± 0.8  1.3 ± 0.3 2.3 ± 0.8 1.4 ± 0.4 
24,25 diH  0.23 ± 0.09 0.17 ± 0.08 0.24 ± 0.15 0.14 ± 0.01 
Desmosterol 35.3 ± 6.7 45.1 ± 6.5 38.1 ± 7.2 47.2 ± 8.4 
7-DHC 67.2 ± 29.p 80.3 ± 33.5 64.3 ± 34.1 72.3 ± 23.6 
24-OHC 61.0 ± 8.6 55.6 ± 7.7 66.8 ± 3.2 54.6 ± 11.1 
27-OHC 0.076 ± 0.014 0.055 ± 0.014 0.069 ± 0.013 0.052 ± 0.015 
7-KC 0.63 ± 0.16 0.64 ± 0.18 0.98 ± 0.50 0.64 ± 0.15 
7β-OHC 0.47 ± 0.24 0.41 ± 0.11 0.57 ± 0.42 0.38 ± 0.12 
β-Sitosterol 3.6 ± 0.9 5.0 ± 1.7 4.5 ± 0.7 4.0 ± 0.6 
Campesterol 26.0 ± 6.6 46.6 ± 7.9 36.5 ± 9.2 40.7 ± 7.6 
Stigmasterol 0.49 ± 0.19 0.71 ± 0.24 0.69 ± 0.22 0.52 ± 0.14 
Brassicasterol 0.25 ± 0.06 0.47 ± 0.12 0.37 ± 0.11 0.42 ± 0.06 
Cholesterola 14.9 ± 2.2 16.6 ± 1.6 15.9 ± 2.3 16.3 ± 2.9 
C
o
rt
ex
 
Lathosterol 34.6 ± 9.7 15.6 ± 4.2 30.8 ± 13.9 14.3 ± 3.2 
Lanosterol 12.0 ± 2.8 7.0 ± 1.7 10.1 ± 4.1 6.7 ± 1.8 
Zymosterol 2.1 ± 1.3  2.6 ± 0.9 2.4 ± 1.2 2.2 ± 0.5 
24,25 diH  0.14 ± 0.07 0.09 ± 0.05 0.15 ± 0.06 0.09 ± 0.03 
Desmosterol 36.0 ± 6.3 43.4 ± 7.6 28.3 ± 8.2 45.7 ± 5.1 
7-DHC 51.8 ± 12.2 55.5 ± 20.6 33.2 ± 9.4 54.1 ± 13.9 
24-OHC 60.5 ± 9.9 50.0 ± 3.7 50.0 ± 13.1 52.9 ± 9.5 
27-OHC 0.061 ± 
0.015 
0.044 ± 
0.018 
0.054 ± 
0.023 
0.047 ± 
0.017 7-KC 0.29 ± 0.08 0.43 ± 0.12 0.47 ± 0.28 0.56 ± 0.35 
7β-OHC 0.15 ± 0.04 0.19 ± 0.06 0.17 ± 0.02 0.21 ± 0.06 
β-Sitosterol 2.5 ± 1.2 2.4 ± 0.64 1.8 ± 0.50 2.6 ± 0.39 
Campesterol 23.5 ± 4.4 37.1 ± 11.1 27.9 ± 9.6 32.9 ± 9.4 
Stigmasterol 0.24 ± 0.15 0.25 ± 0.12 0.22 ± 0.10 0.25 ± 0.06 
Brassicasterol 0.22 ± 0.05 0.34 ± 0.10 0.26 ± 0.09 0.33 ± 1.5 
Cholesterola 12.2 ± 1.0 13.6 ± 1.7 13.1 ± 1.5 13.4 ± 1.4 
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Appendix 9 Absolute concentration of sterols measured in the cortex and striatum of 
combined sexes R6/1 and WT mice receiving dietary supplementation.  GC-MS/MS was used to 
analyse lipids extracted from mouse brain tissue. Mice received either control or berry extract (BE) 
supplemented diets. Values represent ng/mg tissue ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 
 
 
 
 
 
 Combined sexes 
Control BE 
WT R6/1 WT R6/1 
St
ri
at
u
m
 
Lathosterol 33.1 ± 8.2 11.8 ± 4.5 33.3 ± 10.1 10.7 ± 3.1 
Lanosterol 12.8 ± 4.7 6.4 ± 2.7 12.3 ± 4.9 5.6 ± 2.5 
Zymosterol 2.1 ± 0.9 1.3 ± 0.6 2.4 ± 0.7 1.2 ± 0.6 
24,25 diH  0.24 ± 0.09 0.14 ± 0.07 0.23 ± 0.12 0.14 ± 0.05 
Desmosterol 38.5 ± 6.8 42.8 ± 7.9 40.8 ± 7.9 44.7 ± 7.4 
7-DHC 58.3 ± 26.6 73.8 ± 31.4 64.9 ± 24.2 72.4 ± 19.2 
24-OHC 62.8 ± 6.5 55.6 ± 10.9 67.1 ± 4.3 56.5 ± 8.2 
27-OHC 0.077 ± 0.011 0.049 ± 0.016 0.073 ± 0.013 0.050 ± 0.012 
7-KC 0.60 ± 0.22 1.07 ± 0.90 1.01 ± 0.50 1.12 ± 0.82 
7β-OHC 0.39 ± 0.19 0.47 ± 0.17 0.58 ± 0.33 0.60 ± 0.39 
β-Sitosterol 3.7 ± 0.8 4.3 ± 1.8 4.4 ± 0.8 4.3 ± 0.9 
Campesterol 33.5 ± 10.3 42.7 ± 7.3 39.3 ± 10.5 41.1 ± 9.6 
Stigmasterol 0.49 ± 0.15 0.59 ± 0.27 0.59 ± 0.19 0.56 ± 0.15 
Brassicasterol 0.34 ± 0.12 0.44 ± 0.10 0.41 ± 0.11 0.43 ± 0.07 
Cholesterola 15.2 ± 1.7 16.2 ± 1.7 16.2 ± 2.2 16.4 ± 2.3 
C
o
rt
ex
 
Lathosterol 35.6 ± 7.5 16.2 ± 3.7 29.1 ± 10.1 14.5 ± 3.7 
Lanosterol 11.9 ± 2.1 7.4 ± 1.7 10.2 ± 3.1 6.9 ± 2.4 
Zymosterol 2.1 ± 1.0 2.6 ± 1.1 2.1 ± 1.1 2.6 ± 1.0 
24,25 diH  0.18 ± 0.10 0.09 ± 0.05 0.16 ± 0.05 0.09 ± 0.03 
Desmosterol 35.0 ± 6.8 38.7 ± 8.1 33.7 ± 10.9 44.1 ± 8.5 
7-DHC 50.8 ± 14.2 54.6 ± 17.1 39.8 ± 12.4 52.2 ± 11.6 
24-OHC 56.9 ± 10.8 49.9 ± 7.7 53.8 ± 14.4 50.1 ± 8.7 
27-OHC 0.056 ± 
0.016 
0.037 ± 
0.016 
0.051 ± 
0.017 
0.037 ± 
0.016 7-KC 0.35 ± 0.12 0.39 ± 0.11 0.44 ± 0.21 0.46 ± 0.27 
7β-OHC 0.18 ± 0.07 0.20 ± 0.07 0.19 ± 0.06 0.20 ± 0.05 
β-Sitosterol 2.4 ± 0.93 2.5 ± 0.48 1.9 ± 0.42 2.3 ± 0.42 
Campesterol 31.6 ± 9.6 36.9 ± 9.2 31.4 ± 9.0 36.0 ± 8.8 
Stigmasterol 0.25 ± 0.13 0.26 ± 0.09 0.21 ± 0.09 0.24 ± 0.06 
Brassicasterol 0.31 ± 0.11 0.37 ± 0.16 0.32 ± 0.12 0.36 ± 0.14 
Cholesterola 12.5 ± 1.4 13.3 ± 1.8 13.4 ± 1.5 13.6 ± 1.2 
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Appendix 10 Absolute concentration of sterols in human post-mortem brain tissue. GC-MS/MS 
was used to analyse lipids extracted from brain tissue. Values represent ng/mg tissue ± SEM. 
 
 
 
 
 
 
 
 
 
24, 25 diH = 24, 25 dihydro lanosterol; 7-DHC = 7-dehydrocholesterol; 24-OHC = 24(S)-
hydroxycholesterol; 27-OHC = 27-hydroxycholesterol; 7-KC = 7-ketocholesterol; 7β-OHC = 7β-
hydroxycholesterol. aValues expressed as µg/mg tissue. 
 
 
 Brain region 
Putamen Caudate Grey frontal cortex 
Control HD Control HD Control HD 
Lathosterol 4.35 ± 1.48 8.46 ± 5.70 3.62 ± 1.55 3.45 ± 2.50 9.64 ± 4.65 11.72 ± 8.89 
Lanosterol 0.89 ± 0.37 1.33 ± 0.81 0.72 ± 0.31 0.64 ± 0.44 1.81 ± 1.02 1.66 ± 0.99 
Zymosterol 0.11 ± 0.06 0.35 ± 0.22 0.12 ± 0.04 0.11 ± 0.05 0.56 ± 0.24 0.4 0± 0.23 
24,25 diH 0.19±0.07 0.37±0.18 0.18±0.06 0.22±0.10 0.42±0.25 0.61±0.33 
Desmosterol 4.66 ± 2.77 13.68 ± 9.25 3.93 ± 1.82 6.71 ± 4.54 5.19 ± 1.61 5.80 ± 4.20 
7-DHC 19.68 ± 5.01 25.8 ± 11.62 19.77 ± 6.68 16.26 ± 6.04 33.46 ± 12.31 39.97 ± 19.52 
24-OHC 33.00 ± 10.01 13.67 ± 6.22 25.54 ± 13.72 8.78 ± 4.62 15.25 ± 4.27 11.98 ± 3.73 
27-OHC 0.30 ± 0.09 0.87 ± 0.59 0.23 ± 0.21 0.41 ± 0.34 0.22 ± 0.14 0.65 ± 0.50 
7-KC 0.75 ± 0.24 1.28 ± 0.41 0.59 ± 0.22 0.74 ± 0.41 0.70 ± 0.28 1.01 ± 0.48 
7β-OHC 0.61 ± 0.21 0.94 ± 0.42 0.46 ± 0.17 0.61 ± 0.41 0.45 ± 0.20 0.68 ± 0.38 
Squalene 1.81 ± 1.24 1.73 ± 0.99 1.53 ± 0.86 1.41 ± 0.47 1.39 ± 0.38 1.62 ± 0.65 
Campesterol 4.5 ± 2.1  5.5 ± 3.0 3.8 ± 2.0 2.6 ± 2.1 4.3 ± 2.9 2.8 ± 1.2 
Cholesterola 16.57 ± 4.91 21.72 ± 6.38 11.61 ± 5.21 8.52 ± 2.85 14.63 ± 5.31 14.41 ± 5.08 
 Brain region 
White frontal cortex Cerebellum 
Control HD Control HD 
Lathosterol 4.35 ± 1.48 8.46 ± 5.70 3.62 ± 1.55 3.45 ± 2.50 
Lanosterol 0.89 ± 0.37 1.33 ± 0.81 0.72 ± 0.31 0.64 ± 0.44 
Zymosterol 0.11 ± 0.06 0.35 ± 0.22 0.12 ± 0.04 0.11 ± 0.05 
24,25 diH 0.19 ± 0.07 0.37 ± 0.18 0.18 ± 0.06 0.22 ± 0.10 
Desmosterol 4.66 ± 2.77 13.68 ± 9.25 3.93 ± 1.82 6.71 ± 4.54 
7-DHC 19.68 ± 5.01 25.80 ± 11.62 19.77 ± 6.68 16.26 ± 6.04 
24-OHC 33.00 ± 10.01 13.67 ± 6.22 25.54 ± 13.72 8.78 ± 4.62 
27-OHC 0.30 ± 0.09 0.87 ± 0.59 0.23 ± 0.21 0.41 ± 0.34 
7-KC 0.75 ± 0.24 1.28 ± 0.41 0.59 ± 0.22 0.74 ± 0.41 
7β-OHC 0.61 ± 0.21 0.94 ± 0.42 0.46 ± 0.17 0.61 ± 0.41 
Squalene 1.78 ± 1.12 1.92 ± 0.71 1.42 ± 1.07 1.79 ± 1.34 
Campesterol 10.0 ± 6.6 6.1 ± 4.9 7.9 ± 5.0 6.5 ± 4.7 
Cholesterola 16.57 ± 4.91 21.72 ± 6.38 11.61 ± 5.21 8.52 ± 2.85 
